Suramin	B-Claim
is	I-Claim
a	I-Claim
novel	I-Claim
agent	I-Claim
that	I-Claim
has	I-Claim
demonstrated	I-Claim
preliminary	I-Claim
evidence	I-Claim
of	I-Claim
antitumor	I-Claim
activity	I-Claim
in	I-Claim
hormone-refractory	I-Claim
prostate	I-Claim
cancer	I-Claim
(HRPC).	I-Claim

A	O
prospective	O
randomized	O
clinical	O
trial	O
was	O
designed	O
to	O
evaluate	O
pain	O
and	O
opioid	O
analgesic	O
intake	O
as	O
surrogates	O
for	O
antitumor	O
response	O
in	O
HRPC	O
patients	O
with	O
significant,	O
opioid	O
analgesic-dependent	O
pain.	O

A	O
double-blind,	O
placebo-controlled	O
trial	O
randomized	O
patients	O
to	O
receive	O
a	O
78-day,	O
outpatient	O
regimen	O
of	O
either	O
suramin	O
plus	O
hydrocortisone	O
(HC,	O
40	O
mg/d)	O
or	O
placebo	O
plus	O
HC.	O

Treatment	O
assignment	O
was	O
unblinded	O
when	O
either	O
disease	O
progression	O
or	O
dose-limiting	O
toxicity	O
occurred;	O
placebo	O
patients	O
were	O
allowed	O
to	O
cross-over	O
to	O
open-label	O
suramin	O
plus	O
HC.	O

In	O
addition	O
to	O
pain	O
and	O
opioid	O
analgesic	O
intake,	O
prostate-specific	O
antigen	O
(PSA)	O
response,	O
time	O
to	O
disease	O
progression,	O
quality	O
of	O
life,	O
performance	O
status,	O
and	O
survival	O
were	O
compared.	O

Overall	B-Premise
mean	I-Premise
reductions	I-Premise
in	I-Premise
combined	I-Premise
pain	I-Premise
and	I-Premise
opioid	I-Premise
analgesic	I-Premise
intake	I-Premise
were	I-Premise
greater	I-Premise
for	I-Premise
suramin	I-Premise
plus	I-Premise
HC	I-Premise
(rank	I-Premise
sum	I-Premise
P	I-Premise
=.0001).	I-Premise

Pain	B-Premise
response	I-Premise
was	I-Premise
achieved	I-Premise
in	I-Premise
a	I-Premise
higher	I-Premise
proportion	I-Premise
of	I-Premise
patients	I-Premise
receiving	I-Premise
suramin	I-Premise
than	I-Premise
placebo	I-Premise
(43%	I-Premise
v	I-Premise
28%;	I-Premise
P	I-Premise
=.001),	I-Premise
and	O
duration	B-Premise
of	I-Premise
response	I-Premise
was	I-Premise
longer	I-Premise
for	I-Premise
suramin	I-Premise
responders	I-Premise
(median,	I-Premise
240	I-Premise
v	I-Premise
69	I-Premise
days;	I-Premise
P	I-Premise
=.0027).	I-Premise

Time	B-Premise
to	I-Premise
disease	I-Premise
progression	I-Premise
was	I-Premise
longer	I-Premise
(relative	I-Premise
risk	I-Premise
=	I-Premise
1.5;	I-Premise
95%	I-Premise
confidence	I-Premise
interval,	I-Premise
1.2	I-Premise
to	I-Premise
1.9)	I-Premise
and	O
the	B-Premise
proportion	I-Premise
of	I-Premise
patients	I-Premise
with	I-Premise
a	I-Premise
greater	I-Premise
than	I-Premise
50%	I-Premise
decline	I-Premise
in	I-Premise
PSA	I-Premise
was	I-Premise
higher	I-Premise
(33%	I-Premise
v	I-Premise
16%;	I-Premise
P	I-Premise
=.01)	I-Premise
in	I-Premise
patients	I-Premise
who	I-Premise
received	I-Premise
suramin.	I-Premise

Neither	B-Premise
quality	I-Premise
of	I-Premise
life	I-Premise
nor	I-Premise
performance	I-Premise
status	I-Premise
was	I-Premise
decreased	I-Premise
by	I-Premise
suramin	I-Premise
treatment,	I-Premise
and	O
overall	B-Premise
survival	I-Premise
was	I-Premise
similar.	I-Premise

Most	B-Premise
adverse	I-Premise
events	I-Premise
were	I-Premise
of	I-Premise
mild	I-Premise
or	I-Premise
moderate	I-Premise
intensity	I-Premise
and	I-Premise
were	I-Premise
easily	I-Premise
managed	I-Premise
medically.	I-Premise

Outpatient	B-Claim
treatment	I-Claim
with	I-Claim
suramin	I-Claim
plus	I-Claim
HC	I-Claim
is	I-Claim
well	I-Claim
tolerated	I-Claim
and	I-Claim
provides	I-Claim
moderate	I-Claim
palliative	I-Claim
benefit	I-Claim
and	I-Claim
delay	I-Claim
in	I-Claim
disease	I-Claim
progression	I-Claim
for	I-Claim
patients	I-Claim
with	I-Claim
symptomatic	I-Claim
HRPC.	I-Claim

To	O
evaluate	O
whether	O
treatment	O
with	O
single-agent	O
docetaxel	O
would	O
result	O
in	O
longer	O
survival	O
than	O
would	O
best	O
supportive	O
care	O
in	O
patients	O
with	O
non-small-cell	O
lung	O
cancer	O
who	O
had	O
previously	O
been	O
treated	O
with	O
platinum-based	O
chemotherapy.	O

Secondary	O
end	O
points	O
included	O
assessment	O
of	O
response	O
(docetaxel	O
arm	O
only),	O
toxicity,	O
and	O
quality	O
of	O
life.	O

Patients	O
with	O
performance	O
statuses	O
of	O
0	O
to	O
2	O
and	O
stage	O
IIIB/IV	O
non-small-cell	O
lung	O
cancer	O
with	O
either	O
measurable	O
or	O
evaluable	O
lesions	O
were	O
eligible	O
for	O
entry	O
onto	O
the	O
study	O
if	O
they	O
had	O
undergone	O
one	O
or	O
more	O
platinum-based	O
chemotherapy	O
regimens	O
and	O
if	O
they	O
had	O
adequate	O
hematology	O
and	O
biochemistry	O
parameters.	O

They	O
were	O
excluded	O
if	O
they	O
had	O
symptomatic	O
brain	O
metastases	O
or	O
if	O
they	O
had	O
previously	O
been	O
treated	O
with	O
paclitaxel.	O

Patients	O
were	O
stratified	O
by	O
performance	O
status	O
and	O
best	O
response	O
to	O
cisplatin	O
chemotherapy	O
and	O
were	O
then	O
randomized	O
to	O
treatment	O
with	O
docetaxel	O
100	O
mg/m(2)	O
(49	O
patients)	O
or	O
75	O
mg/m(2)	O
(55	O
patients)	O
or	O
best	O
supportive	O
care.	O

Patients	O
in	O
both	O
arms	O
were	O
assessed	O
every	O
3	O
weeks.	O

One	O
hundred	O
four	O
patients	O
(103	O
of	O
whom	O
were	O
eligible	O
for	O
entry	O
onto	O
the	O
study)	O
were	O
well	O
balanced	O
for	O
prognostic	O
factors.	O

Of	O
84	O
patients	O
with	O
measurable	O
lesions,	O
six	O
(7.	O
1%)	O
achieved	O
partial	O
responses	O
(three	O
patients	O
at	O
each	O
dose	O
level).	O

Time	B-Premise
to	I-Premise
progression	I-Premise
was	I-Premise
longer	I-Premise
for	I-Premise
docetaxel	I-Premise
patients	I-Premise
than	I-Premise
for	I-Premise
best	I-Premise
supportive	I-Premise
care	I-Premise
patients	I-Premise
(10.6	I-Premise
v	I-Premise
6.7	I-Premise
weeks,	I-Premise
respectively;	I-Premise
P	I-Premise
<.001),	I-Premise
as	I-Premise
was	I-Premise
median	I-Premise
survival	I-Premise
(7.0	I-Premise
v	I-Premise
4.6	I-Premise
months;	I-Premise
log-rank	I-Premise
test,	I-Premise
P	I-Premise
=.047).	I-Premise

The	B-Premise
difference	I-Premise
was	I-Premise
more	I-Premise
significant	I-Premise
for	I-Premise
docetaxel	I-Premise
75	I-Premise
mg/m(2)	I-Premise
patients,	I-Premise
compared	I-Premise
with	I-Premise
corresponding	I-Premise
best	I-Premise
supportive	I-Premise
care	I-Premise
patients	I-Premise
(7.5	I-Premise
v	I-Premise
4.6	I-Premise
months;	I-Premise
log-rank	I-Premise
test,	I-Premise
P	I-Premise
=.010;	I-Premise
1-year	I-Premise
survival,	I-Premise
37%	I-Premise
v	I-Premise
11%;	I-Premise
chi(2)	I-Premise
test,	I-Premise
P	I-Premise
=.003).	I-Premise

Febrile	B-Premise
neutropenia	I-Premise
occurred	I-Premise
in	I-Premise
11	I-Premise
patients	I-Premise
treated	I-Premise
with	I-Premise
docetaxel	I-Premise
100	I-Premise
mg/m(2),	I-Premise
three	I-Premise
of	I-Premise
whom	I-Premise
died,	I-Premise
and	I-Premise
in	I-Premise
one	I-Premise
patient	I-Premise
treated	I-Premise
with	I-Premise
docetaxel	I-Premise
75	I-Premise
mg/m(2).	I-Premise

Grade	B-Premise
3	I-Premise
or	I-Premise
4	I-Premise
nonhematologic	I-Premise
toxicity,	I-Premise
with	I-Premise
the	I-Premise
exception	I-Premise
of	I-Premise
diarrhea,	I-Premise
occurred	I-Premise
at	I-Premise
a	I-Premise
similar	I-Premise
rate	I-Premise
in	I-Premise
both	I-Premise
the	I-Premise
docetaxel	I-Premise
and	I-Premise
best	I-Premise
supportive	I-Premise
care	I-Premise
groups.	I-Premise

Treatment	B-Claim
with	I-Claim
docetaxel	I-Claim
is	I-Claim
associated	I-Claim
with	I-Claim
significant	I-Claim
prolongation	I-Claim
of	I-Claim
survival,	I-Claim
and	O
at	B-Claim
a	I-Claim
dose	I-Claim
of	I-Claim
75	I-Claim
mg/m(2),	I-Claim
the	I-Claim
benefits	I-Claim
of	I-Claim
docetaxel	I-Claim
therapy	I-Claim
outweigh	I-Claim
the	I-Claim
risks.	I-Claim

In	B-Claim
the	I-Claim
context	I-Claim
of	I-Claim
chronic	I-Claim
physical	I-Claim
illness,	I-Claim
such	I-Claim
as	I-Claim
breast	I-Claim
cancer,	I-Claim
depression	I-Claim
is	I-Claim
associated	I-Claim
with	I-Claim
increased	I-Claim
morbidity,	I-Claim
longer	I-Claim
periods	I-Claim
of	I-Claim
hospitalization,	I-Claim
and	I-Claim
greater	I-Claim
overall	I-Claim
disability.	I-Claim

Prompt	B-Claim
diagnosis	I-Claim
and	I-Claim
effective	I-Claim
treatment	I-Claim
is,	I-Claim
therefore,	I-Claim
essential.	I-Claim

Several	O
small	O
studies	O
have	O
established	O
the	O
efficacy	O
of	O
tricyclic	O
antidepressants	O
(TCAs)	O
in	O
this	O
setting,	O
and	O
the	O
selective	O
serotonin	O
reuptake	O
inhibitors	O
(SSRIs)	O
would	O
appear	O
to	O
be	O
an	O
alternative	O
therapeutic	O
option	O
because	O
of	O
their	O
established	O
efficacy	O
and	O
better	O
tolerability	O
profile.	O

This	O
was	O
a	O
multicenter.	O
double-blind,	O
parallel-group	O
study	O
in	O
which	O
179	O
women	O
with	O
breast	O
cancer	O
were	O
randomized	O
to	O
treatment	O
with	O
either	O
the	O
SSRI	O
paroxetine	O
(20-40	O
mg/day),	O
or	O
the	O
TCA,	O
amitriptyline	O
(75-150	O
mg/day).	O

After	B-Premise
8-weeks	I-Premise
treatment,	I-Premise
depressive	I-Premise
symptomatology	I-Premise
had	I-Premise
improved	I-Premise
markedly	I-Premise
and	I-Premise
to	I-Premise
a	I-Premise
similar	I-Premise
extent	I-Premise
in	I-Premise
both	I-Premise
groups	I-Premise
on	I-Premise
the	I-Premise
Montgomery	I-Premise
Asberg	I-Premise
Depression	I-Premise
Rating	I-Premise
Scale.	I-Premise

Clinical	B-Premise
global	I-Premise
impression	I-Premise
(CGI)	I-Premise
Global	I-Premise
improvement	I-Premise
and	I-Premise
Patient	I-Premise
global	I-Premise
evaluation	I-Premise
scales	I-Premise
indicated	I-Premise
that	I-Premise
patients	I-Premise
were	I-Premise
minimally	I-Premise
to	I-Premise
much	I-Premise
improved	I-Premise
at	I-Premise
study	I-Premise
endpoint:	I-Premise
a	I-Premise
change	I-Premise
from	I-Premise
moderately/mildly	I-Premise
ill	I-Premise
to	I-Premise
borderline	I-Premise
ill	I-Premise
on	I-Premise
the	I-Premise
CGI	I-Premise
severity	I-Premise
of	I-Premise
Illness	I-Premise
scale.	I-Premise

A	B-Claim
steady	I-Claim
improvement	I-Claim
in	I-Claim
quality	I-Claim
of	I-Claim
life	I-Claim
was	I-Claim
also	I-Claim
observed	I-Claim
in	I-Claim
both	I-Claim
groups.	I-Claim

There	B-Premise
were	I-Premise
no	I-Premise
clinically	I-Premise
significant	I-Premise
differences	I-Premise
between	I-Premise
the	I-Premise
groups.	I-Premise

In	B-Premise
total,	I-Premise
47	I-Premise
(53.4%)	I-Premise
patients	I-Premise
in	I-Premise
the	I-Premise
paroxetine	I-Premise
group	I-Premise
and	I-Premise
53	I-Premise
(59.6%)	I-Premise
patients	I-Premise
in	I-Premise
the	I-Premise
amitriptyline	I-Premise
group	I-Premise
had	I-Premise
adverse	I-Premise
experiences,	I-Premise
the	I-Premise
most	I-Premise
common	I-Premise
of	I-Premise
which	I-Premise
were	I-Premise
the	I-Premise
well-recognized	I-Premise
side-effects	I-Premise
of	I-Premise
the	I-Premise
antidepressant	I-Premise
medications	I-Premise
or	I-Premise
chemotherapy.	I-Premise

Anticholinergic	B-Premise
effects	I-Premise
were	I-Premise
almost	I-Premise
twice	I-Premise
as	I-Premise
frequent	I-Premise
in	I-Premise
the	I-Premise
amitriptyline	I-Premise
group	I-Premise
(19.1%)	I-Premise
compared	I-Premise
with	I-Premise
paroxetine	I-Premise
(11.4%).	I-Premise

This	O
study	O
has	O
demonstrated	O
that	O
paroxetine	B-Claim
is	I-Claim
a	I-Claim
suitable	I-Claim
alternative	I-Claim
to	I-Claim
amitriptyline	I-Claim
for	I-Claim
the	I-Claim
treatment	I-Claim
of	I-Claim
depression	I-Claim
in	I-Claim
patients	I-Claim
with	I-Claim
breast	I-Claim
cancer.	I-Claim

In	B-Claim
a	I-Claim
randomized	I-Claim
clinical	I-Claim
trial	I-Claim
in	I-Claim
patients	I-Claim
with	I-Claim
advanced	I-Claim
non-small-cell	I-Claim
lung	I-Claim
cancer	I-Claim
(NSCLC),	I-Claim
infusion	I-Claim
with	I-Claim
adenosine	I-Claim
5'-triphosphate	I-Claim
(ATP)	I-Claim
inhibited	I-Claim
loss	I-Claim
of	I-Claim
body	I-Claim
weight	I-Claim
and	I-Claim
quality	I-Claim
of	I-Claim
life.	I-Claim

In	O
the	O
present	O
article,	O
the	O
effects	O
of	O
ATP	O
on	O
body	O
composition,	O
energy	O
intake,	O
and	O
energy	O
expenditure	O
as	O
secondary	O
outcome	O
measures	O
in	O
the	O
same	O
patients	O
are	O
reported.	O

Patients	O
with	O
NSCLC,	O
stage	O
IIIB	O
or	O
IV,	O
were	O
randomized	O
to	O
receive	O
either	O
10	O
intravenous,	O
30-hour	O
ATP	O
infusions	O
every	O
2	O
to	O
4	O
weeks	O
or	O
no	O
ATP.	O

Fat	O
mass	O
(FM),	O
fat-free	O
mass	O
(FFM),	O
and	O
arm	O
muscle	O
area	O
were	O
assessed	O
at	O
4-week	O
intervals	O
for	O
28	O
weeks.	O

Food	O
intake,	O
body	O
cell	O
mass	O
(BCM),	O
and	O
resting	O
energy	O
expenditure	O
(REE)	O
were	O
assessed	O
at	O
8-week	O
intervals	O
for	O
16	O
weeks.	O

Between-group	O
differences	O
were	O
tested	O
for	O
statistical	O
significance	O
by	O
repeated-measures	O
analysis	O
of	O
covariance.	O

Fifty-eight	O
patients	O
were	O
randomized	O
(28	O
ATP,	O
30	O
control).	O

No	B-Premise
change	I-Premise
in	I-Premise
body	I-Premise
composition	I-Premise
over	I-Premise
the	I-Premise
28-week	I-Premise
follow-up	I-Premise
period	I-Premise
was	I-Premise
found	I-Premise
in	I-Premise
the	I-Premise
ATP	I-Premise
group,	I-Premise
whereas,	I-Premise
per	I-Premise
4	I-Premise
weeks,	I-Premise
the	I-Premise
control	I-Premise
group	I-Premise
lost	I-Premise
0.6	I-Premise
kg	I-Premise
of	I-Premise
FM	I-Premise
(P	I-Premise
=.004),	I-Premise
0.5	I-Premise
kg	I-Premise
of	I-Premise
FFM	I-Premise
(P	I-Premise
=.02),	I-Premise
1.8%	I-Premise
of	I-Premise
arm	I-Premise
muscle	I-Premise
area	I-Premise
(P	I-Premise
=.02),	I-Premise
and	I-Premise
0.6%	I-Premise
of	I-Premise
BCM/kg	I-Premise
body	I-Premise
weight	I-Premise
(P	I-Premise
=.054)	I-Premise
and	I-Premise
decreased	I-Premise
568	I-Premise
KJ/d	I-Premise
in	I-Premise
energy	I-Premise
intake	I-Premise
(P	I-Premise
=.0001).	I-Premise

Appetite	B-Premise
also	I-Premise
remained	I-Premise
stable	I-Premise
in	I-Premise
the	I-Premise
ATP	I-Premise
group	I-Premise
but	I-Premise
decreased	I-Premise
significantly	I-Premise
in	I-Premise
the	I-Premise
control	I-Premise
group	I-Premise
(P	I-Premise
=.0004).	I-Premise

No	B-Premise
significant	I-Premise
differences	I-Premise
in	I-Premise
REE	I-Premise
between	I-Premise
the	I-Premise
ATP	I-Premise
and	I-Premise
control	I-Premise
groups	I-Premise
were	I-Premise
observed.	I-Premise

The	B-Claim
inhibition	I-Claim
of	I-Claim
weight	I-Claim
loss	I-Claim
by	I-Claim
ATP	I-Claim
infusions	I-Claim
in	I-Claim
patients	I-Claim
with	I-Claim
advanced	I-Claim
NSCLC	I-Claim
is	I-Claim
attributed	I-Claim
to	I-Claim
counteracting	I-Claim
the	I-Claim
loss	I-Claim
of	I-Claim
both	I-Claim
metabolically	I-Claim
active	I-Claim
and	I-Claim
inactive	I-Claim
tissues.	I-Claim

These	B-Premise
effects	I-Premise
are	I-Premise
partly	I-Premise
ascribed	I-Premise
to	I-Premise
maintenance	I-Premise
of	I-Premise
energy	I-Premise
intake.	I-Premise

The	O
purpose	O
of	O
the	O
study	O
was	O
to	O
assess	O
response	O
rate,	O
clinical	O
outcome,	O
organ/function	O
preservation	O
and	O
toxicity	O
in	O
head	O
and	O
neck	O
cancer	O
patients	O
treated	O
with	O
induction	O
chemotherapy	O
followed	O
by	O
concomitant	O
chemoradiotherapy	O
and,	O
when	O
necessary,	O
limited	O
surgery.	O

The	O
study	O
design	O
was	O
a	O
phase	O
II	O
non-randomized	O
trial	O
in	O
hospitalized	O
patients	O
setting.	O

The	O
treatment	O
plan	O
consisted	O
of	O
3	O
cycles	O
of	O
induction	O
chemotherapy	O
with	O
cisplatin,	O
fluorouracil	O
(5-FU),	O
l-leucovorin	O
and	O
interferon	O
alpha2b	O
(PFL-IFN)	O
followed	O
by	O
7	O
cycles	O
of	O
5-FU,	O
hydroxyurea	O
and	O
concomitant	O
radiation	O
for	O
5	O
days	O
(FHX)	O
for	O
a	O
total	O
radiation	O
dose	O
of	O
70	O
Gy.	O

13	O
Cis-retinoic	O
acid	O
was	O
added	O
to	O
treatment	O
regimen	O
for	O
chemoprevention	O
and	O
a	O
systematic	O
prophylaxis	O
of	O
mucositis	O
was	O
administered	O
to	O
all	O
patients	O
during	O
FHX.	O

Conservative	O
surgical	O
resection	O
was	O
reserved	O
to	O
patients	O
with	O
no	O
optimal	O
response	O
(PR	O
>	O
or	O
=70%),	O
whereas	O
radical	O
surgery	O
was	O
performed	O
as	O
salvage	O
treatment.	O

Twenty-six	O
patients	O
were	O
treated	O
at	O
one	O
institution:	O
more	O
than	O
90%	O
had	O
stage	O
IV	O
disease	O
and	O
only	O
19.2%	O
had	O
laryngeal	O
cancer.	O

Eighty-one	O
percent	O
of	O
patients	O
had	O
performance	O
status	O
0	O
and	O
23.1%	O
of	O
patients	O
had	O
>5%	O
weight	O
loss	O
at	O
the	O
start	O
of	O
treatment.	O

Nineteen	O
patients	O
were	O
analyzed	O
for	O
response	O
to	O
PFL-IFN:	O
3/19	O
(15.8%)	O
patients	O
achieved	O
a	O
CR	O
and	O
7/19	O
(36.8%)	O
achieved	O
a	O
PR	O
for	O
an	O
ORR	O
of	O
52.6%.	O

FHX	O
was	O
administered	O
on	O
protocol	O
to	O
12	O
patients:	O
6	O
patients	O
(50%)	O
had	O
CR,	O
1	O
patient	O
(8.3%)	O
had	O
PR	O
for	O
an	O
ORR	O
of	O
58.3%,	O
2	O
patients	O
(16.7%)	O
had	O
SD	O
and	O
3	O
patients	O
(25%)	O
had	O
PD.	O

At	O
the	O
completion	O
of	O
FHX,	O
no	O
patient	O
underwent	O
local	O
therapy	O
according	O
to	O
treatment	O
plan.	O

At	B-Premise
a	I-Premise
median	I-Premise
follow-up	I-Premise
time	I-Premise
of	I-Premise
13.5	I-Premise
months	I-Premise
(range	I-Premise
1-28+)	I-Premise
at	I-Premise
June	I-Premise
2001,	I-Premise
among	I-Premise
26	I-Premise
patients	I-Premise
enrolled	I-Premise
12	I-Premise
(46.1%)	I-Premise
were	I-Premise
still	I-Premise
alive	I-Premise
and	I-Premise
9	I-Premise
(75%)	I-Premise
of	I-Premise
them	I-Premise
were	I-Premise
progression-free.	I-Premise

The	B-Premise
median	I-Premise
duration	I-Premise
of	I-Premise
response	I-Premise
was	I-Premise
9	I-Premise
months	I-Premise
(range	I-Premise
0-25+),	I-Premise
the	I-Premise
median	I-Premise
progression-free	I-Premise
survival	I-Premise
was	I-Premise
10.5	I-Premise
months	I-Premise
(range	I-Premise
0-28+),	I-Premise
the	I-Premise
median	I-Premise
overall	I-Premise
survival	I-Premise
time	I-Premise
was	I-Premise
9	I-Premise
months	I-Premise
(range	I-Premise
1-22).	I-Premise

The	B-Premise
toxicity	I-Premise
was	I-Premise
significant	I-Premise
and	I-Premise
consisted	I-Premise
mainly	I-Premise
of	I-Premise
mucositis	I-Premise
and,	I-Premise
to	I-Premise
a	I-Premise
lesser	I-Premise
extent,	I-Premise
neutropenia/thrombocytopenia.	I-Premise

In	O
the	O
present	O
study,	O
the	B-Claim
low	I-Claim
serum	I-Claim
levels	I-Claim
of	I-Claim
leptin	I-Claim
and	I-Claim
the	I-Claim
high	I-Claim
serum	I-Claim
levels	I-Claim
of	I-Claim
proinflammatory	I-Claim
cytokines	I-Claim
in	I-Claim
advanced	I-Claim
stage	I-Claim
cancer	I-Claim
patients	I-Claim
were	I-Claim
confirmed.	I-Claim

In	O
conclusion,	O
this	B-Claim
sequential	I-Claim
induction	I-Claim
chemotherapy	I-Claim
and	I-Claim
chemoradiotherapy	I-Claim
program	I-Claim
has	I-Claim
been	I-Claim
found	I-Claim
moderately	I-Claim
active	I-Claim
and	I-Claim
significantly	I-Claim
toxic;	I-Claim
moreover,	O
the	O
long	O
overall	O
treatment	O
duration	O
must	O
be	O
taken	O
into	O
consideration.	O

For	O
these	O
reasons,	O
this	B-MajorClaim
regimen	I-MajorClaim
could	I-MajorClaim
not	I-MajorClaim
be	I-MajorClaim
recommended	I-MajorClaim
for	I-MajorClaim
a	I-MajorClaim
phase	I-MajorClaim
III	I-MajorClaim
randomized	I-MajorClaim
study.	I-MajorClaim

Laparoscopic-assisted	B-Claim
colectomy	I-Claim
(LAC)	I-Claim
has	I-Claim
emerged	I-Claim
as	I-Claim
the	I-Claim
preferred	I-Claim
minimally	I-Claim
invasive	I-Claim
surgical	I-Claim
strategy	I-Claim
for	I-Claim
diseases	I-Claim
of	I-Claim
the	I-Claim
colon.	I-Claim

The	B-MajorClaim
safety	I-MajorClaim
and	I-MajorClaim
efficacy	I-MajorClaim
of	I-MajorClaim
LAC	I-MajorClaim
for	I-MajorClaim
colon	I-MajorClaim
cancer	I-MajorClaim
are	I-MajorClaim
unknown,	I-MajorClaim
and	O
the	B-MajorClaim
nature	I-MajorClaim
and	I-MajorClaim
magnitude	I-MajorClaim
of	I-MajorClaim
any	I-MajorClaim
quality-of-life	I-MajorClaim
(QOL)	I-MajorClaim
benefit	I-MajorClaim
resulting	I-MajorClaim
from	I-MajorClaim
LAC	I-MajorClaim
for	I-MajorClaim
colon	I-MajorClaim
cancer	I-MajorClaim
is	I-MajorClaim
also	I-MajorClaim
unknown.	I-MajorClaim

To	O
compare	O
short-term	O
QOL	O
outcomes	O
after	O
LAC	O
vs	O
open	O
colectomy	O
for	O
colon	O
cancer.	O

Multicenter,	O
randomized	O
controlled	O
trial	O
(Clinical	O
Outcomes	O
of	O
Surgical	O
Therapy	O
[COST]).	O

Between	O
September	O
1994	O
and	O
February	O
1999,	O
37	O
of	O
48	O
centers	O
provided	O
data	O
for	O
the	O
QOL	O
component	O
of	O
the	O
trial	O
for	O
449	O
consecutive	O
patients	O
with	O
clinically	O
resectable	O
colon	O
cancer.	O

Scores	O
on	O
the	O
Symptoms	O
Distress	O
Scale	O
(SDS),	O
Quality	O
of	O
Life	O
Index,	O
and	O
a	O
single-item	O
global	O
rating	O
scale	O
at	O
2	O
days,	O
2	O
weeks,	O
and	O
2	O
months	O
postoperative;	O
duration	O
of	O
postoperative	O
in-hospital	O
analgesic	O
use;	O
and	O
length	O
of	O
stay.	O

Of	O
449	O
patients,	O
428	O
provided	O
QOL	O
data.	O

In	B-Premise
an	I-Premise
intention-to-treat	I-Premise
analysis	I-Premise
comparing	I-Premise
SDS	I-Premise
pain	I-Premise
intensity,	I-Premise
SDS	I-Premise
summary,	I-Premise
QOL	I-Premise
Index	I-Premise
summary,	I-Premise
and	I-Premise
global	I-Premise
rating	I-Premise
scale	I-Premise
scores	I-Premise
at	I-Premise
each	I-Premise
time	I-Premise
point,	I-Premise
the	I-Premise
only	I-Premise
statistically	I-Premise
significant	I-Premise
difference	I-Premise
observed	I-Premise
between	I-Premise
groups	I-Premise
was	I-Premise
the	I-Premise
global	I-Premise
rating	I-Premise
scale	I-Premise
score	I-Premise
for	I-Premise
2	I-Premise
weeks	I-Premise
postsurgery.	I-Premise

The	B-Premise
mean	I-Premise
(median)	I-Premise
global	I-Premise
rating	I-Premise
scale	I-Premise
scores	I-Premise
for	I-Premise
2	I-Premise
weeks	I-Premise
postsurgery	I-Premise
were	I-Premise
76.9	I-Premise
(80)	I-Premise
for	I-Premise
LAC	I-Premise
vs	I-Premise
74.4	I-Premise
(75)	I-Premise
for	I-Premise
open	I-Premise
colectomy	I-Premise
(P	I-Premise
=.009).	I-Premise

While	B-Premise
in	I-Premise
the	I-Premise
hospital,	I-Premise
patients	I-Premise
assigned	I-Premise
to	I-Premise
LAC	I-Premise
required	I-Premise
fewer	I-Premise
days	I-Premise
of	I-Premise
both	I-Premise
parenteral	I-Premise
analgesics	I-Premise
compared	I-Premise
with	I-Premise
patients	I-Premise
assigned	I-Premise
to	I-Premise
open	I-Premise
colectomy	I-Premise
(mean	I-Premise
[median],	I-Premise
3.2	I-Premise
[3]	I-Premise
vs	I-Premise
4.0	I-Premise
[4]	I-Premise
days;	I-Premise
P<.001)	I-Premise
and	I-Premise
oral	I-Premise
analgesics	I-Premise
(mean	I-Premise
[median],	I-Premise
1.9	I-Premise
[1]	I-Premise
vs	I-Premise
2.2	I-Premise
[2]	I-Premise
days;	I-Premise
P	I-Premise
=.03).	I-Premise

Only	B-Claim
minimal	I-Claim
short-term	I-Claim
QOL	I-Claim
benefits	I-Claim
were	I-Claim
found	I-Claim
with	I-Claim
LAC	I-Claim
for	I-Claim
colon	I-Claim
cancer	I-Claim
compared	I-Claim
with	I-Claim
standard	I-Claim
open	I-Claim
colectomy.	I-Claim

Until	B-Claim
ongoing	I-Claim
trials	I-Claim
establish	I-Claim
that	I-Claim
LAC	I-Claim
is	I-Claim
as	I-Claim
effective	I-Claim
as	I-Claim
open	I-Claim
colectomy	I-Claim
in	I-Claim
preventing	I-Claim
recurrence	I-Claim
and	I-Claim
death	I-Claim
from	I-Claim
colon	I-Claim
cancer,	I-Claim
this	I-Claim
procedure	I-Claim
should	I-Claim
not	I-Claim
be	I-Claim
offered	I-Claim
to	I-Claim
patients	I-Claim
with	I-Claim
colon	I-Claim
cancer.	I-Claim

To	O
evaluate	O
the	O
efficacy	O
and	O
safety	O
of	O
first-line,	O
single-agent	O
trastuzumab	O
in	O
women	O
with	O
HER2-overexpressing	O
metastatic	O
breast	O
cancer.	O

One	O
hundred	O
fourteen	O
women	O
with	O
HER2-overexpressing	O
metastatic	O
breast	O
cancer	O
were	O
randomized	O
to	O
receive	O
first-line	O
treatment	O
with	O
trastuzumab	O
4	O
mg/kg	O
loading	O
dose,	O
followed	O
by	O
2	O
mg/kg	O
weekly,	O
or	O
a	O
higher	O
8	O
mg/kg	O
loading	O
dose,	O
followed	O
by	O
4	O
mg/kg	O
weekly.	O

The	B-Premise
objective	I-Premise
response	I-Premise
rate	I-Premise
was	I-Premise
26%	I-Premise
(95%	I-Premise
confidence	I-Premise
interval	I-Premise
[CI],	I-Premise
18.2%	I-Premise
to	I-Premise
34.4%),	I-Premise
with	I-Premise
seven	I-Premise
complete	I-Premise
and	I-Premise
23	I-Premise
partial	I-Premise
responses.	I-Premise

Response	B-Premise
rates	I-Premise
in	I-Premise
111	I-Premise
assessable	I-Premise
patients	I-Premise
with	I-Premise
3+	I-Premise
and	I-Premise
2+	I-Premise
HER2	I-Premise
overexpression	I-Premise
by	I-Premise
immunohistochemistry	I-Premise
(IHC)	I-Premise
were	I-Premise
35%	I-Premise
(95%	I-Premise
CI,	I-Premise
24.4%	I-Premise
to	I-Premise
44.7%)	I-Premise
and	I-Premise
none	I-Premise
(95%	I-Premise
CI,	I-Premise
0%	I-Premise
to	I-Premise
15.5%),	I-Premise
respectively.	I-Premise

The	B-Premise
clinical	I-Premise
benefit	I-Premise
rates	I-Premise
in	I-Premise
assessable	I-Premise
patients	I-Premise
with	I-Premise
3+	I-Premise
and	I-Premise
2+	I-Premise
HER2	I-Premise
overexpression	I-Premise
were	I-Premise
48%	I-Premise
and	I-Premise
7%,	I-Premise
respectively.	I-Premise

The	B-Premise
response	I-Premise
rates	I-Premise
in	I-Premise
108	I-Premise
assessable	I-Premise
patients	I-Premise
with	I-Premise
and	I-Premise
without	I-Premise
HER2	I-Premise
gene	I-Premise
amplification	I-Premise
by	I-Premise
fluorescence	I-Premise
in	I-Premise
situ	I-Premise
hybridization	I-Premise
(FISH)	I-Premise
analysis	I-Premise
were	I-Premise
34%	I-Premise
(95%	I-Premise
CI,	I-Premise
23.9%	I-Premise
to	I-Premise
45.7%)	I-Premise
and	I-Premise
7%	I-Premise
(95%	I-Premise
CI,	I-Premise
0.8%	I-Premise
to	I-Premise
22.8%),	I-Premise
respectively.	I-Premise

Seventeen	B-Premise
(57%)	I-Premise
of	I-Premise
30	I-Premise
patients	I-Premise
with	I-Premise
an	I-Premise
objective	I-Premise
response	I-Premise
and	I-Premise
22	I-Premise
(51%)	I-Premise
of	I-Premise
43	I-Premise
patients	I-Premise
with	I-Premise
clinical	I-Premise
benefit	I-Premise
had	I-Premise
not	I-Premise
experienced	I-Premise
disease	I-Premise
progression	I-Premise
at	I-Premise
follow-up	I-Premise
at	I-Premise
12	I-Premise
months	I-Premise
or	I-Premise
later.	I-Premise

The	B-Premise
most	I-Premise
common	I-Premise
treatment-related	I-Premise
adverse	I-Premise
events	I-Premise
were	I-Premise
chills	I-Premise
(25%	I-Premise
of	I-Premise
patients),	I-Premise
asthenia	I-Premise
(23%),	I-Premise
fever	I-Premise
(22%),	I-Premise
pain	I-Premise
(18%),	I-Premise
and	I-Premise
nausea	I-Premise
(14%).	I-Premise

Cardiac	B-Premise
dysfunction	I-Premise
occurred	I-Premise
in	I-Premise
two	I-Premise
patients	I-Premise
(2%);	I-Premise
both	I-Premise
had	I-Premise
histories	I-Premise
of	I-Premise
cardiac	I-Premise
disease	I-Premise
and	I-Premise
did	I-Premise
not	I-Premise
require	I-Premise
additional	I-Premise
intervention	I-Premise
after	I-Premise
discontinuation	I-Premise
of	I-Premise
trastuzumab.	I-Premise

There	B-Claim
was	I-Claim
no	I-Claim
clear	I-Claim
evidence	I-Claim
of	I-Claim
a	I-Claim
dose-response	I-Claim
relationship	I-Claim
for	I-Claim
response,	I-Claim
survival,	I-Claim
or	I-Claim
adverse	I-Claim
events.	I-Claim

Single-agent	B-Claim
trastuzumab	I-Claim
is	I-Claim
active	I-Claim
and	I-Claim
well	I-Claim
tolerated	I-Claim
as	I-Claim
first-line	I-Claim
treatment	I-Claim
of	I-Claim
women	I-Claim
with	I-Claim
metastatic	I-Claim
breast	I-Claim
cancer	I-Claim
with	I-Claim
HER2	I-Claim
3+	I-Claim
overexpression	I-Claim
by	I-Claim
IHC	I-Claim
or	I-Claim
gene	I-Claim
amplification	I-Claim
by	I-Claim
FISH.	I-Claim

Older	B-Claim
patients,	I-Claim
even	I-Claim
if	I-Claim
fit,	I-Claim
are	I-Claim
often	I-Claim
considered	I-Claim
incapable	I-Claim
of	I-Claim
tolerating	I-Claim
platinum-based	I-Claim
systemic	I-Claim
therapy.	I-Claim

We	O
performed	O
a	O
retrospective	O
analysis	O
of	O
Eastern	O
Cooperative	O
Oncology	O
Group	O
(ECOG)	O
5592,	O
a	O
phase	O
III	O
randomized	O
trial	O
of	O
platinum-based	O
chemotherapy	O
regimens	O
for	O
non-small-cell	O
lung	O
cancer	O
(NSCLC),	O
and	O
compared	O
outcomes	O
in	O
enrollees	O
70	O
years	O
of	O
age	O
and	O
older	O
with	O
those	O
in	O
younger	O
patients.	O

ECOG	O
carried	O
out	O
a	O
randomized	O
phase	O
III	O
trial	O
of	O
cisplatin	O
plus	O
either	O
etoposide	O
or	O
paclitaxel	O
in	O
chemotherapy-naÃ¯ve	O
NSCLC	O
patients	O
with	O
stages	O
III(B)	O
or	O
IV	O
disease.	O

Toxic	O
effects,	O
response	O
rates,	O
and	O
survival	O
rates	O
were	O
compared	O
between	O
age	O
groups.	O

All	O
P	O
values	O
were	O
two-sided.	O

A	O
total	O
of	O
574	O
patients	O
enrolled	O
from	O
August	O
1993	O
through	O
December	O
1994	O
were	O
evaluable.	O

Eighty-six	O
(15%)	O
were	O
70	O
years	O
old	O
or	O
older.	O

Older	B-Premise
patients	I-Premise
had	I-Premise
a	I-Premise
higher	I-Premise
incidence	I-Premise
of	I-Premise
cardiovascular	I-Premise
(P	I-Premise
=.009)	I-Premise
and	I-Premise
respiratory	I-Premise
(P	I-Premise
=.04)	I-Premise
comorbidities	I-Premise
and	I-Premise
nonanalgesic	I-Premise
medication	I-Premise
use	I-Premise
(P	I-Premise
=.02).	I-Premise

Leukopenia	B-Premise
(P<.001)	I-Premise
and	I-Premise
neuropsychiatric	I-Premise
toxicity	I-Premise
(P	I-Premise
=.002)	I-Premise
were	I-Premise
more	I-Premise
common	I-Premise
in	I-Premise
elderly	I-Premise
men	I-Premise
than	I-Premise
in	I-Premise
younger	I-Premise
men.	I-Premise

Elderly	B-Premise
women	I-Premise
lost	I-Premise
more	I-Premise
weight	I-Premise
than	I-Premise
younger	I-Premise
women	I-Premise
(P	I-Premise
=.006).	I-Premise

Other	B-Premise
toxic	I-Premise
effects	I-Premise
were	I-Premise
similar	I-Premise
in	I-Premise
older	I-Premise
and	I-Premise
younger	I-Premise
patients.	I-Premise

The	B-Premise
proportions	I-Premise
with	I-Premise
clinical	I-Premise
partial	I-Premise
or	I-Premise
complete	I-Premise
response	I-Premise
(21.5%	I-Premise
versus	I-Premise
23.3%;	I-Premise
Fisher's	I-Premise
exact	I-Premise
test,	I-Premise
P	I-Premise
=.66),	I-Premise
median	I-Premise
time	I-Premise
to	I-Premise
progression	I-Premise
(4.37	I-Premise
versus	I-Premise
4.30	I-Premise
months;	I-Premise
log-rank	I-Premise
test,	I-Premise
P	I-Premise
=.29),	I-Premise
and	I-Premise
survival	I-Premise
distribution	I-Premise
(log-rank	I-Premise
test,	I-Premise
P	I-Premise
=.29;	I-Premise
median	I-Premise
survival,	I-Premise
9.05	I-Premise
versus	I-Premise
8.53	I-Premise
months;	I-Premise
1-year	I-Premise
survival,	I-Premise
38%	I-Premise
versus	I-Premise
29%;	I-Premise
and	I-Premise
2-year	I-Premise
survival,	I-Premise
14%	I-Premise
versus	I-Premise
12%)	I-Premise
were	I-Premise
similar	I-Premise
in	I-Premise
patients	I-Premise
younger	I-Premise
than	I-Premise
70	I-Premise
years	I-Premise
and	I-Premise
70	I-Premise
years	I-Premise
old	I-Premise
or	I-Premise
older.	I-Premise

Baseline	B-Premise
quality-of-life	I-Premise
and	I-Premise
treatment-outcome	I-Premise
indices	I-Premise
were	I-Premise
similar.	I-Premise

Equivalent	B-Premise
declines	I-Premise
over	I-Premise
time	I-Premise
in	I-Premise
functional	I-Premise
well-being	I-Premise
occurred	I-Premise
in	I-Premise
both	I-Premise
groups.	I-Premise

Response	B-Claim
rate,	I-Claim
toxicity,	I-Claim
and	I-Claim
survival	I-Claim
in	I-Claim
fit,	I-Claim
elderly	I-Claim
NSCLC	I-Claim
patients	I-Claim
receiving	I-Claim
platinum-based	I-Claim
treatment	I-Claim
appear	I-Claim
to	I-Claim
be	I-Claim
similar	I-Claim
to	I-Claim
those	I-Claim
in	I-Claim
younger	I-Claim
patients,	I-Claim
although	B-Claim
patients	I-Claim
70	I-Claim
years	I-Claim
old	I-Claim
or	I-Claim
older	I-Claim
have	I-Claim
more	I-Claim
comorbidities	I-Claim
and	I-Claim
can	I-Claim
expect	I-Claim
more	I-Claim
leukopenia	I-Claim
and	I-Claim
neuropsychiatric	I-Claim
toxicity.	I-Claim

Advanced	B-Claim
age	I-Claim
alone	I-Claim
should	I-Claim
not	I-Claim
preclude	I-Claim
appropriate	I-Claim
NSCLC	I-Claim
treatment.	I-Claim

SIR-Spheres	O
are	O
radioactive	O
yttrium90	O
microspheres	O
(SIR-Spheres,	O
Sirtex	O
Medical	O
Limited,	O
Australia)	O
used	O
to	O
selectively	O
target	O
high	O
levels	O
of	O
ionising	O
radiation	O
to	O
tumors	O
within	O
the	O
liver.	O

This	O
trial	O
was	O
designed	O
to	O
measure	O
any	O
increased	O
patient	O
benefit	O
by	O
adding	O
a	O
single	O
administration	O
of	O
SIR-Spheres	O
to	O
a	O
regimen	O
of	O
regional	O
hepatic	O
artery	O
chemotherapy	O
(HAC)	O
administered	O
as	O
a	O
12	O
day	O
infusion	O
of	O
floxuridine	O
and	O
repeated	O
at	O
monthly	O
intervals,	O
vs.	O
the	O
same	O
chemotherapy	O
alone.	O

A	O
phase	O
III	O
randomised	O
clinical	O
trial	O
entering	O
74	O
patients	O
was	O
undertaken	O
on	O
patients	O
with	O
bi-lobar	O
non-resectable	O
liver	O
metastases	O
from	O
primary	O
adenocarcinoma	O
of	O
the	O
large	O
bowel.	O

Patient	O
benefit	O
criteria	O
assessed	O
in	O
the	O
trial	O
were	O
tumor	O
response,	O
time	O
to	O
disease	O
progression	O
in	O
the	O
liver,	O
overall	O
survival,	O
quality	O
of	O
life,	O
and	O
treatment	O
related	O
toxicity.	O

Tumor	O
response	O
was	O
measured	O
by	O
serial	O
changes	O
in	O
both	O
cross-sectional	O
tumor	O
areas	O
and	O
total	O
tumor	O
volumes,	O
provided	O
any	O
response	O
lasted	O
not	O
less	O
than	O
three	O
months	O
as	O
well	O
as	O
changes	O
in	O
serum	O
carcino-embryonic	O
antigen	O
(CEA).	O

The	B-Premise
partial	I-Premise
and	I-Premise
complete	I-Premise
response	I-Premise
rate	I-Premise
(PR	I-Premise
+	I-Premise
CR)	I-Premise
was	I-Premise
significantly	I-Premise
greater	I-Premise
for	I-Premise
patients	I-Premise
receiving	I-Premise
SIR-Spheres	I-Premise
when	I-Premise
measured	I-Premise
by	I-Premise
tumor	I-Premise
areas	I-Premise
(44%)	I-Premise
vs.	I-Premise
17.6%,	I-Premise
P	I-Premise
=	I-Premise
0.01)	I-Premise
tumor	I-Premise
volumes	I-Premise
(50%	I-Premise
vs.	I-Premise
24%,	I-Premise
P	I-Premise
=	I-Premise
0.03)	I-Premise
and	I-Premise
CEA	I-Premise
(72%	I-Premise
vs.	I-Premise
47%,	I-Premise
P	I-Premise
=	I-Premise
0.004).	I-Premise

The	B-Premise
median	I-Premise
time	I-Premise
to	I-Premise
disease	I-Premise
progression	I-Premise
in	I-Premise
the	I-Premise
liver	I-Premise
was	I-Premise
significantly	I-Premise
longer	I-Premise
for	I-Premise
patients	I-Premise
receiving	I-Premise
SIR-Spheres	I-Premise
in	I-Premise
comparison	I-Premise
to	I-Premise
patients	I-Premise
receiving	I-Premise
HAC	I-Premise
alone	I-Premise
when	I-Premise
measured	I-Premise
by	I-Premise
either	I-Premise
tumor	I-Premise
areas	I-Premise
(9.7	I-Premise
vs.	I-Premise
15.9	I-Premise
months,	I-Premise
P	I-Premise
=	I-Premise
0.001),	I-Premise
tumor	I-Premise
volumes	I-Premise
(7.6	I-Premise
vs.	I-Premise
12.0	I-Premise
months,	I-Premise
P	I-Premise
=	I-Premise
0.04)	I-Premise
or	I-Premise
CEA	I-Premise
(5.7	I-Premise
vs.	I-Premise
6.7	I-Premise
months,	I-Premise
P	I-Premise
=	I-Premise
0.06).	I-Premise

The	B-Premise
one,	I-Premise
two,	I-Premise
three	I-Premise
and	I-Premise
five-year	I-Premise
survival	I-Premise
for	I-Premise
patients	I-Premise
receiving	I-Premise
SIR-Spheres	I-Premise
was	I-Premise
72%,	I-Premise
39%,	I-Premise
17%	I-Premise
and	I-Premise
3.5%,	I-Premise
compared	I-Premise
to	I-Premise
68%,	I-Premise
29%,	I-Premise
6.5%	I-Premise
and	I-Premise
0%	I-Premise
for	I-Premise
HAC	I-Premise
alone.	I-Premise

Cox	B-Premise
regression	I-Premise
analysis	I-Premise
suggests	I-Premise
an	I-Premise
improvement	I-Premise
in	I-Premise
survival	I-Premise
for	I-Premise
patients	I-Premise
treated	I-Premise
with	I-Premise
SIR-Spheres	I-Premise
who	I-Premise
survive	I-Premise
more	I-Premise
than	I-Premise
15	I-Premise
months	I-Premise
(P	I-Premise
=	I-Premise
0.06).	I-Premise

There	B-Premise
was	I-Premise
no	I-Premise
increase	I-Premise
in	I-Premise
grade	I-Premise
3-4	I-Premise
treatment	I-Premise
related	I-Premise
toxicity	I-Premise
and	I-Premise
no	I-Premise
loss	I-Premise
of	I-Premise
quality	I-Premise
of	I-Premise
life	I-Premise
for	I-Premise
patients	I-Premise
receiving	I-Premise
SIR-Spheres	I-Premise
in	I-Premise
comparison	I-Premise
to	I-Premise
patients	I-Premise
receiving	I-Premise
HAC	I-Premise
alone.	I-Premise

The	B-Claim
combination	I-Claim
of	I-Claim
a	I-Claim
single	I-Claim
injection	I-Claim
of	I-Claim
SIR-Spheres	I-Claim
plus	I-Claim
HAC	I-Claim
is	I-Claim
substantially	I-Claim
more	I-Claim
effective	I-Claim
in	I-Claim
increasing	I-Claim
tumor	I-Claim
responses	I-Claim
and	I-Claim
progression	I-Claim
free	I-Claim
survival	I-Claim
than	I-Claim
the	I-Claim
same	I-Claim
regimen	I-Claim
of	I-Claim
HAC	I-Claim
alone.	I-Claim

Phase	B-Claim
II	I-Claim
and	I-Claim
III	I-Claim
studies	I-Claim
have	I-Claim
shown	I-Claim
that	I-Claim
the	I-Claim
addition	I-Claim
of	I-Claim
interleukin-2	I-Claim
(IL-2)	I-Claim
and	I-Claim
interferon	I-Claim
alpha-2b	I-Claim
(IFN	I-Claim
alpha-2b)	I-Claim
in	I-Claim
multiagent	I-Claim
chemotherapy	I-Claim
(CT)	I-Claim
for	I-Claim
advanced	I-Claim
melanoma	I-Claim
increases	I-Claim
overall	I-Claim
response	I-Claim
(OR),	I-Claim
albeit	I-Claim
without	I-Claim
clear	I-Claim
evidence	I-Claim
of	I-Claim
an	I-Claim
improvement	I-Claim
in	I-Claim
overall	I-Claim
survival	I-Claim
(OS).	I-Claim

Treatment	B-Claim
with	I-Claim
high-dose	I-Claim
IL-2	I-Claim
can	I-Claim
cause	I-Claim
severe	I-Claim
toxicity	I-Claim
and	I-Claim
is	I-Claim
normally	I-Claim
administered	I-Claim
in	I-Claim
an	I-Claim
inpatient	I-Claim
setting.	I-Claim

We	O
conducted	O
a	O
multicenter	O
prospective	O
randomized	O
clinical	O
trial	O
in	O
outpatients	O
with	O
metastatic	O
melanoma	O
to	O
compare	O
CT	O
with	O
biochemotherapy	O
(bioCT)	O
using	O
immunomodulant	O
doses	O
of	O
IL-2	O
and	O
IFN	O
alpha-2b.	O

One	O
hundred	O
seventy-six	O
eligible	O
patients	O
with	O
advanced	O
melanoma	O
were	O
randomized	O
to	O
receive	O
CT	O
(cisplatin	O
and	O
dacarbazine	O
with	O
or	O
without	O
carmustine	O
every	O
21	O
days)	O
or	O
bioCT	O
comprising	O
the	O
same	O
CT	O
regimen	O
followed	O
by	O
low-dose	O
subcutaneous	O
IL-2	O
for	O
8	O
days	O
and	O
IFN	O
alpha-2b	O
three	O
times	O
a	O
week,	O
both	O
for	O
six	O
cycles.	O

At	B-Premise
a	I-Premise
median	I-Premise
follow-up	I-Premise
of	I-Premise
18	I-Premise
(CT)	I-Premise
and	I-Premise
16	I-Premise
(bioCT)	I-Premise
months,	I-Premise
median	I-Premise
OS	I-Premise
was	I-Premise
9.5	I-Premise
versus	I-Premise
11.0	I-Premise
months	I-Premise
(P	I-Premise
=.51),	I-Premise
respectively.	I-Premise

In	B-Premise
the	I-Premise
89	I-Premise
CT-arm	I-Premise
patients,	I-Premise
18	I-Premise
ORs	I-Premise
(20.2%)	I-Premise
(three	I-Premise
complete	I-Premise
responders	I-Premise
[CRs]	I-Premise
and	I-Premise
15	I-Premise
partial	I-Premise
responders	I-Premise
[PRs])	I-Premise
were	I-Premise
observed	I-Premise
according	I-Premise
to	I-Premise
World	I-Premise
Health	I-Premise
Organization	I-Premise
criteria.	I-Premise

In	B-Premise
the	I-Premise
87	I-Premise
bioCT-arm	I-Premise
patients,	I-Premise
22	I-Premise
ORs	I-Premise
(25.3%)	I-Premise
(three	I-Premise
CRs	I-Premise
and	I-Premise
19	I-Premise
PRs)	I-Premise
(P	I-Premise
=.70)	I-Premise
were	I-Premise
recorded.	I-Premise

Treatment-related	B-Premise
toxicity	I-Premise
was	I-Premise
fairly	I-Premise
similar	I-Premise
in	I-Premise
both	I-Premise
arms.	I-Premise

The	B-Claim
addition	I-Claim
of	I-Claim
low-dose	I-Claim
immunotherapy	I-Claim
did	I-Claim
not	I-Claim
produce	I-Claim
a	I-Claim
statistically	I-Claim
significant	I-Claim
advantage	I-Claim
in	I-Claim
OS,	I-Claim
time	I-Claim
to	I-Claim
progression,	I-Claim
or	I-Claim
OR.	I-Claim

However,	B-Claim
the	I-Claim
11-month	I-Claim
median	I-Claim
OS	I-Claim
in	I-Claim
the	I-Claim
bioCT	I-Claim
arm	I-Claim
does	I-Claim
not	I-Claim
differ	I-Claim
greatly	I-Claim
from	I-Claim
the	I-Claim
best	I-Claim
results	I-Claim
with	I-Claim
high-dose	I-Claim
IL-2-containing	I-Claim
regimens	I-Claim
reported	I-Claim
in	I-Claim
the	I-Claim
literature.	I-Claim

Furthermore,	O
our	B-Claim
treatment	I-Claim
schedule	I-Claim
was	I-Claim
carried	I-Claim
out	I-Claim
on	I-Claim
outpatients	I-Claim
and	I-Claim
had	I-Claim
an	I-Claim
acceptable	I-Claim
level	I-Claim
of	I-Claim
toxicity.	I-Claim

To	O
evaluate	O
the	O
effect	O
of	O
epoetin	O
alfa	O
on	O
quality	O
of	O
life	O
(QOL)	O
in	O
patients	O
with	O
solid	O
tumors	O
and	O
mild-to-moderate	O
anemia	O
receiving	O
platinum-based	O
chemotherapy	O
relative	O
to	O
population	O
norms.	O

In	O
the	O
original	O
study,	O
patients	O
(n	O
=	O
316)	O
with	O
hemoglobin	O
(Hb)	O
levels	O
<	O
or	O
=12.1	O
g/dl	O
were	O
randomized	O
2:1	O
to	O
receive	O
either	O
epoetin	O
alfa	O
at	O
a	O
dose	O
of	O
10,000	O
U	O
thrice	O
weekly	O
s.c.	O
or	O
best	O
supportive	O
care	O
(BSC)	O
to	O
compare	O
the	O
effects	O
on	O
transfusion	O
use,	O
hematologic	O
response,	O
and	O
QOL	O
(measured	O
by	O
the	O
Functional	O
Assessment	O
of	O
Cancer	O
Therapy-Anemia	O
[FACT-An]and	O
Cancer	O
Linear	O
Analogue	O
Scale	O
[CLAS]).	O

The	O
QOL	O
data	O
from	O
this	O
previously	O
reported	O
trial	O
were	O
reanalyzed	O
here	O
relative	O
to	O
population	O
norms.	O

Mean	O
baseline	O
QOL	O
scores	O
were	O
similar	O
between	O
groups.	O

At	O
study	O
completion,	O
mean	O
CLAS,	O
FACT-An,	O
FACT-An	O
Anemia	O
subscale,	O
and	O
FACT-An	O
Fatigue	O
subscale	O
scores	O
were	O
significantly	O
higher	O
for	O
patients	O
given	O
epoetin	O
alfa	O
than	O
for	O
those	O
treated	O
with	O
BSC.	O

Compared	O
with	O
population	O
norms,	O
both	O
groups	O
had	O
impaired	O
QOL	O
at	O
baseline.	O

Differences	B-Premise
in	I-Premise
mean	I-Premise
QOL	I-Premise
change	I-Premise
scores	I-Premise
from	I-Premise
baseline	I-Premise
to	I-Premise
study	I-Premise
end	I-Premise
for	I-Premise
epoetin	I-Premise
alfa	I-Premise
versus	I-Premise
BSC	I-Premise
were	I-Premise
3.17	I-Premise
points	I-Premise
for	I-Premise
the	I-Premise
FACT-General	I-Premise
Total,	I-Premise
9.90	I-Premise
for	I-Premise
the	I-Premise
FACT-An	I-Premise
Fatigue	I-Premise
subscale,	I-Premise
and	I-Premise
7.30	I-Premise
for	I-Premise
the	I-Premise
FACT-An	I-Premise
Anemia	I-Premise
subscale.	I-Premise

This	B-Premise
was	I-Premise
equivalent	I-Premise
to	I-Premise
corrections	I-Premise
in	I-Premise
QOL	I-Premise
deficits	I-Premise
attributable	I-Premise
to	I-Premise
epoetin	I-Premise
alfa	I-Premise
of	I-Premise
97.3%,	I-Premise
40.7%,	I-Premise
and	I-Premise
38.0%	I-Premise
for	I-Premise
the	I-Premise
FACT-General	I-Premise
Total,	I-Premise
FACT-An	I-Premise
Fatigue,	I-Premise
and	I-Premise
FACT-An	I-Premise
Anemia	I-Premise
subscale	I-Premise
scores,	I-Premise
respectively,	I-Premise
versus	I-Premise
BSC.	I-Premise

A	B-Premise
somewhat	I-Premise
greater	I-Premise
QOL	I-Premise
benefit	I-Premise
was	I-Premise
observed	I-Premise
for	I-Premise
the	I-Premise
FACT-An	I-Premise
Fatigue	I-Premise
and	I-Premise
FACT-An	I-Premise
Anemia	I-Premise
subscales	I-Premise
in	I-Premise
the	I-Premise
subset	I-Premise
of	I-Premise
patients	I-Premise
with	I-Premise
baseline	I-Premise
Hb	I-Premise
levels	I-Premise
>10.5	I-Premise
g/dl.	I-Premise

Patients	B-Premise
in	I-Premise
this	I-Premise
study	I-Premise
had	I-Premise
impaired	I-Premise
QOL	I-Premise
compared	I-Premise
with	I-Premise
population	I-Premise
norms.	I-Premise

Early	B-Claim
treatment	I-Claim
with	I-Claim
epoetin	I-Claim
alfa	I-Claim
to	I-Claim
correct	I-Claim
anemia	I-Claim
improved	I-Claim
QOL	I-Claim
in	I-Claim
a	I-Claim
statistically	I-Claim
significant	I-Claim
and	I-Claim
clinically	I-Claim
meaningful	I-Claim
way,	I-Claim
and	I-Claim
improvements	I-Claim
were	I-Claim
greater	I-Claim
in	I-Claim
patients	I-Claim
with	I-Claim
baseline	I-Claim
Hb	I-Claim
levels	I-Claim
>10.5	I-Claim
g/dl.	I-Claim

This	O
analysis	O
of	O
the	O
results	O
of	O
a	O
randomized,	O
controlled	O
trial	O
evaluating	O
the	O
effects	O
of	O
epoetin	O
alfa	O
(EPO)	O
therapy	O
on	O
transfusion	O
requirements,	O
hemoglobin	O
(Hb),	O
and	O
quality	O
of	O
life	O
(QOL)	O
in	O
patients	O
with	O
cancer	O
receiving	O
platinum-based	O
chemotherapy	O
was	O
conducted	O
to	O
evaluate	O
the	O
effect	O
of	O
initial	O
Hb	O
level	O
on	O
study	O
outcomes.	O

Patients	O
with	O
Hb	O
levels	O
<	O
or	O
=12.1	O
g/dl	O
were	O
randomized	O
2:1	O
to	O
receive	O
EPO,	O
10,000	O
U	O
three	O
times	O
weekly	O
s.c.	O
or	O
best	O
supportive	O
care	O
(BSC)	O
until	O
4	O
weeks	O
after	O
their	O
last	O
chemotherapy	O
cycle.	O

For	O
this	O
analysis,	O
patients	O
were	O
stratified	O
by	O
baseline	O
Hb	O
level	O
(<	O
or	O
=9.7	O
g/dl,	O
>9.7	O
g/dl	O
to	O
<	O
or	O
=10.5	O
g/dl,	O
>10.5	O
g/dl	O
to	O
<	O
or	O
=11.3	O
g/dl,	O
and	O
>11.3	O
g/dl	O
to	O
<	O
or	O
=12.1	O
g/dl),	O
and	O
study	O
results	O
were	O
reanalyzed.	O

Significantly	B-Premise
fewer	I-Premise
EPO	I-Premise
patients	I-Premise
than	I-Premise
BSC	I-Premise
patients	I-Premise
with	I-Premise
initial	I-Premise
Hb	I-Premise
levels	I-Premise
>9.7	I-Premise
g/dl	I-Premise
to	I-Premise
<	I-Premise
or	I-Premise
=12.1	I-Premise
g/dl	I-Premise
required	I-Premise
transfusions.	I-Premise

EPO	B-Premise
maintained	I-Premise
Hb	I-Premise
levels	I-Premise
throughout	I-Premise
the	I-Premise
study	I-Premise
for	I-Premise
patients	I-Premise
with	I-Premise
Hb	I-Premise
levels	I-Premise
>11.3	I-Premise
g/dl	I-Premise
to	I-Premise
<	I-Premise
or	I-Premise
=12.1	I-Premise
g/dl,	I-Premise
compared	I-Premise
with	I-Premise
a	I-Premise
decrease	I-Premise
with	I-Premise
BSC.	I-Premise

For	B-Premise
patients	I-Premise
with	I-Premise
baseline	I-Premise
Hb	I-Premise
levels	I-Premise
>10.5	I-Premise
g/dl,	I-Premise
for	I-Premise
whom	I-Premise
the	I-Premise
mean	I-Premise
changes	I-Premise
from	I-Premise
baseline	I-Premise
to	I-Premise
last	I-Premise
assessment	I-Premise
were	I-Premise
measured	I-Premise
by	I-Premise
the	I-Premise
Cancer	I-Premise
Linear	I-Premise
Analogue	I-Premise
Scale	I-Premise
assessments	I-Premise
of	I-Premise
energy	I-Premise
and	I-Premise
overall	I-Premise
QOL	I-Premise
as	I-Premise
well	I-Premise
as	I-Premise
by	I-Premise
the	I-Premise
Functional	I-Premise
Assessment	I-Premise
of	I-Premise
Cancer	I-Premise
Therapy	I-Premise
(FACT)-Fatigue	I-Premise
and	I-Premise
FACT-An	I-Premise
Anemia	I-Premise
subscale,	I-Premise
QOL	I-Premise
scores	I-Premise
were	I-Premise
significantly	I-Premise
greater	I-Premise
with	I-Premise
EPO	I-Premise
than	I-Premise
with	I-Premise
BSC.	I-Premise

QOL	B-Premise
declined	I-Premise
in	I-Premise
patients	I-Premise
receiving	I-Premise
BSC,	I-Premise
and	O
the	B-Premise
mean	I-Premise
decreases	I-Premise
in	I-Premise
QOL	I-Premise
scores	I-Premise
were	I-Premise
greater	I-Premise
for	I-Premise
BSC	I-Premise
patients	I-Premise
with	I-Premise
baseline	I-Premise
Hb	I-Premise
levels	I-Premise
>10.5	I-Premise
g/dl,	I-Premise
compared	I-Premise
with	I-Premise
the	I-Premise
overall	I-Premise
BSC	I-Premise
group.	I-Premise

In	B-Claim
patients	I-Claim
with	I-Claim
cancer	I-Claim
receiving	I-Claim
platinum-based	I-Claim
chemotherapy	I-Claim
and	I-Claim
with	I-Claim
baseline	I-Claim
Hb	I-Claim
levels	I-Claim
>10.5	I-Claim
g/dl,	I-Claim
early	I-Claim
intervention	I-Claim
with	I-Claim
EPO	I-Claim
reduces	I-Claim
transfusions,	I-Claim
maintains	I-Claim
Hb	I-Claim
level,	I-Claim
and	I-Claim
maintains	I-Claim
or	I-Claim
improves	I-Claim
QOL.	I-Claim

This	B-Claim
study	I-Claim
supports	I-Claim
the	I-Claim
positive	I-Claim
effects	I-Claim
of	I-Claim
early	I-Claim
intervention	I-Claim
when	I-Claim
analyzed	I-Claim
according	I-Claim
to	I-Claim
initial	I-Claim
Hb	I-Claim
value.	I-Claim

To	O
evaluate	O
the	O
difference	O
of	O
efficacy,	O
side-effects	O
and	O
quality	O
of	O
life	O
in	O
advanced	O
non-small-cell	O
lung	O
cancer	O
(NSCLC)	O
patients	O
treated	O
with	O
oxaliplatin	O
plus	O
vinorelbine	O
or	O
cisplatin	O
plus	O
vinorelbine.	O

Eligible	O
patients	O
were	O
randomly	O
assigned	O
to	O
NL	O
(oxaliplatin	O
+	O
vinorelbine)	O
group	O
and	O
NP	O
(cisplatin	O
+	O
vinorelbine)	O
group	O
in	O
a	O
2:1	O
ratio.	O

In	O
the	O
NL	O
group,	O
70	O
evaluable	O
cases	O
were	O
treated	O
with	O
oxaliplatin	O
130	O
mg/m(2)	O
i.v.	O
on	O
day	O
2,	O
and	O
vinorelbine	O
25	O
mg/m(2)	O
i.v.	O
on	O
days	O
1	O
and	O
8	O
in	O
21	O
days	O
per	O
cycle.	O

In	O
the	O
NP	O
group,	O
32	O
evaluable	O
cases	O
were	O
treated	O
with	O
cisplatin	O
80	O
mg/m(2)	O
i.v.	O
divided	O
to	O
2	O
-	O
3	O
days	O
dosing,	O
21	O
days	O
per	O
cycle,	O
and	O
vinorelbine	O
administered	O
by	O
the	O
same	O
way	O
as	O
in	O
the	O
NL	O
group.	O

The	O
response	O
rate,	O
time	O
to	O
progression	O
(TTP),	O
one-year	O
survival,	O
side-effects	O
and	O
the	O
quality	O
of	O
life	O
were	O
observed.	O

The	B-Premise
response	I-Premise
rate	I-Premise
was	I-Premise
35.7%	I-Premise
vs.	I-Premise
43.8%	I-Premise
(P	I-Premise
=	I-Premise
0.4),	I-Premise
median	I-Premise
TTP	I-Premise
was	I-Premise
4.7	I-Premise
months	I-Premise
vs.	I-Premise
5.5	I-Premise
months	I-Premise
(P	I-Premise
=	I-Premise
0.6),	I-Premise
one-year	I-Premise
survival	I-Premise
rate	I-Premise
was	I-Premise
38.5%	I-Premise
vs.	I-Premise
58.6%	I-Premise
(P	I-Premise
=	I-Premise
0.07)	I-Premise
in	I-Premise
the	I-Premise
NL	I-Premise
and	I-Premise
NP	I-Premise
groups,	I-Premise
respectively.	I-Premise

Grade	B-Premise
I-II	I-Premise
neuro-sensory	I-Premise
toxicity	I-Premise
occurred	I-Premise
significantly	I-Premise
more	I-Premise
frequent	I-Premise
in	I-Premise
NL	I-Premise
group	I-Premise
than	I-Premise
in	I-Premise
NP	I-Premise
group	I-Premise
(68.4%	I-Premise
vs.	I-Premise
36.4%,	I-Premise
P	I-Premise
=	I-Premise
0.0017).	I-Premise

However,	B-Premise
Grade	I-Premise
I-II	I-Premise
granulocytopenia	I-Premise
was	I-Premise
significantly	I-Premise
less	I-Premise
occurred	I-Premise
in	I-Premise
NL	I-Premise
group	I-Premise
than	I-Premise
in	I-Premise
NP	I-Premise
group	I-Premise
(49.4%	I-Premise
vs.	I-Premise
70.6%,	I-Premise
P	I-Premise
=	I-Premise
0.037).	I-Premise

There	B-Premise
was	I-Premise
no	I-Premise
statistically	I-Premise
difference	I-Premise
between	I-Premise
the	I-Premise
two	I-Premise
groups	I-Premise
regarding	I-Premise
quality	I-Premise
of	I-Premise
life.	I-Premise

Due	B-Claim
to	I-Claim
good	I-Claim
efficacy	I-Claim
and	I-Claim
tolerability,	I-Claim
the	I-Claim
NL	I-Claim
regimen	I-Claim
offered	I-Claim
a	I-Claim
new	I-Claim
candidate	I-Claim
for	I-Claim
treating	I-Claim
advanced	I-Claim
NSCLC.	I-Claim

The	B-MajorClaim
impact	I-MajorClaim
of	I-MajorClaim
prolonged	I-MajorClaim
subclinical	I-MajorClaim
hyperthyroidism	I-MajorClaim
on	I-MajorClaim
quality	I-MajorClaim
of	I-MajorClaim
life	I-MajorClaim
is	I-MajorClaim
unclear.	I-MajorClaim

Therefore,	O
we	O
evaluated	O
quality	O
of	O
life	O
in	O
patients	O
with	O
differentiated	O
thyroid	O
carcinoma	O
(DTC)	O
on	O
TSH-suppressive	O
thyroxine	O
therapy	O
as	O
a	O
model	O
for	O
subclinical	O
hyperthyroidism	O
and	O
we	O
investigated	O
whether	O
restoration	O
to	O
euthyroidism	O
affects	O
quality	O
of	O
life.	O

We	O
performed	O
a	O
prospective,	O
single-blinded,	O
placebo-controlled,	O
randomized	O
trial	O
of	O
6	O
months'	O
duration	O
with	O
two	O
parallel	O
groups.	O

Twenty-four	O
subjects	O
with	O
a	O
history	O
of	O
differentiated	O
thyroid	O
carcinoma	O
with	O
>	O
10	O
years	O
TSH-suppressive	O
therapy	O
with	O
L-thyroxine	O
completed	O
the	O
study.	O

L-thyroxine	O
dose	O
was	O
replaced	O
by	O
study	O
medication	O
containing	O
L-thyroxine	O
or	O
L-thyroxine	O
plus	O
placebo.	O

Medication	O
was	O
titrated	O
to	O
establish	O
continuation	O
of	O
TSH	O
suppression	O
(low-TSH	O
group)	O
and	O
euthyroidism	O
(euthyroid	O
group).	O

Both	O
groups	O
consisted	O
of	O
12	O
patients.	O

We	O
evaluated	O
quality	O
of	O
life	O
using	O
five	O
validated	O
questionnaires.	O

At	O
baseline,	O
the	O
somatic	O
disorder	O
questionnaire	O
(SDQ)	O
indicated	O
more	O
somatic	O
dysfunction	O
in	O
patients	O
as	O
compared	O
with	O
reference	O
values,	O
whereas	O
the	O
depression	O
score	O
(HADS)	O
revealed	O
a	O
better	O
score	O
than	O
the	O
reference	O
group.	O

All	O
other	O
quality	O
of	O
life	O
parameters	O
were	O
normal.	O

At	O
baseline,	O
no	O
significant	O
differences	O
between	O
the	O
low-TSH	O
and	O
the	O
euthyroidism	O
groups	O
were	O
observed.	O

After	B-Premise
6	I-Premise
months,	I-Premise
none	I-Premise
of	I-Premise
the	I-Premise
quality	I-Premise
of	I-Premise
life	I-Premise
parameters	I-Premise
in	I-Premise
the	I-Premise
low-TSH	I-Premise
group	I-Premise
was	I-Premise
different	I-Premise
from	I-Premise
baseline	I-Premise
values.	I-Premise

In	B-Premise
the	I-Premise
euthyroid	I-Premise
group,	I-Premise
motivation	I-Premise
was	I-Premise
significantly	I-Premise
improved	I-Premise
(Multidimensional	I-Premise
Fatigue	I-Premise
Index-20,	I-Premise
P	I-Premise
=	I-Premise
0.003),	I-Premise
although	B-Premise
this	I-Premise
parameter	I-Premise
did	I-Premise
not	I-Premise
differ	I-Premise
from	I-Premise
the	I-Premise
reference	I-Premise
group	I-Premise
at	I-Premise
baseline.	I-Premise

A	B-Premise
probable	I-Premise
worsening	I-Premise
in	I-Premise
role	I-Premise
limitations	I-Premise
as	I-Premise
a	I-Premise
result	I-Premise
of	I-Premise
physical	I-Premise
problems	I-Premise
(Short	I-Premise
Form-36;	I-Premise
P	I-Premise
=	I-Premise
0.050)	I-Premise
was	I-Premise
observed.	I-Premise

No	B-Premise
improvement	I-Premise
in	I-Premise
the	I-Premise
SDQ	I-Premise
score	I-Premise
was	I-Premise
observed.	I-Premise

In	B-Claim
summary,	I-Claim
quality	I-Claim
of	I-Claim
life	I-Claim
in	I-Claim
patients	I-Claim
with	I-Claim
DTC	I-Claim
and	I-Claim
long-term	I-Claim
subclinical	I-Claim
hyperthyroidism	I-Claim
in	I-Claim
general	I-Claim
is	I-Claim
preserved.	I-Claim

Restoration	B-Claim
of	I-Claim
euthyroidism	I-Claim
in	I-Claim
general	I-Claim
does	I-Claim
not	I-Claim
affect	I-Claim
quality	I-Claim
of	I-Claim
life.	I-Claim

For	B-MajorClaim
patients	I-MajorClaim
with	I-MajorClaim
advanced	I-MajorClaim
gastric	I-MajorClaim
or	I-MajorClaim
gastroesophageal	I-MajorClaim
cancer	I-MajorClaim
(AGGEC)	I-MajorClaim
providing	I-MajorClaim
clinical	I-MajorClaim
benefit	I-MajorClaim
with	I-MajorClaim
improved	I-MajorClaim
palliation	I-MajorClaim
is	I-MajorClaim
highly	I-MajorClaim
desirable.	I-MajorClaim

However,	O
a	O
prospective	O
evaluation	O
of	O
clinical	O
benefit	O
in	O
AGGEC	O
patients	O
has	O
never	O
before	O
been	O
reported	O
in	O
a	O
phase	O
III	O
setting.	O

In	O
a	O
multinational	O
trial	O
(V325),	O
445	O
patients	O
were	O
randomly	O
assigned	O
and	O
treated	O
with	O
either	O
docetaxel	O
plus	O
cisplatin	O
and	O
fluorouracil	O
(DCF)	O
or	O
cisplatin	O
and	O
fluorouracil	O
(CF).	O

Clinical	O
benefit	O
was	O
prospectively	O
evaluated	O
in	O
this	O
trial	O
as	O
a	O
secondary	O
end	O
point.	O

The	O
primary	O
measure	O
for	O
clinical	O
benefit	O
analysis	O
was	O
time	O
to	O
definitive	O
worsening	O
by	O
one	O
or	O
more	O
categories	O
of	O
Karnofsky	O
performance	O
status	O
(KPS).	O

Secondary	O
clinical	O
benefit	O
end	O
points	O
included	O
time	O
to	O
5%	O
definitive	O
weight	O
loss,	O
time	O
to	O
definitive	O
worsening	O
of	O
appetite	O
by	O
one	O
grade,	O
pain-free	O
survival	O
(defined	O
as	O
time	O
to	O
first	O
appearance	O
of	O
pain),	O
and	O
time	O
to	O
first	O
cancer	O
pain-related	O
opioid	O
intake.	O

Clinical	O
benefit	O
assessments	O
were	O
recorded	O
at	O
each	O
clinic	O
visit.	O

Clinical	O
benefit	O
assessments	O
were	O
performed	O
in	O
more	O
than	O
75%	O
of	O
patients	O
throughout	O
V325.	O

DCF	B-Premise
significantly	I-Premise
prolonged	I-Premise
time	I-Premise
to	I-Premise
definitive	I-Premise
worsening	I-Premise
of	I-Premise
KPS	I-Premise
compared	I-Premise
with	I-Premise
CF	I-Premise
(median,	I-Premise
6.1	I-Premise
v	I-Premise
4.8	I-Premise
months;	I-Premise
hazard	I-Premise
ratio,	I-Premise
1.38;	I-Premise
95%	I-Premise
CI,	I-Premise
1.08	I-Premise
to	I-Premise
1.76;	I-Premise
log-rank	I-Premise
P	I-Premise
=	I-Premise
.009).	I-Premise

Although	B-Premise
time	I-Premise
to	I-Premise
definitive	I-Premise
weight	I-Premise
loss	I-Premise
and	I-Premise
time	I-Premise
to	I-Premise
definitive	I-Premise
worsening	I-Premise
of	I-Premise
appetite	I-Premise
favored	I-Premise
DCF,	I-Premise
the	B-Premise
results	I-Premise
were	I-Premise
not	I-Premise
statistically	I-Premise
significant.	I-Premise

Pain-free	B-Premise
survival	I-Premise
and	I-Premise
time	I-Premise
to	I-Premise
first	I-Premise
cancer	I-Premise
pain-related	I-Premise
opioid	I-Premise
intake	I-Premise
were	I-Premise
comparable.	I-Premise

To	O
our	O
knowledge,	O
V325	O
is	O
the	O
first	O
phase	O
III	O
trial	O
to	O
report	O
clinical	O
benefit	O
in	O
AGGEC	O
patients.	O

Clinical	O
benefit	O
was	O
assessed	O
beyond	O
protocol-specific	O
chemotherapy.	O

The	B-Claim
addition	I-Claim
of	I-Claim
D	I-Claim
to	I-Claim
CF	I-Claim
not	I-Claim
only	I-Claim
significantly	I-Claim
improved	I-Claim
clinical	I-Claim
benefit	I-Claim
but	I-Claim
also	I-Claim
improved	I-Claim
quality	I-Claim
of	I-Claim
life,	I-Claim
time	I-Claim
to	I-Claim
progression,	I-Claim
and	I-Claim
overall	I-Claim
survival	I-Claim
compared	I-Claim
with	I-Claim
CF.	I-Claim

Somatostatin	O
analogs	O
are	O
indicated	O
for	O
symptom	O
control	O
in	O
patients	O
with	O
gastroenteropancreatic	O
neuroendocrine	O
tumors	O
(NETs).	O

The	O
ability	O
of	O
somatostatin	O
analogs	O
to	O
control	O
the	O
growth	O
of	O
well-differentiated	O
metastatic	O
NETs	O
is	O
a	O
matter	O
of	O
debate.	O

We	O
performed	O
a	O
placebo-controlled,	O
double-blind,	O
phase	O
IIIB	O
study	O
in	O
patients	O
with	O
well-differentiated	O
metastatic	O
midgut	O
NETs.	O

The	O
hypothesis	O
was	O
that	O
octreotide	O
LAR	O
prolongs	O
time	O
to	O
tumor	O
progression	O
and	O
survival.	O

Treatment-naive	O
patients	O
were	O
randomly	O
assigned	O
to	O
either	O
placebo	O
or	O
octreotide	O
LAR	O
30	O
mg	O
intramuscularly	O
in	O
monthly	O
intervals	O
until	O
tumor	O
progression	O
or	O
death.	O

The	O
primary	O
efficacy	O
end	O
point	O
was	O
time	O
to	O
tumor	O
progression.	O

Secondary	O
end	O
points	O
were	O
survival	O
time	O
and	O
tumor	O
response.	O

This	O
report	O
is	O
based	O
on	O
67	O
tumor	O
progressions	O
and	O
16	O
observed	O
deaths	O
in	O
85	O
patients	O
at	O
the	O
time	O
of	O
the	O
planned	O
interim	O
analysis.	O

Median	B-Premise
time	I-Premise
to	I-Premise
tumor	I-Premise
progression	I-Premise
in	I-Premise
the	I-Premise
octreotide	I-Premise
LAR	I-Premise
and	I-Premise
placebo	I-Premise
groups	I-Premise
was	I-Premise
14.3	I-Premise
and	I-Premise
6	I-Premise
months,	I-Premise
respectively	I-Premise
(hazard	I-Premise
ratio	I-Premise
[HR]	I-Premise
=	I-Premise
0.34;	I-Premise
95%	I-Premise
CI,	I-Premise
0.20	I-Premise
to	I-Premise
0.59;	I-Premise
P	I-Premise
=	I-Premise
.000072).	I-Premise

After	B-Premise
6	I-Premise
months	I-Premise
of	I-Premise
treatment,	I-Premise
stable	I-Premise
disease	I-Premise
was	I-Premise
observed	I-Premise
in	I-Premise
66.7%	I-Premise
of	I-Premise
patients	I-Premise
in	I-Premise
the	I-Premise
octreotide	I-Premise
LAR	I-Premise
group	I-Premise
and	I-Premise
37.2%	I-Premise
of	I-Premise
patients	I-Premise
in	I-Premise
the	I-Premise
placebo	I-Premise
group.	I-Premise

Functionally	O
active	O
and	O
inactive	O
tumors	O
responded	O
similarly.	O

The	B-Premise
most	I-Premise
favorable	I-Premise
effect	I-Premise
was	I-Premise
observed	I-Premise
in	I-Premise
patients	I-Premise
with	I-Premise
low	I-Premise
hepatic	I-Premise
tumor	I-Premise
load	I-Premise
and	I-Premise
resected	I-Premise
primary	I-Premise
tumor.	I-Premise

Seven	B-Premise
and	I-Premise
nine	I-Premise
deaths	I-Premise
were	I-Premise
observed	I-Premise
in	I-Premise
the	I-Premise
octreotide	I-Premise
LAR	I-Premise
and	I-Premise
placebo	I-Premise
groups,	I-Premise
respectively.	I-Premise

The	B-Premise
HR	I-Premise
for	I-Premise
overall	I-Premise
survival	I-Premise
was	I-Premise
0.81	I-Premise
(95%	I-Premise
CI,	I-Premise
0.30	I-Premise
to	I-Premise
2.18).	I-Premise

Octreotide	B-Claim
LAR	I-Claim
significantly	I-Claim
lengthens	I-Claim
time	I-Claim
to	I-Claim
tumor	I-Claim
progression	I-Claim
compared	I-Claim
with	I-Claim
placebo	I-Claim
in	I-Claim
patients	I-Claim
with	I-Claim
functionally	I-Claim
active	I-Claim
and	I-Claim
inactive	I-Claim
metastatic	I-Claim
midgut	I-Claim
NETs.	I-Claim

Because	B-Premise
of	I-Premise
the	I-Premise
low	I-Premise
number	I-Premise
of	I-Premise
observed	I-Premise
deaths,	I-Premise
survival	I-Premise
analysis	I-Premise
was	I-Premise
not	I-Premise
confirmatory.	I-Premise

To	O
evaluate	O
the	O
combination	O
of	O
the	O
gastrin	O
antagonist	O
Z-360	O
and	O
gemcitabine	O
for	O
advanced	O
pancreatic	O
cancer.	O

Previously	O
untreated	O
patients	O
with	O
PC	O
were	O
randomly	O
allocated	O
to	O
Z-360	O
120	O
mg,	O
240	O
mg	O
or	O
placebo.	O

Z-360/placebo	O
was	O
given	O
on	O
day	O
-3	O
and	O
gemcitabine	O
1000	O
mg/m(2)	O
commenced	O
on	O
day	O
1	O
followed	O
by	O
Z-360	O
on	O
day	O
2.	O

Thereafter	O
Z-360/placebo	O
was	O
given	O
twice	O
daily	O
concurrently	O
with	O
standard	O
dose	O
of	O
gemcitabine.	O

Pharmacokinetics	O
for	O
both	O
drugs	O
was	O
measured	O
alone	O
and	O
in	O
combination.	O

Toxicity,	O
response	O
and	O
quality	O
of	O
life	O
were	O
also	O
recorded.	O

Thirty-three	O
patients	O
with	O
a	O
median	O
age	O
of	O
62	O
years	O
were	O
randomised	O
of	O
which	O
six	O
had	O
locally	O
advanced	O
disease	O
and	O
26	O
had	O
metastatic	O
disease.	O

Analysis	O
of	O
the	O
area	O
under	O
the	O
plasma	O
concentration	O
versus	O
time	O
curve	O
(AUC),	O
the	O
maximum	O
observed	O
concentration	O
(Cmax(obs))	O
and	O
the	O
time	O
of	O
the	O
maximum	O
observed	O
concentration	O
(Tmax(obs))	O
for	O
Z-360,	O
gemcitabine	O
and	O
2,2-difluorodeoxyuridine	O
(dFdU),	O
could	O
not	O
exclude	O
an	O
effect	O
on	O
the	O
systemic	O
exposure	O
to	O
Z-360,	O
gemcitabine	O
and	O
dFdU	O
when	O
co-administration	O
of	O
Z-360	O
and	O
gemcitabine	O
was	O
compared	O
with	O
single	O
agent	O
administration.	O

The	B-Premise
most	I-Premise
commonly	I-Premise
reported	I-Premise
adverse	I-Premise
events	I-Premise
were	I-Premise
nausea,	I-Premise
abdominal	I-Premise
pain,	I-Premise
vomiting	I-Premise
and	I-Premise
fatigue.	I-Premise

At	B-Premise
the	I-Premise
end	I-Premise
of	I-Premise
the	I-Premise
study,	I-Premise
62.5%,	I-Premise
25%	I-Premise
and	I-Premise
60%	I-Premise
had	I-Premise
stable	I-Premise
disease	I-Premise
in	I-Premise
the	I-Premise
120	I-Premise
mg,	I-Premise
240	I-Premise
mg	I-Premise
and	I-Premise
placebo	I-Premise
group,	I-Premise
respectively.	I-Premise

A	B-Premise
higher	I-Premise
proportion	I-Premise
of	I-Premise
patients	I-Premise
in	I-Premise
Z-360	I-Premise
groups	I-Premise
reported	I-Premise
improvement	I-Premise
in	I-Premise
pain.	I-Premise

Z-360	B-Claim
is	I-Claim
safe	I-Claim
and	I-Claim
well	I-Claim
tolerated	I-Claim
when	I-Claim
combined	I-Claim
with	I-Claim
gemcitabine.	I-Claim

A	O
Phase	O
III	O
trial	O
is	O
needed	O
to	O
determine	O
whether	O
the	O
combination	O
of	O
Z-360	O
and	O
gemcitabine	O
is	O
superior	O
to	O
gemcitabine	O
alone	O
in	O
advanced	O
PC.	O

Restoring	O
sensory	O
innervation	O
may	O
be	O
a	O
useful	O
adjunct	O
in	O
free	O
flap	O
head	O
and	O
neck	O
reconstruction	O
but,	O
as	O
yet,	O
has	O
not	O
been	O
shown	O
to	O
improve	O
outcomes	O
of	O
breast	O
reconstruction.	O

The	O
authors'	O
previous	O
study	O
demonstrated	O
objectively	O
improved	O
sensation	O
in	O
a	O
group	O
of	O
innervated	O
transverse	O
rectus	O
abdominis	O
musculocutaneous	O
(TRAM)	O
flap	O
breast	O
reconstruction	O
patients	O
relative	O
to	O
noninnervated	O
flaps.	O

This	O
study	O
compared	O
patient-rated	O
outcomes	O
of	O
free	O
TRAM	O
breast	O
reconstruction	O
in	O
innervated	O
versus	O
noninnervated	O
flaps.	O

Twenty-seven	O
women	O
were	O
randomized	O
prospectively	O
to	O
undergo	O
either	O
innervated	O
or	O
noninnervated	O
free	O
TRAM	O
flap	O
breast	O
reconstruction.	O

For	O
innervated	O
flaps,	O
the	O
T10	O
intercostal	O
nerve	O
was	O
harvested	O
with	O
the	O
TRAM	O
flap	O
and	O
neurotized	O
to	O
the	O
T4	O
sensory	O
nerve	O
at	O
the	O
recipient	O
site.	O

Three	O
validated	O
outcome	O
tools	O
were	O
administered	O
after	O
surgery:	O
the	O
Medical	O
Outcomes	O
Study	O
36-Item	O
Short	O
Form	O
Health	O
Survey,	O
the	O
Body	O
Image	O
after	O
Breast	O
Cancer	O
Questionnaire,	O
and	O
the	O
Functional	O
Assessment	O
of	O
Cancer	O
Therapy-Breast.	O

Results	B-Premise
were	I-Premise
correlated	I-Premise
with	I-Premise
previously	I-Premise
reported	I-Premise
objective	I-Premise
sensibility	I-Premise
outcomes.	I-Premise

Eighteen	O
of	O
27	O
women	O
returned	O
their	O
questionnaires	O
a	O
mean	O
48	O
months	O
after	O
free	O
TRAM	O
flap	O
reconstruction.	O

Demographic	O
analysis	O
revealed	O
no	O
significant	O
differences	O
in	O
patient	O
age,	O
height,	O
smoking,	O
radiation	O
therapy,	O
and	O
nipple-areola	O
complex	O
reconstruction	O
between	O
randomized	O
patient	O
groups.	O

There	B-Premise
was	I-Premise
a	I-Premise
statistically	I-Premise
significant	I-Premise
improvement	I-Premise
in	I-Premise
all	I-Premise
three	I-Premise
measures	I-Premise
in	I-Premise
patients	I-Premise
who	I-Premise
were	I-Premise
randomized	I-Premise
to	I-Premise
receive	I-Premise
innervated	I-Premise
free	I-Premise
TRAM	I-Premise
flaps	I-Premise
compared	I-Premise
with	I-Premise
those	I-Premise
receiving	I-Premise
noninnervated	I-Premise
flaps.	I-Premise

This	B-Claim
study	I-Claim
demonstrates	I-Claim
that	I-Claim
innervation	I-Claim
of	I-Claim
free	I-Claim
TRAM	I-Claim
flaps	I-Claim
used	I-Claim
for	I-Claim
breast	I-Claim
reconstruction	I-Claim
not	I-Claim
only	I-Claim
improves	I-Claim
sensibility	I-Claim
but	I-Claim
also	I-Claim
has	I-Claim
a	I-Claim
positive	I-Claim
effect	I-Claim
on	I-Claim
patient-rated	I-Claim
quality	I-Claim
of	I-Claim
life.	I-Claim

To	O
assess	O
toxicities,	O
functional	O
outcomes,	O
and	O
health-related	O
quality	O
of	O
life	O
associated	O
with	O
concurrent	O
chemoradiation	O
therapy	O
(CRT)	O
in	O
patients	O
with	O
head	O
and	O
neck	O
cancer.	O

Prospective	O
and	O
retrospective	O
outcomes	O
study.	O

Tertiary	O
care	O
institution.	O

Participants	O
in	O
the	O
longitudinal	O
Outcomes	O
Assessment	O
Project	O
whose	O
head	O
and	O
neck	O
cancer	O
was	O
treated	O
with	O
CRT	O
between	O
February	O
1,	O
2000,	O
and	O
March	O
1,	O
2007	O
(n	O
=	O
104).	O

Patients	O
prospectively	O
provided	O
functional	O
and	O
health-related	O
quality	O
of	O
life	O
information,	O
including	O
data	O
from	O
the	O
1-year	O
and	O
most	O
current	O
follow-up	O
visits.	O

Medical	O
records	O
were	O
reviewed	O
to	O
determine	O
toxicity	O
and	O
survival	O
rates.	O

Well-defined	O
acute	O
and	O
late	O
toxicities;	O
functional	O
outcomes	O
(diet,	O
dentition,	O
tracheostomies);	O
head	O
and	O
neck	O
cancer-specific,	O
general	O
health,	O
and	O
depression	O
outcomes;	O
and	O
survival	O
rates.	O

Most	O
patients	O
had	O
oropharyngeal	O
or	O
laryngeal	O
tumors	O
(87.5%)	O
and	O
advanced-stage	O
disease	O
(75.0%).	O

Approximately	B-Premise
one-half	I-Premise
had	I-Premise
hematologic	I-Premise
toxicities	I-Premise
and	I-Premise
toxicity-related	I-Premise
treatment	I-Premise
delays.	I-Premise

Approximately	B-Premise
one-quarter	I-Premise
had	I-Premise
neurotoxicities	I-Premise
and/or	I-Premise
ototoxicites,	I-Premise
moist	I-Premise
desquamation,	I-Premise
pneumonia,	I-Premise
nausea	I-Premise
and	I-Premise
vomiting	I-Premise
requiring	I-Premise
hospitalization	I-Premise
or	I-Premise
intravenous	I-Premise
fluids,	I-Premise
dehydration	I-Premise
or	I-Premise
malnutrition	I-Premise
requiring	I-Premise
hospitalization,	I-Premise
and	I-Premise
mild	I-Premise
or	I-Premise
moderate	I-Premise
fever.	I-Premise

Although	B-Premise
patients	I-Premise
receiving	I-Premise
the	I-Premise
current	I-Premise
intensity-modulated	I-Premise
radiation	I-Premise
therapy	I-Premise
(IMRT)	I-Premise
protocol	I-Premise
using	I-Premise
the	I-Premise
Pinnacle(3)	I-Premise
planning	I-Premise
system	I-Premise
had	I-Premise
more	I-Premise
toxicity-related	I-Premise
treatment	I-Premise
delays,	I-Premise
they	B-Premise
had	I-Premise
fewer	I-Premise
toxicities	I-Premise
and	I-Premise
better	I-Premise
functional	I-Premise
and	I-Premise
health-related	I-Premise
quality	I-Premise
of	I-Premise
life	I-Premise
outcomes	I-Premise
compared	I-Premise
with	I-Premise
those	I-Premise
receiving	I-Premise
conventional	I-Premise
lateral	I-Premise
opposing-field	I-Premise
radiation	I-Premise
or	I-Premise
the	I-Premise
initial	I-Premise
IMRT	I-Premise
protocol	I-Premise
using	I-Premise
the	I-Premise
Best	I-Premise
nomos	I-Premise
PEACOCK	I-Premise
planning	I-Premise
system.	I-Premise

Patients	B-Claim
receiving	I-Claim
CRT	I-Claim
experience	I-Claim
a	I-Claim
substantial	I-Claim
number	I-Claim
of	I-Claim
treatment-related	I-Claim
adverse	I-Claim
events,	I-Claim
primarily	I-Claim
affecting	I-Claim
oropharyngeal	I-Claim
and	I-Claim
laryngeal	I-Claim
function,	I-Claim
with	I-Claim
improvement	I-Claim
noted	I-Claim
for	I-Claim
the	I-Claim
current	I-Claim
IMRT	I-Claim
protocol.	I-Claim

Improving	O
dental	O
prosthetic	O
rehabilitation	O
and	O
including	O
evaluations	O
with	O
speech	O
and	O
swallowing	O
pathologists	O
before	O
and	O
during	O
treatment	O
may	O
enhance	O
patient	O
outcomes.	O

Despite	O
improvements	O
in	O
surgical	O
techniques,	O
urinary	O
incontinence	O
(UI)	O
is	O
not	O
uncommon	O
after	O
radical	O
prostatectomy	O
(RP),	O
and	O
it	O
may	O
dramatically	O
worsen	O
quality	O
of	O
life	O
(QoL).	O

To	O
determine	O
the	O
benefit	O
of	O
starting	O
pelvic	O
floor	O
muscle	O
exercise	O
(PFME)	O
30d	O
before	O
RP	O
and	O
of	O
continuing	O
PFME	O
postoperatively	O
for	O
early	O
recovery	O
of	O
continence.	O

A	O
randomised,	O
prospective	O
study	O
was	O
designed.	O

Men	O
with	O
localised	O
prostate	O
cancer	O
(PCa)	O
who	O
underwent	O
an	O
open	O
radical	O
retropubic	O
prostatectomy	O
(RRP)	O
at	O
our	O
department	O
of	O
urology	O
were	O
included.	O

Patients	O
were	O
randomised	O
to	O
start	O
PFME	O
preoperatively	O
and	O
continue	O
postoperatively	O
(active	O
group:	O
A)	O
or	O
to	O
start	O
PFME	O
postoperatively	O
alone	O
(control	O
group:	O
B).	O

The	O
primary	O
outcome	O
measure	O
was	O
self-reported	O
continence	O
after	O
surgery.	O

Secondary	O
outcome	O
measures	O
were	O
assessed	O
by	O
degree	O
of	O
UI	O
based	O
on	O
a	O
24-h	O
pad	O
test	O
and	O
QoL	O
instruments	O
(International	O
Continence	O
Society	O
[ICS]	O
male	O
short	O
form	O
[SF]).	O

Of	O
143	O
men	O
evaluated	O
for	O
the	O
study,	O
118	O
were	O
randomised	O
either	O
to	O
start	O
PFME	O
preoperatively	O
and	O
continue	O
postoperatively	O
(group	O
A;	O
n=59)	O
or	O
to	O
start	O
postoperative	O
PFME	O
(group	O
B;	O
n=59).	O

After	B-Premise
1	I-Premise
mo,	I-Premise
44.1%	I-Premise
(26	I-Premise
of	I-Premise
59)	I-Premise
of	I-Premise
patients	I-Premise
were	I-Premise
continent	I-Premise
in	I-Premise
group	I-Premise
A,	I-Premise
while	I-Premise
20.3%	I-Premise
(12	I-Premise
of	I-Premise
59)	I-Premise
were	I-Premise
continent	I-Premise
in	I-Premise
group	I-Premise
B	I-Premise
(p=0.018).	I-Premise

At	B-Premise
3	I-Premise
mo,	I-Premise
59.3%	I-Premise
(35	I-Premise
of	I-Premise
59)	I-Premise
and	I-Premise
37.3%	I-Premise
(22	I-Premise
of	I-Premise
59)	I-Premise
patients	I-Premise
were	I-Premise
continent	I-Premise
in	I-Premise
group	I-Premise
A	I-Premise
and	I-Premise
group	I-Premise
B,	I-Premise
respectively	I-Premise
(p=0.028).	I-Premise

The	B-Premise
ICS	I-Premise
male	I-Premise
SF	I-Premise
mean	I-Premise
score	I-Premise
showed	I-Premise
better	I-Premise
results	I-Premise
in	I-Premise
group	I-Premise
A	I-Premise
than	I-Premise
in	I-Premise
group	I-Premise
B	I-Premise
patients	I-Premise
at	I-Premise
both	I-Premise
1	I-Premise
mo	I-Premise
(14.6	I-Premise
vs	I-Premise
18.3)	I-Premise
and	I-Premise
3	I-Premise
mo	I-Premise
(8.1	I-Premise
vs	I-Premise
12.2)	I-Premise
after	I-Premise
RP	I-Premise
(p=0.002).	I-Premise

In	B-Premise
age-adjusted	I-Premise
logistic	I-Premise
regression	I-Premise
analyses,	I-Premise
patients	I-Premise
who	I-Premise
performed	I-Premise
preoperative	I-Premise
PFME	I-Premise
had	I-Premise
a	I-Premise
0.41-fold	I-Premise
lower	I-Premise
risk	I-Premise
of	I-Premise
being	I-Premise
incontinent	I-Premise
1	I-Premise
mo	I-Premise
after	I-Premise
RP	I-Premise
and	I-Premise
a	I-Premise
0.38-fold	I-Premise
lower	I-Premise
risk	I-Premise
of	I-Premise
being	I-Premise
incontinent	I-Premise
3	I-Premise
mo	I-Premise
after	I-Premise
RP	I-Premise
(pâ¤0.001).	I-Premise

Preoperative	B-Claim
PFME	I-Claim
may	I-Claim
improve	I-Claim
early	I-Claim
continence	I-Claim
and	I-Claim
QoL	I-Claim
outcomes	I-Claim
after	I-Claim
RP.	I-Claim

Further	B-Claim
studies	I-Claim
are	I-Claim
needed	I-Claim
to	I-Claim
corroborate	I-Claim
our	I-Claim
results.	I-Claim

In	O
anorectal	O
cancer	O
patients,	O
an	O
acute	O
side	O
effect	O
of	O
chemoradiotherapy	O
is	O
gastrointestinal	O
toxicity,	O
which	O
often	O
impedes	O
treatment	O
delivery.	O

Based	O
on	O
previous	O
trials,	O
octreotide	O
acetate	O
is	O
widely	O
recommended	O
for	O
the	O
control	O
of	O
chemotherapy-induced	O
diarrhea.	O

However,	O
the	O
effectiveness	O
of	O
octreotide	O
in	O
preventing	O
or	O
controlling	O
radiation-	O
and	O
chemoradiation-induced	O
diarrhea	O
is	O
not	O
known.	O

A	O
randomized,	O
double-blinded,	O
placebo-controlled	O
trial	O
was	O
designed	O
to	O
determine	O
the	O
efficacy	O
of	O
long-acting	O
octreotide	O
acetate	O
(LAO)	O
in	O
preventing	O
the	O
onset	O
of	O
acute	O
diarrhea	O
in	O
patients	O
undergoing	O
chemoradiation	O
therapy	O
for	O
rectal	O
or	O
anal	O
cancer.	O

Between	O
4	O
and	O
7	O
days	O
before	O
the	O
start	O
of	O
radiation	O
therapy,	O
patients	O
received	O
a	O
30-mg	O
dose	O
of	O
LAO	O
(109	O
patients)	O
or	O
placebo	O
(106	O
patients)	O
via	O
intramuscular	O
injection.	O

A	O
second	O
dose	O
was	O
given	O
on	O
day	O
22	O
(+/-3	O
days)	O
of	O
radiation	O
treatment.	O

A	O
total	O
of	O
215	O
patients	O
were	O
included	O
in	O
the	O
final	O
analysis.	O

The	O
primary	O
endpoint	O
was	O
the	O
incidence	O
of	O
grade	O
2-4	O
acute	O
diarrhea;	O
secondary	O
endpoints	O
included	O
treatment	O
compliance,	O
medical	O
resource	O
utilization,	O
patient-reported	O
bowel	O
function,	O
and	O
quality	O
of	O
life	O
(QoL).	O

Statistical	O
tests	O
were	O
one-	O
or	O
two-sided,	O
as	O
specified.	O

After	B-Premise
a	I-Premise
median	I-Premise
follow-up	I-Premise
time	I-Premise
of	I-Premise
9.64	I-Premise
months,	I-Premise
incidence	I-Premise
rates	I-Premise
of	I-Premise
grades	I-Premise
2-4	I-Premise
acute	I-Premise
diarrhea	I-Premise
were	I-Premise
similar	I-Premise
in	I-Premise
both	I-Premise
groups	I-Premise
(49%	I-Premise
placebo	I-Premise
vs	I-Premise
44%	I-Premise
LAO;	I-Premise
P	I-Premise
=	I-Premise
.21).	I-Premise

No	B-Premise
statistically	I-Premise
significant	I-Premise
treatment	I-Premise
differences	I-Premise
in	I-Premise
chemotherapy	I-Premise
or	I-Premise
radiation	I-Premise
delivery,	I-Premise
medical	I-Premise
resource	I-Premise
utilization,	I-Premise
patient-reported	I-Premise
bowel	I-Premise
function,	I-Premise
or	I-Premise
QoL	I-Premise
were	I-Premise
observed.	I-Premise

In	B-Claim
this	I-Claim
study,	I-Claim
the	I-Claim
prophylactic	I-Claim
use	I-Claim
of	I-Claim
LAO	I-Claim
did	I-Claim
not	I-Claim
prevent	I-Claim
the	I-Claim
incidence	I-Claim
or	I-Claim
reduce	I-Claim
the	I-Claim
severity	I-Claim
of	I-Claim
diarrhea	I-Claim
and	I-Claim
had	I-Claim
no	I-Claim
notable	I-Claim
impact	I-Claim
on	I-Claim
patient-reported	I-Claim
bowel	I-Claim
function	I-Claim
or	I-Claim
QoL.	I-Claim

To	O
compare	O
vinflunine	O
(VFL)	O
to	O
docetaxel	O
in	O
patients	O
with	O
stage	O
IIIB/IV	O
non-small-cell	O
lung	O
cancer	O
(NSCLC)	O
who	O
have	O
experienced	O
treatment	O
failure	O
with	O
first-line	O
platinum-based	O
chemotherapy.	O

Randomized,	O
multicenter,	O
phase	O
III	O
study,	O
551	O
patients	O
received	O
either	O
vinflunine	O
320	O
mg/m(2)	O
or	O
docetaxel	O
75	O
mg/m(2)	O
every	O
21	O
days	O
until	O
disease	O
progression	O
or	O
serious	O
toxicity.	O

The	O
primary	O
end	O
point	O
was	O
progression-free	O
survival	O
(PFS).	O

The	O
noninferiority	O
analysis	O
was	O
based	O
on	O
a	O
10%	O
difference	O
(types	O
I/II	O
error	O
rates:	O
5%/20%).	O

Secondary	O
end	O
points	O
included	O
response	O
rate	O
(ORR),	O
response	O
duration,	O
overall	O
survival	O
(OS),	O
clinical	O
benefit,	O
quality	O
of	O
life	O
(QOL),	O
and	O
safety.	O

Median	B-Premise
PFS	I-Premise
was	I-Premise
2.3	I-Premise
months	I-Premise
for	I-Premise
each	I-Premise
arm	I-Premise
(HR,	I-Premise
1.004;	I-Premise
95%	I-Premise
CI,	I-Premise
0.841	I-Premise
to	I-Premise
1.199).	I-Premise

ORR,	B-Premise
stable	I-Premise
disease,	I-Premise
median	I-Premise
OS,	I-Premise
were	I-Premise
4.4%	I-Premise
versus	I-Premise
5.5%,	I-Premise
36.0%	I-Premise
versus	I-Premise
39.6%,	I-Premise
6.7	I-Premise
versus	I-Premise
7.2	I-Premise
months	I-Premise
(HR,	I-Premise
0.973;	I-Premise
95%	I-Premise
CI,	I-Premise
0.805	I-Premise
to	I-Premise
1.176),	I-Premise
respectively.	I-Premise

No	B-Premise
significant	I-Premise
difference	I-Premise
in	I-Premise
patient	I-Premise
benefit	I-Premise
and	I-Premise
QOL	I-Premise
(Functional	I-Premise
Assessment	I-Premise
of	I-Premise
Cancer	I-Premise
Therapy-Lung).	I-Premise

No	B-Premise
unexpected	I-Premise
adverse	I-Premise
events	I-Premise
were	I-Premise
observed.	I-Premise

Grade	B-Premise
higher	I-Premise
than	I-Premise
0	I-Premise
(vinflunine	I-Premise
v	I-Premise
docetaxel)	I-Premise
anemia	I-Premise
(82.1%	I-Premise
v	I-Premise
79.8%),	I-Premise
neutropenia	I-Premise
(49.3	I-Premise
v	I-Premise
39.02%),	I-Premise
thrombocytopenia	I-Premise
(30.6%	I-Premise
v	I-Premise
14.3%),	I-Premise
febrile	I-Premise
neutropenia	I-Premise
(3.3%	I-Premise
v	I-Premise
4.7%),	I-Premise
constipation	I-Premise
(39.2%	I-Premise
v	I-Premise
11.7%),	I-Premise
fatigue	I-Premise
(36.6%	I-Premise
v	I-Premise
33.9%),	I-Premise
injection	I-Premise
site	I-Premise
reaction	I-Premise
(31.9%	I-Premise
v	I-Premise
0.7%),	I-Premise
nausea	I-Premise
(26.7%	I-Premise
v	I-Premise
23.7%),	I-Premise
vomiting	I-Premise
(23.8%	I-Premise
v	I-Premise
14.2%),	I-Premise
alopecia	I-Premise
(19.8%	I-Premise
v	I-Premise
35.4%),	I-Premise
stomatis	I-Premise
(19.4%	I-Premise
v	I-Premise
12.4%),	I-Premise
abdominal	I-Premise
pain	I-Premise
(20.1%	I-Premise
v	I-Premise
3.6%),	I-Premise
myalgia	I-Premise
(14.7%	I-Premise
v	I-Premise
6.6%),	I-Premise
peripheral	I-Premise
neuropathy	I-Premise
(10.7%	I-Premise
v	I-Premise
15.0%),	I-Premise
arthralgia	I-Premise
(7.0%	I-Premise
v	I-Premise
7.7%),	I-Premise
diarrhea	I-Premise
(6.2%	I-Premise
v	I-Premise
12.4%),	I-Premise
edema	I-Premise
(1.5%	I-Premise
v	I-Premise
5.4%),	I-Premise
and	I-Premise
nail	I-Premise
disorders	I-Premise
(1.1%	I-Premise
v	I-Premise
5;1%)	I-Premise
were	I-Premise
observed.	I-Premise

This	B-Claim
noninferiority	I-Claim
phase	I-Claim
III	I-Claim
study	I-Claim
showed	I-Claim
similar	I-Claim
efficacy	I-Claim
end	I-Claim
points	I-Claim
for	I-Claim
vinflunine	I-Claim
and	I-Claim
docetaxel.	I-Claim

Despite	B-Claim
higher	I-Claim
rates	I-Claim
of	I-Claim
some	I-Claim
adverse	I-Claim
effects	I-Claim
(anemia,	I-Claim
abdominal	I-Claim
pain,	I-Claim
constipation,	I-Claim
fatigue)	I-Claim
the	B-Claim
overall	I-Claim
toxicity	I-Claim
profile	I-Claim
of	I-Claim
vinflunine	I-Claim
was	I-Claim
manageable.	I-Claim

Therefore,	O
VFL	B-MajorClaim
may	I-MajorClaim
be	I-MajorClaim
another	I-MajorClaim
option	I-MajorClaim
in	I-MajorClaim
the	I-MajorClaim
second-line	I-MajorClaim
treatment	I-MajorClaim
of	I-MajorClaim
patients	I-MajorClaim
with	I-MajorClaim
advanced	I-MajorClaim
NSCLC.	I-MajorClaim

A	O
significant	O
proportion	O
of	O
patients	O
develop	O
urinary	O
incontinence	O
early	O
after	O
radical	O
prostatectomy.	O

Posterior	O
reconstruction	O
of	O
supporting	O
tissues	O
has	O
been	O
found	O
to	O
reduce	O
incontinence	O
in	O
open	O
and	O
conventional	O
laparoscopic	O
prostatectomy	O
series.	O

To	O
investigate	O
whether	O
our	O
version	O
of	O
a	O
posterior	O
musculofascial	O
reconstruction	O
will	O
reduce	O
early	O
incontinence	O
and	O
have	O
a	O
beneficial	O
effect	O
on	O
patients'	O
quality	O
of	O
life	O
(QoL).	O

One	O
hundred	O
seven	O
consecutive	O
patients	O
undergoing	O
primary	O
robot-assisted	O
radical	O
laparoscopic	O
prostatectomy	O
(RALP)	O
performed	O
by	O
a	O
single	O
surgeon	O
at	O
one	O
tertiary	O
referral	O
oncology	O
institution	O
were	O
alternately	O
assigned	O
(not	O
randomised)	O
to	O
intervention	O
(n=53)	O
or	O
control	O
groups	O
(n=54).	O

RALP	O
with	O
median	O
fibrous	O
raphe	O
reconstruction	O
(MFRR)	O
followed	O
by	O
formation	O
of	O
the	O
urethrovesical	O
anastomosis	O
(intervention	O
group)	O
versus	O
standard	O
anastomosis	O
without	O
posterior	O
reconstruction	O
(control	O
group).	O

Measurements	O
included	O
incontinence	O
at	O
baseline	O
and	O
3-mo	O
intervals;	O
QoL	O
as	O
measured	O
by	O
a	O
simple	O
questionnaire,	O
the	O
European	O
Organisation	O
for	O
Research	O
and	O
Treatment	O
of	O
Cancer	O
(EORTC)	O
Quality	O
of	O
Life-Core	O
30	O
(QLQ-C30),	O
and	O
Prostate	O
Cancer	O
Module	O
(PR25)	O
questionnaires	O
preoperatively	O
and	O
at	O
6	O
mo	O
postprocedure;	O
tumour	O
characteristics;	O
operative	O
time;	O
fascial	O
preservation	O
score;	O
duration	O
of	O
catheterisation;	O
and	O
anastomotic	O
leakage	O
on	O
cystogram.	O

For	B-Premise
intervention	I-Premise
and	I-Premise
control	I-Premise
groups	I-Premise
respectively,	I-Premise
mean	I-Premise
catheter	I-Premise
duration	I-Premise
was	I-Premise
11.74	I-Premise
d	I-Premise
and	I-Premise
12.74	I-Premise
d	I-Premise
(p=0.451);	I-Premise
leakage	I-Premise
on	I-Premise
cystogram	I-Premise
was	I-Premise
present	I-Premise
in	I-Premise
six	I-Premise
and	I-Premise
eight	I-Premise
cases	I-Premise
(p=0.28);	I-Premise
and	I-Premise
incontinence	I-Premise
(any	I-Premise
involuntary	I-Premise
urine	I-Premise
loss)	I-Premise
at	I-Premise
3	I-Premise
mo	I-Premise
was	I-Premise
75%	I-Premise
and	I-Premise
69%	I-Premise
(p=0.391)	I-Premise
and	I-Premise
at	I-Premise
6	I-Premise
mo	I-Premise
was	I-Premise
51%	I-Premise
and	I-Premise
43%	I-Premise
(p=0.686).	I-Premise

Urinary	B-Premise
retention	I-Premise
occurred	I-Premise
only	I-Premise
in	I-Premise
one	I-Premise
case	I-Premise
(control	I-Premise
group).	I-Premise

The	B-Premise
percentage	I-Premise
of	I-Premise
cases	I-Premise
returning	I-Premise
to	I-Premise
baseline	I-Premise
in	I-Premise
all	I-Premise
QoL	I-Premise
domains	I-Premise
(except	I-Premise
insomnia)	I-Premise
was	I-Premise
similar	I-Premise
at	I-Premise
6	I-Premise
mo	I-Premise
between	I-Premise
the	I-Premise
two	I-Premise
groups.	I-Premise

Short	B-Premise
follow-up,	I-Premise
lack	I-Premise
of	I-Premise
blinding,	I-Premise
and	I-Premise
probable	I-Premise
small	I-Premise
differences	I-Premise
in	I-Premise
our	I-Premise
method	I-Premise
of	I-Premise
MFRR	I-Premise
performed	I-Premise
compared	I-Premise
with	I-Premise
other	I-Premise
studies	I-Premise
were	I-Premise
identified	I-Premise
as	I-Premise
significant	I-Premise
limitations.	I-Premise

No	B-Premise
significant	I-Premise
difference	I-Premise
in	I-Premise
any	I-Premise
of	I-Premise
the	I-Premise
analysed	I-Premise
outcome	I-Premise
measures	I-Premise
was	I-Premise
observed.	I-Premise

Posterior	B-Claim
reconstruction	I-Claim
of	I-Claim
the	I-Claim
musculofascial	I-Claim
complex	I-Claim
does	I-Claim
not	I-Claim
appear	I-Claim
to	I-Claim
improve	I-Claim
early	I-Claim
urinary	I-Claim
incontinence	I-Claim
after	I-Claim
RALP.	I-Claim

The	O
role	O
of	O
chemotherapy	O
for	O
advanced	O
NSCLC	O
patients	O
and	O
ECOG	O
PS2	O
remains	O
controversial.	O

We	O
evaluated	O
4	O
doses	O
of	O
3-weekly	O
docetaxel	O
to	O
identify	O
a	O
less	O
toxic,	O
clinically	O
effective	O
dose.	O

Seventy-three	O
patients	O
with	O
stage	O
III	O
(22%)	O
(unsuitable	O
for	O
radical	O
surgery/radiotherapy)	O
and	O
IV	O
(78%)	O
NSCLC	O
were	O
randomized	O
to	O
receive	O
4	O
doses	O
of	O
3-weekly	O
docetaxel,	O
for	O
4	O
cycles:	O
arm	O
(A)	O
40	O
mg/m(2)	O
(n=17),	O
arm	O
(B)	O
50	O
mg/m(2)	O
(n=17),	O
arm	O
(C)	O
60	O
mg/m(2)	O
(n=19),	O
arm	O
(D)	O
50	O
mg/m(2)	O
escalated	O
by	O
10	O
mg/m(2)	O
to	O
a	O
maximum	O
of	O
70	O
mg/m(2)	O
(n=19).	O

Primary	O
endpoints:	O
maximum	O
tolerated	O
dose,	O
RR,	O
duration	O
of	O
response,	O
symptom	O
improvement,	O
toxicity	O
and	O
QoL.	O

Secondary	O
endpoint:	O
overall	O
survival	O
(OS).	O

Patients	O
and	O
disease	O
characteristics	O
were	O
well	O
balanced.	O

Median	O
age	O
was	O
67	O
(range	O
45-81),	O
there	O
were	O
32	O
male	O
and	O
41	O
female,	O
histology	O
subtype:	O
squamous/adenocarcinoma/mixed/NOS=42%/49%/4%/5%.	O

Seven	O
patients	O
did	O
not	O
receive	O
any	O
treatment	O
because	O
of	O
deterioration	O
in	O
PS	O
or	O
death.	O

50%	O
of	O
patients	O
in	O
arm	O
D,	O
who	O
received	O
more	O
than	O
one	O
cycle,	O
received	O
dose	O
escalation.	O

There	B-Premise
was	I-Premise
no	I-Premise
statistical	I-Premise
difference	I-Premise
in	I-Premise
the	I-Premise
number	I-Premise
of	I-Premise
cycles	I-Premise
administered	I-Premise
(arms	I-Premise
A,	I-Premise
B	I-Premise
and	I-Premise
D:	I-Premise
median	I-Premise
2	I-Premise
cycles	I-Premise
and	I-Premise
arm	I-Premise
C:	I-Premise
median	I-Premise
3	I-Premise
cycles)	I-Premise
and	I-Premise
no	I-Premise
difference	I-Premise
in	I-Premise
RR:	I-Premise
arm	I-Premise
A=6%,	I-Premise
arm	I-Premise
B=6%,	I-Premise
arm	I-Premise
C=10%,	I-Premise
and	I-Premise
arm	I-Premise
D=0%.	I-Premise

There	B-Premise
was	I-Premise
no	I-Premise
statistically	I-Premise
significant	I-Premise
difference	I-Premise
in	I-Premise
grade	I-Premise
3/4	I-Premise
neutropenia	I-Premise
and	I-Premise
thrombocytopenia	I-Premise
between	I-Premise
the	I-Premise
four	I-Premise
arms.	I-Premise

No	B-Premise
difference	I-Premise
was	I-Premise
observed	I-Premise
in	I-Premise
hospitalization	I-Premise
rate,	I-Premise
blood	I-Premise
transfusions,	I-Premise
antibiotics	I-Premise
administration	I-Premise
and	I-Premise
non-haematological	I-Premise
toxicity.	I-Premise

QoL:	O
no	O
difference	O
in	O
total	O
scores	O
between	O
baseline	O
and	O
cycles	O
1-4.	O

There	B-Premise
was	I-Premise
a	I-Premise
significant	I-Premise
decrease	I-Premise
in	I-Premise
pain	I-Premise
scores	I-Premise
from	I-Premise
baseline	I-Premise
to	I-Premise
post	I-Premise
cycles	I-Premise
2	I-Premise
and	I-Premise
3	I-Premise
(p=0.025	I-Premise
and	I-Premise
p=0.002,	I-Premise
respectively).	I-Premise

There	B-Premise
was	I-Premise
no	I-Premise
difference	I-Premise
in	I-Premise
OS	I-Premise
(p=0.992).	I-Premise

Median	B-Premise
survival	I-Premise
and	I-Premise
6-month	I-Premise
survival	I-Premise
were	I-Premise
61,	I-Premise
86,	I-Premise
88	I-Premise
and	I-Premise
97	I-Premise
days	I-Premise
and	I-Premise
29%,	I-Premise
33%,	I-Premise
21%	I-Premise
and	I-Premise
26%	I-Premise
for	I-Premise
arms	I-Premise
A,	I-Premise
B,	I-Premise
C,	I-Premise
and	I-Premise
D,	I-Premise
respectively.	I-Premise

Clinical	B-Claim
efficacy	I-Claim
of	I-Claim
docetaxel	I-Claim
was	I-Claim
observed	I-Claim
at	I-Claim
all	I-Claim
dose	I-Claim
levels.	I-Claim

Higher	B-Claim
dose	I-Claim
levels	I-Claim
were	I-Claim
not	I-Claim
associated	I-Claim
with	I-Claim
increased	I-Claim
toxicities,	I-Claim
use	I-Claim
of	I-Claim
IV	I-Claim
antibiotics	I-Claim
or	I-Claim
hospitalization	I-Claim
rates.	I-Claim

However,	O
the	B-Premise
median	I-Premise
survival	I-Premise
observed	I-Premise
is	I-Premise
shorter	I-Premise
than	I-Premise
historical	I-Premise
data	I-Premise
and	I-Premise
do	I-Premise
not	I-Premise
support	I-Premise
further	I-Premise
evaluation	I-Premise
of	I-Premise
these	I-Premise
doses	I-Premise
of	I-Premise
single	I-Premise
agent	I-Premise
docetaxel	I-Premise
in	I-Premise
this	I-Premise
population.	I-Premise

To	O
assess	O
whether	O
omission	O
of	O
post-operative	O
radiotherapy	O
(RT)	O
in	O
women	O
with	O
'low-risk'	O
axillary	O
node-negative	O
breast	O
cancer	O
[tumour	O
size	O
of	O
less	O
than	O
5	O
cm	O
(T0-2)	O
although	O
the	O
eligibility	O
criteria	O
further	O
reduce	O
the	O
eligible	O
size	O
to	O
a	O
maximum	O
of	O
3	O
cm]	O
treated	O
by	O
breast-conserving	O
surgery	O
and	O
endocrine	O
therapy	O
improves	O
quality	O
of	O
life	O
and	O
is	O
more	O
cost-effective.	O

A	O
randomised	O
controlled	O
clinical	O
trial,	O
using	O
a	O
method	O
of	O
minimisation	O
balanced	O
by	O
centre,	O
grade	O
of	O
cancer,	O
age,	O
lymphovascular	O
invasion	O
and	O
preoperative	O
endocrine	O
therapy	O
was	O
performed.	O

Breast	O
cancer	O
clinics	O
in	O
cancer	O
centres	O
in	O
the	O
UK.	O

Patients	O
aged	O
â¥	O
65	O
years	O
were	O
eligible	O
provided	O
that	O
their	O
breast	O
cancers	O
were	O
considered	O
to	O
be	O
at	O
low	O
risk	O
of	O
local	O
recurrence,	O
they	O
were	O
suitable	O
for	O
breast	O
conservation	O
surgery,	O
they	O
were	O
receiving	O
endocrine	O
therapy	O
and	O
they	O
were	O
willing	O
and	O
able	O
to	O
give	O
informed	O
consent.	O

The	O
standard	O
treatment	O
of	O
post-operative	O
whole	O
breast	O
irradiation	O
or	O
the	O
omission	O
of	O
RT.	O

Quality	O
of	O
life	O
was	O
the	O
primary	O
outcome	O
measure,	O
together	O
with	O
anxiety	O
and	O
depression	O
and	O
cost-effectiveness.	O

Secondary	O
outcome	O
measures	O
were	O
recurrence	O
rates	O
and	O
survival,	O
and	O
treatment-related	O
morbidity.	O

The	O
principal	O
method	O
of	O
data	O
collection	O
was	O
by	O
questionnaire,	O
completed	O
at	O
home	O
with	O
a	O
research	O
nurse	O
on	O
four	O
occasions	O
over	O
15	O
months,	O
then	O
by	O
postal	O
questionnaire	O
at	O
3	O
and	O
5	O
years	O
after	O
surgery.	O

The	O
hypothesised	O
improvement	O
in	O
overall	O
quality	O
of	O
life	O
with	O
the	O
omission	O
of	O
RT	O
was	O
not	O
seen	O
in	O
the	O
summary	O
domains	O
of	O
the	O
European	O
Organisation	O
for	O
Research	O
in	O
the	O
Treatment	O
of	O
Cancer	O
(EORTC)	O
scales.	O

Some	O
differences	O
were	O
apparent	O
within	O
subscales	O
of	O
the	O
EORTC	O
questionnaires,	O
and	O
insights	O
into	O
the	O
impact	O
of	O
treatment	O
were	O
also	O
provided	O
by	O
the	O
qualitative	O
data	O
obtained	O
by	O
open-ended	O
questions	O
added	O
by	O
the	O
trial	O
team.	O

Differences	O
were	O
most	O
apparent	O
shortly	O
after	O
the	O
time	O
of	O
completion	O
of	O
RT.	O

RT	B-Premise
was	I-Premise
then	I-Premise
associated	I-Premise
with	I-Premise
increased	I-Premise
breast	I-Premise
symptoms	I-Premise
and	I-Premise
with	I-Premise
greater	I-Premise
(self-reported)	I-Premise
fatigue,	I-Premise
but	I-Premise
with	I-Premise
lower	I-Premise
levels	I-Premise
of	I-Premise
insomnia	I-Premise
and	I-Premise
endocrine	I-Premise
side	I-Premise
effects.	I-Premise

These	B-Premise
statistically	I-Premise
significant	I-Premise
differences	I-Premise
in	I-Premise
breast	I-Premise
symptoms	I-Premise
persisted	I-Premise
for	I-Premise
up	I-Premise
to	I-Premise
5	I-Premise
years	I-Premise
after	I-Premise
RT	I-Premise
[mean	I-Premise
difference,	I-Premise
RT	I-Premise
was	I-Premise
5.27	I-Premise
units	I-Premise
greater	I-Premise
than	I-Premise
no	I-Premise
RT,	I-Premise
95%	I-Premise
confidence	I-Premise
interval	I-Premise
(CI)	I-Premise
of	I-Premise
1.46	I-Premise
to	I-Premise
9.07],	I-Premise
with	I-Premise
similar,	I-Premise
though	I-Premise
non-significant,	I-Premise
trends	I-Premise
in	I-Premise
insomnia.	I-Premise

No	B-Premise
significant	I-Premise
difference	I-Premise
was	I-Premise
found	I-Premise
in	I-Premise
the	I-Premise
overall	I-Premise
quality	I-Premise
of	I-Premise
life	I-Premise
measure,	I-Premise
with	I-Premise
the	I-Premise
no	I-Premise
RT	I-Premise
group	I-Premise
having	I-Premise
0.36	I-Premise
units	I-Premise
greater	I-Premise
quality	I-Premise
of	I-Premise
life	I-Premise
than	I-Premise
the	I-Premise
RT	I-Premise
group	I-Premise
(95%	I-Premise
CI	I-Premise
-5.09	I-Premise
to	I-Premise
5.81).	I-Premise

Breast	B-Claim
RT	I-Claim
is	I-Claim
tolerated	I-Claim
well	I-Claim
by	I-Claim
most	I-Claim
older	I-Claim
breast	I-Claim
cancer	I-Claim
patients	I-Claim
without	I-Claim
impairing	I-Claim
their	I-Claim
overall	I-Claim
health-related	I-Claim
quality	I-Claim
of	I-Claim
life	I-Claim
(HRQoL).	I-Claim

Although	O
HRQoL	O
should	O
always	O
be	O
taken	O
into	O
account	O
when	O
determining	O
treatment,	O
our	B-Claim
results	I-Claim
show	I-Claim
that	I-Claim
the	I-Claim
addition	I-Claim
of	I-Claim
RT	I-Claim
does	I-Claim
not	I-Claim
impair	I-Claim
overall	I-Claim
quality	I-Claim
of	I-Claim
life.	I-Claim

Further	B-Claim
economic	I-Claim
modelling	I-Claim
on	I-Claim
the	I-Claim
longer-term	I-Claim
costs	I-Claim
and	I-Claim
consequences	I-Claim
of	I-Claim
omitting	I-Claim
RT	I-Claim
is	I-Claim
required.	I-Claim

Evaluation	O
of	O
health-related	O
quality-of-life	O
(HRQoL)	O
and	O
symptom	O
improvement	O
were	O
preplanned	O
secondary	O
objectives	O
for	O
the	O
overall	O
population	O
and	O
posthoc	O
analyses	O
for	O
epidermal	O
growth	O
factor	O
receptor	O
(EGFR)	O
mutation-positive/negative	O
subgroups	O
in	O
IPASS.	O

HRQoL	O
was	O
assessed	O
using	O
the	O
Functional	O
Assessment	O
of	O
Cancer	O
Therapy-Lung	O
(FACT-L)	O
and	O
Trial	O
Outcome	O
Index	O
(TOI);	O
symptom	O
improvement	O
by	O
the	O
Lung	O
Cancer	O
Subscale	O
(LCS).	O

Improvements	O
defined	O
as:	O
6	O
or	O
more	O
(FACT-L;	O
TOI),	O
2	O
or	O
more	O
(LCS)	O
points	O
increase	O
maintained	O
for	O
21	O
or	O
more	O
days.	O

Overall	O
(n	O
=	O
1151/1217	O
evaluable),	O
HRQoL	O
improvement	O
rates	O
were	O
significantly	O
greater	O
with	O
gefitinib	O
versus	O
carboplatin/paclitaxel;	O
symptom	O
improvement	O
rates	O
were	O
similar	O
for	O
both	O
treatments.	O

Significantly	B-Premise
more	I-Premise
patients	I-Premise
recorded	I-Premise
improvements	I-Premise
in	I-Premise
HRQoL	I-Premise
and	I-Premise
symptoms	I-Premise
with	I-Premise
gefitinib	I-Premise
in	I-Premise
the	I-Premise
EGFR	I-Premise
mutation-positive	I-Premise
subgroup	I-Premise
(n	I-Premise
=	I-Premise
259;	I-Premise
FACT-L	I-Premise
70.2%	I-Premise
versus	I-Premise
44.5%;	I-Premise
odds	I-Premise
ratio,	I-Premise
3.01	I-Premise
[95%	I-Premise
confidence	I-Premise
interval,	I-Premise
1.79-5.07];	I-Premise
p	I-Premise
<	I-Premise
0.001;	I-Premise
TOI	I-Premise
70.2%	I-Premise
versus	I-Premise
38.3%;	I-Premise
3.96	I-Premise
[2.33-6.71];	I-Premise
p	I-Premise
<	I-Premise
0.001;	I-Premise
LCS	I-Premise
75.6%	I-Premise
versus	I-Premise
53.9%;	I-Premise
2.70	I-Premise
[1.58-4.62];	I-Premise
p	I-Premise
<	I-Premise
0.001),	I-Premise
and	I-Premise
with	I-Premise
carboplatin/paclitaxel	I-Premise
in	I-Premise
the	I-Premise
EGFR	I-Premise
mutation-negative	I-Premise
subgroup	I-Premise
(n	I-Premise
=	I-Premise
169;	I-Premise
FACT-L	I-Premise
14.6%	I-Premise
versus	I-Premise
36.3%;	I-Premise
odds	I-Premise
ratio,	I-Premise
0.31	I-Premise
[0.15-0.65];	I-Premise
p	I-Premise
=	I-Premise
0.002;	I-Premise
TOI	I-Premise
12.4%	I-Premise
versus	I-Premise
28.8%;	I-Premise
0.35	I-Premise
[0.16-0.79];	I-Premise
p	I-Premise
=	I-Premise
0.011;	I-Premise
LCS	I-Premise
20.2%	I-Premise
versus	I-Premise
47.5%;	I-Premise
0.28	I-Premise
[0.14-0.55];	I-Premise
p	I-Premise
<	I-Premise
0.001).	I-Premise

Median	B-Premise
time-to-worsening	I-Premise
(months)	I-Premise
FACT-L	I-Premise
score	I-Premise
was	I-Premise
longer	I-Premise
with	I-Premise
gefitinib	I-Premise
versus	I-Premise
carboplatin/paclitaxel	I-Premise
for	I-Premise
the	I-Premise
overall	I-Premise
population	I-Premise
(8.3	I-Premise
versus	I-Premise
2.5)	I-Premise
and	I-Premise
EGFR	I-Premise
mutation-positive	I-Premise
subgroup	I-Premise
(15.6	I-Premise
versus	I-Premise
3.0),	I-Premise
and	I-Premise
similar	I-Premise
for	I-Premise
both	I-Premise
treatments	I-Premise
in	I-Premise
the	I-Premise
EGFR	I-Premise
mutation-negative	I-Premise
subgroup	I-Premise
(1.4	I-Premise
versus	I-Premise
1.4).	I-Premise

Median	B-Premise
time-to-improvement	I-Premise
with	I-Premise
gefitinib	I-Premise
was	I-Premise
8	I-Premise
days	I-Premise
in	I-Premise
patients	I-Premise
with	I-Premise
EGFR	I-Premise
mutation-positive	I-Premise
tumors	I-Premise
who	I-Premise
improved.	I-Premise

HRQoL	B-Claim
and	I-Claim
symptom	I-Claim
endpoints	I-Claim
were	I-Claim
consistent	I-Claim
with	I-Claim
efficacy	I-Claim
outcomes	I-Claim
in	I-Claim
IPASS	I-Claim
and	I-Claim
favored	I-Claim
gefitinib	I-Claim
in	I-Claim
patients	I-Claim
with	I-Claim
EGFR	I-Claim
mutation-positive	I-Claim
tumors	I-Claim
and	I-Claim
carboplatin/paclitaxel	I-Claim
in	I-Claim
patients	I-Claim
with	I-Claim
EGFR	I-Claim
mutation-negative	I-Claim
tumors.	I-Claim

To	O
observe	O
the	O
effect	O
of	O
Chinese	O
medicine	O
(CM)	O
comprehensive	O
regimen	O
as	O
the	O
maintenance	O
therapy	O
(MT)	O
on	O
time	O
to	O
progression	O
(TTP)	O
and	O
quality	O
of	O
life	O
(QOL)	O
of	O
patients	O
with	O
advanced	O
non-small-cell	O
lung	O
cancer	O
(NSCLC).	O

The	O
study	O
was	O
a	O
prospective,	O
randomized	O
and	O
controlled	O
clinical	O
trial.	O

Fifty	O
non-progressive	O
patients	O
with	O
advanced	O
NSCLC	O
who	O
responded	O
to	O
first-line	O
therapy	O
were	O
randomized	O
into	O
the	O
test	O
group	O
(25	O
cases,	O
treated	O
with	O
CM	O
comprehensive	O
regimen:	O
intravenous	O
dripping	O
of	O
Chinese	O
herbal	O
preparation,	O
oral	O
administration	O
of	O
Chinese	O
herbal	O
decoction,	O
and	O
point	O
application)	O
and	O
the	O
control	O
group	O
[25	O
cases,	O
treated	O
with	O
one	O
of	O
three	O
single-agent	O
maintenance	O
chemotherapy	O
regimens:	O
pemetrexed	O
(500	O
mg/m2,	O
day	O
1),	O
docetaxel	O
(75	O
mg/m2,	O
day	O
1),	O
and	O
gemcitabine	O
(1000	O
mg/mi,	O
day	O
1	O
and	O
day	O
8)	O
in	O
the	O
ratio	O
of	O
1:1].	O

Each	O
cycle	O
consisted	O
of	O
21	O
days.	O

Cycles	O
were	O
repeated	O
until	O
the	O
disease	O
progressed,	O
or	O
intolerable	O
toxic	O
or	O
adverse	O
reaction	O
occurred,	O
or	O
patients	O
refused	O
to	O
continue	O
the	O
treatment.	O

The	O
primary	O
end	O
point	O
was	O
TTP	O
and	O
the	O
secondary	O
end	O
point	O
was	O
QOL.	O

QOL	O
was	O
evaluated	O
using	O
the	O
European	O
Organization	O
for	O
Research	O
and	O
Treatment	O
of	O
Cancer	O
quality-of-life	O
questionnaire	O
QLQ-LC43	O
(EORTC	O
QLQ-LC43).	O

TTP	O
of	O
fifty	O
patients	O
and	O
QOL	O
of	O
43	O
patients	O
had	O
been	O
statistically	O
analyzed.	O

(1)	O
The	B-Premise
TTP	I-Premise
in	I-Premise
the	I-Premise
test	I-Premise
group	I-Premise
was	I-Premise
prolonged	I-Premise
for	I-Premise
23	I-Premise
days	I-Premise
when	I-Premise
compared	I-Premise
with	I-Premise
that	I-Premise
of	I-Premise
the	I-Premise
control	I-Premise
group,	I-Premise
with	I-Premise
insignificant	I-Premise
difference	I-Premise
(87	I-Premise
days	I-Premise
vs	I-Premise
64	I-Premise
days,	I-Premise
P=0.063).	I-Premise

(2)	O
The	B-Premise
scores	I-Premise
of	I-Premise
domains	I-Premise
in	I-Premise
EORTC	I-Premise
QLQ-LC43	I-Premise
were	I-Premise
statistically	I-Premise
significantly	I-Premise
better	I-Premise
in	I-Premise
the	I-Premise
test	I-Premise
group	I-Premise
than	I-Premise
in	I-Premise
the	I-Premise
control	I-Premise
group	I-Premise
(P<0.05)	I-Premise
except	B-Premise
cognitive	I-Premise
and	I-Premise
social	I-Premise
functions,	I-Premise
the	I-Premise
symptoms	I-Premise
of	I-Premise
dysphagia	I-Premise
and	I-Premise
pain	I-Premise
in	I-Premise
other	I-Premise
parts.	I-Premise

(1)	O
The	B-Claim
CM	I-Claim
comprehensive	I-Claim
regimen	I-Claim
as	I-Claim
MT	I-Claim
had	I-Claim
equivalent	I-Claim
efficacy	I-Claim
on	I-Claim
TTP	I-Claim
when	I-Claim
compared	I-Claim
with	I-Claim
single-agent	I-Claim
maintenance	I-Claim
chemotherapy	I-Claim
regimen.	I-Claim

It	B-Claim
was	I-Claim
advantageous	I-Claim
over	I-Claim
improving	I-Claim
the	I-Claim
QOL.	I-Claim

(2)	O
It	B-Claim
is	I-Claim
necessary	I-Claim
to	I-Claim
enlarge	I-Claim
the	I-Claim
sample	I-Claim
size	I-Claim
to	I-Claim
further	I-Claim
confirm	I-Claim
the	I-Claim
therapeutic	I-Claim
efficacy	I-Claim
of	I-Claim
CM	I-Claim
comprehensive	I-Claim
regimen	I-Claim
as	I-Claim
MT	I-Claim
in	I-Claim
treatment	I-Claim
of	I-Claim
patients	I-Claim
with	I-Claim
advanced	I-Claim
NSCLC.	I-Claim

Implant-based	O
reconstruction	O
is	O
performed	O
in	O
the	O
majority	O
of	O
women	O
offered	O
primary	O
reconstruction	O
for	O
breast	O
cancer.	O

Two	O
different	O
expander	O
implants	O
were	O
compared	O
prospectively.	O

The	O
primary	O
endpoint	O
was	O
the	O
number	O
of	O
operations	O
needed	O
in	O
each	O
group	O
to	O
obtain	O
patient	O
satisfaction.	O

Secondary	O
endpoints	O
were	O
evaluation	O
of	O
breast	O
volume	O
and	O
shape	O
and	O
aspects	O
of	O
quality	O
of	O
life.	O

Seventy	O
consecutive	O
breast	O
cancer	O
patients	O
were	O
randomized	O
to	O
either	O
a	O
one-stage	O
reconstruction	O
with	O
a	O
round	O
permanent	O
expander	O
implant	O
(Becker	O
25;	O
n=35)	O
or	O
a	O
two-stage	O
reconstruction	O
with	O
a	O
crescent-shaped	O
expander	O
(LV	O
133;	O
n=35),	O
later	O
replaced	O
by	O
a	O
form-stable	O
anatomical	O
implant.	O

Thirty	O
patients	O
had	O
to	O
be	O
excluded	O
and	O
40	O
patients,	O
20	O
in	O
each	O
group,	O
were	O
evaluated.	O

The	O
median	O
follow-up	O
for	O
both	O
groups	O
was	O
3.5	O
years	O
(range,	O
1.5	O
to	O
5	O
years).	O

Plastic	O
cups,	O
plastic	O
casts,	O
and	O
two	O
-and	O
three-dimensional	O
scanning	O
techniques	O
were	O
used	O
for	O
objective	O
assessment	O
of	O
breast	O
volume	O
and	O
shape.	O

The	O
aesthetic	O
outcome	O
was	O
evaluated	O
by	O
a	O
panel	O
of	O
experts	O
and	O
lay	O
people,	O
and	O
by	O
the	O
patients.	O

Quality	O
of	O
life	O
was	O
evaluated	O
with	O
a	O
validated	O
questionnaire	O
(36-Item	O
Short	O
Form	O
Health	O
Survey).	O

Of	B-Premise
the	I-Premise
patients	I-Premise
in	I-Premise
the	I-Premise
one-stage	I-Premise
group,	I-Premise
70	I-Premise
percent	I-Premise
had	I-Premise
revision	I-Premise
surgery,	I-Premise
mostly	I-Premise
because	I-Premise
of	I-Premise
upper	I-Premise
pole	I-Premise
fullness	I-Premise
and	I-Premise
poor	I-Premise
ptosis.	I-Premise

These	O
findings	O
agreed	O
with	O
the	O
data	O
from	O
the	O
two-dimensional	O
scanning	O
and	O
from	O
the	O
expert	O
panel	O
and	O
the	O
patients'	O
subjective	O
judgment.	O

Quality	B-Premise
of	I-Premise
life	I-Premise
was	I-Premise
similar	I-Premise
in	I-Premise
the	I-Premise
two	I-Premise
groups.	I-Premise

The	B-Claim
permanent	I-Claim
expander	I-Claim
method	I-Claim
failed	I-Claim
significantly	I-Claim
as	I-Claim
a	I-Claim
one-stage	I-Claim
procedure.	I-Claim

The	B-Claim
crescent	I-Claim
two-stage	I-Claim
method	I-Claim
gave	I-Claim
the	I-Claim
most	I-Claim
acceptable	I-Claim
results	I-Claim
both	I-Claim
objectively	I-Claim
and	I-Claim
subjectively.	I-Claim

Intermittent	O
dosing	O
may	O
reduce	O
the	O
adverse	O
events	O
(AEs)	O
of	O
androgen-deprivation	O
therapy	O
(ADT).	O

To	O
compare	O
intermittent	O
androgen	O
deprivation	O
(IAD)	O
and	O
continuous	O
androgen	O
deprivation	O
(CAD)	O
with	O
regard	O
to	O
health-related	O
quality	O
of	O
life	O
(QoL).	O

A	O
total	O
of	O
852	O
men	O
with	O
advanced	O
prostate	O
cancer	O
(PCa)	O
were	O
enrolled	O
to	O
receive	O
goserelin	O
acetate	O
3.6	O
mg	O
every	O
28	O
d	O
for	O
24	O
wk.	O

A	O
total	O
of	O
554	O
patients	O
whose	O
prostate-specific	O
antigen	O
(PSA)	O
decreased	O
to	O
<10	O
ng/ml	O
or	O
by	O
â¥50%	O
(<20	O
ng/ml	O
at	O
baseline)	O
were	O
randomised	O
to	O
IAD	O
or	O
CAD.	O

In	O
the	O
IAD	O
arm,	O
ADT	O
was	O
resumed	O
for	O
at	O
least	O
24	O
wk	O
whenever	O
PSA	O
increased	O
>20	O
ng/ml	O
or	O
above	O
baseline.	O

QoL	O
was	O
monitored	O
with	O
a	O
validated	O
Cleary	O
30-item	O
questionnaire	O
and	O
analysed	O
by	O
the	O
Mann-Whitney	O
U	O
test,	O
0.5	O
standard	O
deviation	O
rule,	O
and	O
repeated	O
measures	O
analysis	O
of	O
variance.	O

AEs	O
and	O
adverse	O
drug	O
reactions	O
(ADRs)	O
were	O
analysed	O
by	O
the	O
chi-square	O
test.	O

Median	O
follow-up	O
was	O
65	O
mo.	O

Significant	B-Premise
differences	I-Premise
in	I-Premise
QoL	I-Premise
emerged	I-Premise
in	I-Premise
activity	I-Premise
limitation,	I-Premise
physical	I-Premise
capacity,	I-Premise
and	I-Premise
sexual	I-Premise
functioning,	I-Premise
favouring	I-Premise
IAD.	I-Premise

No	B-Premise
significant	I-Premise
differences	I-Premise
emerged	I-Premise
in	I-Premise
the	I-Premise
prevalence	I-Premise
of	I-Premise
AEs:	I-Premise
87	I-Premise
patients	I-Premise
in	I-Premise
the	I-Premise
IAD	I-Premise
arm	I-Premise
(31.8%)	I-Premise
and	I-Premise
95	I-Premise
in	I-Premise
the	I-Premise
CAD	I-Premise
arm	I-Premise
(33.9%)	I-Premise
had	I-Premise
cardiovascular	I-Premise
(CV)	I-Premise
AEs	I-Premise
(p=0.59),	I-Premise
with	I-Premise
25	I-Premise
(9.1%)	I-Premise
and	I-Premise
29	I-Premise
(10.4%)	I-Premise
withdrawn	I-Premise
(p=0.62),	I-Premise
and	I-Premise
21	I-Premise
(7.7%)	I-Premise
and	I-Premise
24	I-Premise
(8.6%)	I-Premise
dying	I-Premise
because	I-Premise
of	I-Premise
a	I-Premise
CV	I-Premise
event	I-Premise
(p=0.70),	I-Premise
respectively;	I-Premise
bone	B-Premise
fractures	I-Premise
occurred	I-Premise
in	I-Premise
19	I-Premise
(6.9%)	I-Premise
and	I-Premise
15	I-Premise
(5.4%)	I-Premise
patients	I-Premise
(p=0.44),	I-Premise
respectively.	I-Premise

Hot	B-Premise
flushes	I-Premise
or	I-Premise
night	I-Premise
sweats	I-Premise
were	I-Premise
the	I-Premise
most	I-Premise
common	I-Premise
ADRs	I-Premise
(47.1%	I-Premise
vs	I-Premise
50.4%;	I-Premise
p=0.44).	I-Premise

Erectile	B-Premise
dysfunction	I-Premise
(15.7%	I-Premise
vs	I-Premise
7.9%;	I-Premise
p=0.042)	I-Premise
and	I-Premise
depressed	I-Premise
mood	I-Premise
(2.2	I-Premise
vs	I-Premise
0%;	I-Premise
p=0.032)	I-Premise
were	I-Premise
more	I-Premise
common	I-Premise
in	I-Premise
the	I-Premise
IAD	I-Premise
arm.	I-Premise

IAD	B-Claim
showed	I-Claim
benefits	I-Claim
in	I-Claim
the	I-Claim
treatment	I-Claim
of	I-Claim
advanced	I-Claim
PCa	I-Claim
with	I-Claim
respect	I-Claim
to	I-Claim
QoL.	I-Claim

The	B-Claim
prevalence	I-Claim
of	I-Claim
AEs	I-Claim
was	I-Claim
not	I-Claim
significantly	I-Claim
lower	I-Claim
with	I-Claim
IAD.	I-Claim

Patients	O
who	O
develop	O
castration-resistant	O
prostate	O
cancer	O
(CRPCa)	O
typically	O
continue	O
on	O
androgen	O
deprivation	O
therapy	O
(ADT).	O

Whether	O
these	O
patients	O
need	O
to	O
remain	O
on	O
ADT	O
has	O
not	O
been	O
well	O
studied.	O

We	O
conducted	O
a	O
multicenter	O
randomized	O
trial	O
to	O
compare	O
an	O
intermittent	O
versus	O
continuous	O
approach	O
to	O
ADT	O
in	O
CRPCa	O
patients.	O

Overall	O
survival,	O
health-related	O
quality	O
of	O
life	O
(QOL),	O
and	O
cost	O
were	O
the	O
main	O
endpoints.	O

CRPCa	O
patients	O
were	O
randomized	O
2:1	O
to	O
intermittent	O
or	O
continuous	O
luteinizing	O
hormone-releasing	O
hormone	O
agonists	O
(LHRHa).	O

Patients	O
were	O
followed	O
with	O
clinical	O
assessments,	O
laboratory	O
investigations,	O
and	O
QOL	O
questionnaires	O
(EORTC	O
QLQ-C30	O
or	O
PROSQOLI)	O
every	O
2	O
months.	O

If	O
the	O
serum	O
testosterone	O
rose	O
above	O
castrate	O
levels	O
(1.75	O
nmol/L),	O
LHRHa	O
were	O
reinitiated.	O

The	O
study	O
was	O
designed	O
to	O
close	O
if	O
>50%	O
of	O
patients	O
needed	O
to	O
restart	O
ADT	O
in	O
the	O
intermittent	O
arm.	O

Thirty-one	O
patients	O
were	O
followed	O
with	O
a	O
median	O
follow-up	O
of	O
26.8	O
months-18	O
in	O
the	O
intermittent	O
arm	O
and	O
13	O
in	O
the	O
continuous.	O

Twelve	O
of	O
18	O
patients	O
on	O
the	O
intermittent	O
arm	O
were	O
reinitiated	O
on	O
LHRHa	O
at	O
a	O
median	O
time	O
of	O
17.9	O
months.	O

There	B-Premise
was	I-Premise
no	I-Premise
difference	I-Premise
in	I-Premise
overall	I-Premise
or	I-Premise
cancer-specific	I-Premise
survival	I-Premise
between	I-Premise
the	I-Premise
2	I-Premise
arms.	I-Premise

There	B-Premise
was	I-Premise
no	I-Premise
statistically	I-Premise
significant	I-Premise
difference	I-Premise
in	I-Premise
QOL	I-Premise
between	I-Premise
the	I-Premise
2	I-Premise
arms	I-Premise
at	I-Premise
0	I-Premise
and	I-Premise
12	I-Premise
months.	I-Premise

The	B-Premise
total	I-Premise
mean	I-Premise
costs	I-Premise
at	I-Premise
24	I-Premise
months	I-Premise
were	I-Premise
significantly	I-Premise
lower	I-Premise
in	I-Premise
the	I-Premise
intermittent	I-Premise
arm	I-Premise
($3135	I-Premise
vs.	I-Premise
$8253	I-Premise
Canadian	I-Premise
dollars,	I-Premise
P=0.0167)	I-Premise
compared	I-Premise
with	I-Premise
the	I-Premise
continuous.	I-Premise

The	B-Premise
main	I-Premise
limitation	I-Premise
of	I-Premise
this	I-Premise
study	I-Premise
is	I-Premise
the	I-Premise
small	I-Premise
sample	I-Premise
size.	I-Premise

We	B-Claim
have	I-Claim
observed	I-Claim
that	I-Claim
intermittent	I-Claim
ADT	I-Claim
in	I-Claim
patients	I-Claim
with	I-Claim
CRPCa,	I-Claim
using	I-Claim
a	I-Claim
testosterone	I-Claim
of	I-Claim
>1.75	I-Claim
ngmol/L	I-Claim
as	I-Claim
a	I-Claim
trigger	I-Claim
to	I-Claim
reinitiate	I-Claim
LHRHa,	I-Claim
results	I-Claim
in	I-Claim
a	I-Claim
substantial	I-Claim
cost	I-Claim
savings	I-Claim
with	I-Claim
no	I-Claim
negative	I-Claim
impact	I-Claim
on	I-Claim
oncologic	I-Claim
and	I-Claim
QOL	I-Claim
outcomes.	I-Claim

Most	O
patients	O
with	O
glioblastoma	O
are	O
older	O
than	O
60	O
years,	O
but	O
treatment	O
guidelines	O
are	O
based	O
on	O
trials	O
in	O
patients	O
aged	O
only	O
up	O
to	O
70	O
years.	O

We	O
did	O
a	O
randomised	O
trial	O
to	O
assess	O
the	O
optimum	O
palliative	O
treatment	O
in	O
patients	O
aged	O
60	O
years	O
and	O
older	O
with	O
glioblastoma.	O

Patients	O
with	O
newly	O
diagnosed	O
glioblastoma	O
were	O
recruited	O
from	O
Austria,	O
Denmark,	O
France,	O
Norway,	O
Sweden,	O
Switzerland,	O
and	O
Turkey.	O

They	O
were	O
assigned	O
by	O
a	O
computer-generated	O
randomisation	O
schedule,	O
stratified	O
by	O
centre,	O
to	O
receive	O
temozolomide	O
(200	O
mg/m(2)	O
on	O
days	O
1-5	O
of	O
every	O
28	O
days	O
for	O
up	O
to	O
six	O
cycles),	O
hypofractionated	O
radiotherapy	O
(34Â·0	O
Gy	O
administered	O
in	O
3Â·4	O
Gy	O
fractions	O
over	O
2	O
weeks),	O
or	O
standard	O
radiotherapy	O
(60Â·0	O
Gy	O
administered	O
in	O
2Â·0	O
Gy	O
fractions	O
over	O
6	O
weeks).	O

Patients	O
and	O
study	O
staff	O
were	O
aware	O
of	O
treatment	O
assignment.	O

The	O
primary	O
endpoint	O
was	O
overall	O
survival.	O

Analyses	O
were	O
done	O
by	O
intention	O
to	O
treat.	O

This	O
trial	O
is	O
registered,	O
number	O
ISRCTN81470623.	O

342	O
patients	O
were	O
enrolled,	O
of	O
whom	O
291	O
were	O
randomised	O
across	O
three	O
treatment	O
groups	O
(temozolomide	O
n=93,	O
hypofractionated	O
radiotherapy	O
n=98,	O
standard	O
radiotherapy	O
n=100)	O
and	O
51	O
of	O
whom	O
were	O
randomised	O
across	O
only	O
two	O
groups	O
(temozolomide	O
n=26,	O
hypofractionated	O
radiotherapy	O
n=25).	O

In	B-Premise
the	I-Premise
three-group	I-Premise
randomisation,	I-Premise
in	I-Premise
comparison	I-Premise
with	I-Premise
standard	I-Premise
radiotherapy,	I-Premise
median	I-Premise
overall	I-Premise
survival	I-Premise
was	I-Premise
significantly	I-Premise
longer	I-Premise
with	I-Premise
temozolomide	I-Premise
(8Â·3	I-Premise
months	I-Premise
[95%	I-Premise
CI	I-Premise
7Â·1-9Â·5;	I-Premise
n=93]	I-Premise
vs	I-Premise
6Â·0	I-Premise
months	I-Premise
[95%	I-Premise
CI	I-Premise
5Â·1-6Â·8;	I-Premise
n=100],	I-Premise
hazard	I-Premise
ratio	I-Premise
[HR]	I-Premise
0Â·70;	I-Premise
95%	I-Premise
CI	I-Premise
0Â·52-0Â·93,	I-Premise
p=0Â·01),	I-Premise
but	I-Premise
not	I-Premise
with	I-Premise
hypofractionated	I-Premise
radiotherapy	I-Premise
(7Â·5	I-Premise
months	I-Premise
[6Â·5-8Â·6;	I-Premise
n=98],	I-Premise
HR	I-Premise
0Â·85	I-Premise
[0Â·64-1Â·12],	I-Premise
p=0Â·24).	I-Premise

For	B-Premise
all	I-Premise
patients	I-Premise
who	I-Premise
received	I-Premise
temozolomide	I-Premise
or	I-Premise
hypofractionated	I-Premise
radiotherapy	I-Premise
(n=242)	I-Premise
overall	I-Premise
survival	I-Premise
was	I-Premise
similar	I-Premise
(8Â·4	I-Premise
months	I-Premise
[7Â·3-9Â·4;	I-Premise
n=119]	I-Premise
vs	I-Premise
7Â·4	I-Premise
months	I-Premise
[6Â·4-8Â·4;	I-Premise
n=123];	I-Premise
HR	I-Premise
0Â·82,	I-Premise
95%	I-Premise
CI	I-Premise
0Â·63-1Â·06;	I-Premise
p=0Â·12).	I-Premise

For	B-Premise
age	I-Premise
older	I-Premise
than	I-Premise
70	I-Premise
years,	I-Premise
survival	I-Premise
was	I-Premise
better	I-Premise
with	I-Premise
temozolomide	I-Premise
and	I-Premise
with	I-Premise
hypofractionated	I-Premise
radiotherapy	I-Premise
than	I-Premise
with	I-Premise
standard	I-Premise
radiotherapy	I-Premise
(HR	I-Premise
for	I-Premise
temozolomide	I-Premise
vs	I-Premise
standard	I-Premise
radiotherapy	I-Premise
0Â·35	I-Premise
[0Â·21-0Â·56],	I-Premise
p<0Â·0001;	I-Premise
HR	I-Premise
for	I-Premise
hypofractionated	I-Premise
vs	I-Premise
standard	I-Premise
radiotherapy	I-Premise
0Â·59	I-Premise
[95%	I-Premise
CI	I-Premise
0Â·37-0Â·93],	I-Premise
p=0Â·02).	I-Premise

Patients	B-Premise
treated	I-Premise
with	I-Premise
temozolomide	I-Premise
who	I-Premise
had	I-Premise
tumour	I-Premise
MGMT	I-Premise
promoter	I-Premise
methylation	I-Premise
had	I-Premise
significantly	I-Premise
longer	I-Premise
survival	I-Premise
than	I-Premise
those	I-Premise
without	I-Premise
MGMT	I-Premise
promoter	I-Premise
methylation	I-Premise
(9Â·7	I-Premise
months	I-Premise
[95%	I-Premise
CI	I-Premise
8Â·0-11Â·4]	I-Premise
vs	I-Premise
6Â·8	I-Premise
months	I-Premise
[5Â·9-7Â·7];	I-Premise
HR	I-Premise
0Â·56	I-Premise
[95%	I-Premise
CI	I-Premise
0Â·34-0Â·93],	I-Premise
p=0Â·02),	I-Premise
but	I-Premise
no	I-Premise
difference	I-Premise
was	I-Premise
noted	I-Premise
between	I-Premise
those	I-Premise
with	I-Premise
methylated	I-Premise
and	I-Premise
unmethylated	I-Premise
MGMT	I-Premise
promoter	I-Premise
treated	I-Premise
with	I-Premise
radiotherapy	I-Premise
(HR	I-Premise
0Â·97	I-Premise
[95%	I-Premise
CI	I-Premise
0Â·69-1Â·38];	I-Premise
p=0Â·81).	I-Premise

As	O
expected,	O
the	B-Premise
most	I-Premise
common	I-Premise
grade	I-Premise
3-4	I-Premise
adverse	I-Premise
events	I-Premise
in	I-Premise
the	I-Premise
temozolomide	I-Premise
group	I-Premise
were	I-Premise
neutropenia	I-Premise
(n=12)	I-Premise
and	I-Premise
thrombocytopenia	I-Premise
(n=18).	I-Premise

Grade	B-Premise
3-5	I-Premise
infections	I-Premise
in	I-Premise
all	I-Premise
randomisation	I-Premise
groups	I-Premise
were	I-Premise
reported	I-Premise
in	I-Premise
18	I-Premise
patients.	I-Premise

Two	B-Premise
patients	I-Premise
had	I-Premise
fatal	I-Premise
infections	I-Premise
(one	I-Premise
in	I-Premise
the	I-Premise
temozolomide	I-Premise
group	I-Premise
and	I-Premise
one	I-Premise
in	I-Premise
the	I-Premise
standard	I-Premise
radiotherapy	I-Premise
group)	I-Premise
and	I-Premise
one	I-Premise
in	I-Premise
the	I-Premise
temozolomide	I-Premise
group	I-Premise
with	I-Premise
grade	I-Premise
2	I-Premise
thrombocytopenia	I-Premise
died	I-Premise
from	I-Premise
complications	I-Premise
after	I-Premise
surgery	I-Premise
for	I-Premise
a	I-Premise
gastrointestinal	I-Premise
bleed.	I-Premise

Standard	B-Claim
radiotherapy	I-Claim
was	I-Claim
associated	I-Claim
with	I-Claim
poor	I-Claim
outcomes,	I-Claim
especially	I-Claim
in	I-Claim
patients	I-Claim
older	I-Claim
than	I-Claim
70	I-Claim
years.	I-Claim

Both	B-Claim
temozolomide	I-Claim
and	I-Claim
hypofractionated	I-Claim
radiotherapy	I-Claim
should	I-Claim
be	I-Claim
considered	I-Claim
as	I-Claim
standard	I-Claim
treatment	I-Claim
options	I-Claim
in	I-Claim
elderly	I-Claim
patients	I-Claim
with	I-Claim
glioblastoma.	I-Claim

MGMT	B-Claim
promoter	I-Claim
methylation	I-Claim
status	I-Claim
might	I-Claim
be	I-Claim
a	I-Claim
useful	I-Claim
predictive	I-Claim
marker	I-Claim
for	I-Claim
benefit	I-Claim
from	I-Claim
temozolomide.	I-Claim

This	O
randomised,	O
placebo-controlled	O
single-blind	O
trial	O
investigated	O
the	O
safety	O
and	O
efficacy	O
of	O
SAMITALÂ®,	O
a	O
formulation	O
of	O
highly	O
standardised	O
botanical	O
extracts,	O
in	O
the	O
treatment	O
of	O
chemo/radiotherapy-induced	O
oral	O
mucositis	O
(OM)	O
in	O
patients	O
with	O
head	O
and	O
neck	O
cancer.	O

Patients	O
received	O
SAMITALÂ®	O
or	O
placebo	O
four	O
times	O
daily	O
for	O
up	O
to	O
50	O
days	O
during	O
scheduled	O
chemo/radiotherapy.	O

Severity	O
of	O
OM	O
was	O
monitored	O
according	O
to	O
a	O
modified	O
WHO	O
severity	O
scale,	O
and	O
pain	O
and	O
quality-of-life	O
assessments	O
were	O
based	O
on	O
the	O
effect	O
of	O
symptoms	O
of	O
OM	O
on	O
relevant	O
daily	O
activities,	O
according	O
to	O
a	O
visual	O
analogue	O
scale.	O

Mean	B-Premise
scores	I-Premise
for	I-Premise
the	I-Premise
severity	I-Premise
of	I-Premise
OM	I-Premise
were	I-Premise
significantly	I-Premise
(p	I-Premise
<	I-Premise
0.05	I-Premise
versus	I-Premise
baseline)	I-Premise
reduced	I-Premise
from	I-Premise
day	I-Premise
31	I-Premise
until	I-Premise
the	I-Premise
end	I-Premise
of	I-Premise
treatment	I-Premise
in	I-Premise
patients	I-Premise
treated	I-Premise
with	I-Premise
SAMITALÂ®	I-Premise
(n	I-Premise
=	I-Premise
20).	I-Premise

No	B-Premise
significant	I-Premise
improvement	I-Premise
was	I-Premise
observed	I-Premise
in	I-Premise
the	I-Premise
placebo	I-Premise
group	I-Premise
(n	I-Premise
=	I-Premise
10).	I-Premise

Pain	B-Premise
reduction	I-Premise
was	I-Premise
significant	I-Premise
from	I-Premise
day	I-Premise
4	I-Premise
till	I-Premise
end	I-Premise
of	I-Premise
treatment	I-Premise
with	I-Premise
SAMITALÂ®	I-Premise
and	I-Premise
from	I-Premise
days	I-Premise
7	I-Premise
to	I-Premise
21	I-Premise
in	I-Premise
placebo	I-Premise
patients.	I-Premise

SAMITALÂ®	B-Premise
also	I-Premise
significantly	I-Premise
improved	I-Premise
quality	I-Premise
of	I-Premise
life,	I-Premise
as	I-Premise
shown	I-Premise
by	I-Premise
improvements	I-Premise
in	I-Premise
scores	I-Premise
for	I-Premise
relevant	I-Premise
daily	I-Premise
activities	I-Premise
including	I-Premise
eating,	I-Premise
drinking	I-Premise
and	I-Premise
sleeping.	I-Premise

All	O
SAMITALÂ®	O
patients	O
completed	O
the	O
treatment	O
period,	O
but	O
no	O
placebo	O
recipients	O
completed	O
treatment.	O

No	B-Premise
severe	I-Premise
adverse	I-Premise
events	I-Premise
were	I-Premise
observed	I-Premise
with	I-Premise
SAMITALÂ®,	I-Premise
and	I-Premise
systemic	I-Premise
absorption	I-Premise
of	I-Premise
relevant	I-Premise
active	I-Premise
ingredients	I-Premise
was	I-Premise
undetectable.	I-Premise

SAMITALÂ®	B-Claim
significantly	I-Claim
decreased	I-Claim
the	I-Claim
severity	I-Claim
of	I-Claim
chemo/radiotherapy-induced	I-Claim
OM	I-Claim
in	I-Claim
patients	I-Claim
with	I-Claim
head	I-Claim
and	I-Claim
neck	I-Claim
cancer,	I-Claim
with	I-Claim
no	I-Claim
treatment-related	I-Claim
adverse	I-Claim
events.	I-Claim

Pain	B-Claim
relief	I-Claim
lasted	I-Claim
through	I-Claim
the	I-Claim
treatment	I-Claim
period,	I-Claim
and	I-Claim
improvements	I-Claim
in	I-Claim
quality	I-Claim
of	I-Claim
life	I-Claim
were	I-Claim
reflected	I-Claim
by	I-Claim
the	I-Claim
significant	I-Claim
benefits	I-Claim
of	I-Claim
SAMITALÂ®	I-Claim
on	I-Claim
activities	I-Claim
like	I-Claim
drinking,	I-Claim
eating	I-Claim
and	I-Claim
speaking.	I-Claim

We	O
investigated	O
the	O
influence	O
of	O
bladder	O
neck	O
preservation	O
on	O
urinary	O
continence,	O
quality	O
of	O
life	O
and	O
surgical	O
margins	O
after	O
radical	O
prostatectomy.	O

A	O
total	O
of	O
208	O
men	O
who	O
presented	O
for	O
radical	O
prostatectomy	O
were	O
randomized	O
to	O
complete	O
bladder	O
neck	O
preservation	O
with	O
subsequent	O
urethro-urethral	O
anastomosis	O
or	O
to	O
no	O
preservation	O
as	O
controls.	O

Patients	O
with	O
failed	O
bladder	O
neck	O
preservation	O
were	O
not	O
included	O
in	O
study.	O

We	O
documented	O
objective	O
continence	O
by	O
the	O
24-hour	O
pad	O
test,	O
social	O
continence	O
by	O
the	O
number	O
of	O
pads	O
per	O
day	O
and	O
quality	O
of	O
life	O
outcomes	O
by	O
the	O
validated	O
Incontinence	O
Quality	O
of	O
Life	O
questionnaire	O
in	O
a	O
single	O
blind	O
setting.	O

Cancer	O
resection	O
was	O
assessed	O
by	O
surgical	O
margin	O
status.	O

At	B-Premise
0,	I-Premise
3,	I-Premise
6	I-Premise
and	I-Premise
12	I-Premise
months	I-Premise
mean	I-Premise
urine	I-Premise
loss	I-Premise
in	I-Premise
the	I-Premise
control	I-Premise
vs	I-Premise
the	I-Premise
bladder	I-Premise
neck	I-Premise
preservation	I-Premise
group	I-Premise
was	I-Premise
713.3	I-Premise
vs	I-Premise
237.0,	I-Premise
49.6	I-Premise
vs	I-Premise
15.6,	I-Premise
44.4	I-Premise
vs	I-Premise
5.5	I-Premise
and	I-Premise
25.4	I-Premise
vs	I-Premise
3.1	I-Premise
gm,	I-Premise
respectively	I-Premise
(each	I-Premise
p	I-Premise
<0.001).	I-Premise

At	B-Premise
3,	I-Premise
6	I-Premise
and	I-Premise
12	I-Premise
months	I-Premise
in	I-Premise
the	I-Premise
control	I-Premise
vs	I-Premise
the	I-Premise
preservation	I-Premise
group	I-Premise
the	I-Premise
social	I-Premise
continence	I-Premise
rate	I-Premise
was	I-Premise
55.3%	I-Premise
vs	I-Premise
84.2%	I-Premise
(p	I-Premise
<0.001),	I-Premise
74.8%	I-Premise
vs	I-Premise
89.5%	I-Premise
(p	I-Premise
=	I-Premise
0.05)	I-Premise
and	I-Premise
81.4%	I-Premise
vs	I-Premise
94.7%	I-Premise
(p	I-Premise
=	I-Premise
0.027),	I-Premise
and	I-Premise
the	I-Premise
quality	I-Premise
of	I-Premise
life	I-Premise
score	I-Premise
was	I-Premise
80.4	I-Premise
vs	I-Premise
90.3	I-Premise
(p	I-Premise
<0.001),	I-Premise
85.4	I-Premise
vs	I-Premise
91.7	I-Premise
(p	I-Premise
=	I-Premise
0.016)	I-Premise
and	I-Premise
86.0	I-Premise
vs	I-Premise
93.8	I-Premise
(p	I-Premise
=	I-Premise
0.001),	I-Premise
respectively.	I-Premise

We	B-Premise
noted	I-Premise
significantly	I-Premise
less	I-Premise
urine	I-Premise
loss,	I-Premise
higher	I-Premise
objective	I-Premise
and	I-Premise
social	I-Premise
continence	I-Premise
rates,	I-Premise
and	I-Premise
higher	I-Premise
quality	I-Premise
of	I-Premise
life	I-Premise
scores	I-Premise
after	I-Premise
complete	I-Premise
bladder	I-Premise
neck	I-Premise
preservation	I-Premise
at	I-Premise
all	I-Premise
followup	I-Premise
points.	I-Premise

On	O
multiple	O
logistic	O
regression	O
analysis	O
complete	O
bladder	O
neck	O
preservation	O
was	O
an	O
independent	O
positive	O
predictor	O
of	O
continence.	O

No	B-Premise
significant	I-Premise
difference	I-Premise
was	I-Premise
found	I-Premise
in	I-Premise
surgical	I-Premise
margin	I-Premise
status	I-Premise
between	I-Premise
the	I-Premise
control	I-Premise
and	I-Premise
bladder	I-Premise
neck	I-Premise
preservation	I-Premise
groups	I-Premise
(12.5%	I-Premise
vs	I-Premise
14.7%,	I-Premise
p	I-Premise
=	I-Premise
0.65).	I-Premise

In	B-Claim
what	I-Claim
is	I-Claim
to	I-Claim
our	I-Claim
knowledge	I-Claim
the	I-Claim
first	I-Claim
prospective,	I-Claim
randomized,	I-Claim
controlled,	I-Claim
single	I-Claim
blind	I-Claim
trial	I-Claim
complete	I-Claim
bladder	I-Claim
neck	I-Claim
preservation	I-Claim
during	I-Claim
radical	I-Claim
prostatectomy	I-Claim
was	I-Claim
associated	I-Claim
with	I-Claim
a	I-Claim
significantly	I-Claim
higher	I-Claim
urinary	I-Claim
continence	I-Claim
rate	I-Claim
and	I-Claim
increased	I-Claim
patient	I-Claim
satisfaction	I-Claim
without	I-Claim
compromising	I-Claim
resection	I-Claim
margins.	I-Claim

Docetaxel	O
administered	O
every	O
3	O
weeks	O
is	O
a	O
standard	O
treatment	O
for	O
castration-resistant	O
advanced	O
prostate	O
cancer.	O

We	O
hypothesised	O
that	O
2-weekly	O
administration	O
of	O
docetaxel	O
would	O
be	O
better	O
tolerated	O
than	O
3-weekly	O
docetaxel	O
in	O
patients	O
with	O
castration-resistant	O
advanced	O
prostate	O
cancer,	O
and	O
did	O
a	O
prospective,	O
multicentre,	O
randomised,	O
phase	O
3	O
study	O
to	O
compare	O
efficacy	O
and	O
safety.	O

Eligible	O
patients	O
had	O
advanced	O
prostate	O
cancer	O
(metastasis,	O
a	O
prostate-specific-antigen	O
test	O
result	O
of	O
more	O
than	O
10Â·0	O
ng/mL,	O
and	O
WHO	O
performance	O
status	O
score	O
of	O
0-2),	O
had	O
received	O
no	O
chemotherapy	O
(except	O
with	O
estramustine),	O
had	O
undergone	O
surgical	O
or	O
chemical	O
castration,	O
and	O
had	O
been	O
referred	O
to	O
a	O
treatment	O
centre	O
in	O
Finland,	O
Ireland,	O
or	O
Sweden.	O

Enrolment	O
and	O
treatment	O
were	O
done	O
between	O
March	O
1,	O
2004,	O
and	O
May	O
31,	O
2009.	O

Randomisation	O
was	O
done	O
centrally	O
and	O
stratified	O
by	O
centre	O
and	O
WHO	O
performance	O
status	O
score	O
of	O
0-1	O
vs	O
2.	O

Patients	O
were	O
assigned	O
75	O
mg/m(2)	O
docetaxel	O
intravenously	O
on	O
day	O
1	O
of	O
a	O
3-week	O
cycle,	O
or	O
50	O
mg/m(2)	O
docetaxel	O
intravenously	O
on	O
days	O
1	O
and	O
15	O
of	O
a	O
4-week	O
cycle.	O

10	O
mg	O
oral	O
prednisolone	O
was	O
administered	O
daily	O
to	O
all	O
patients.	O

The	O
primary	O
endpoint	O
was	O
time	O
to	O
treatment	O
failure	O
(TTTF).	O

We	O
assessed	O
data	O
in	O
the	O
per-protocol	O
population.	O

177	O
patients	O
were	O
randomly	O
assigned	O
to	O
the	O
2-weekly	O
docetaxel	O
group	O
and	O
184	O
to	O
the	O
3-weekly	O
group.	O

170	O
patients	O
in	O
the	O
2-weekly	O
group	O
and	O
176	O
in	O
the	O
3-weekly	O
group	O
were	O
included	O
in	O
the	O
analysis.	O

The	B-Premise
2-weekly	I-Premise
administration	I-Premise
was	I-Premise
associated	I-Premise
with	I-Premise
significantly	I-Premise
longer	I-Premise
TTTF	I-Premise
than	I-Premise
was	I-Premise
3-weekly	I-Premise
administration	I-Premise
(5Â·6	I-Premise
months,	I-Premise
95%	I-Premise
CI	I-Premise
5Â·0-6Â·2	I-Premise
vs	I-Premise
4Â·9	I-Premise
months,	I-Premise
4Â·5-5Â·4;	I-Premise
hazard	I-Premise
ratio	I-Premise
1Â·3,	I-Premise
95%	I-Premise
CI	I-Premise
1Â·1-1Â·6,	I-Premise
p=0Â·014).	I-Premise

Grade	B-Premise
3-4	I-Premise
adverse	I-Premise
events	I-Premise
occurred	I-Premise
more	I-Premise
frequently	I-Premise
in	I-Premise
the	I-Premise
3-weekly	I-Premise
than	I-Premise
in	I-Premise
the	I-Premise
2-weekly	I-Premise
administration	I-Premise
group,	I-Premise
including	I-Premise
neutropenia	I-Premise
(93	I-Premise
[53%]	I-Premise
vs	I-Premise
61	I-Premise
[36%]),	I-Premise
leucopenia	I-Premise
(51	I-Premise
[29%]	I-Premise
vs	I-Premise
22	I-Premise
[13%]),	I-Premise
and	I-Premise
febrile	I-Premise
neutropenia	I-Premise
(25	I-Premise
[14%]	I-Premise
vs	I-Premise
six	I-Premise
[4%]).	I-Premise

Neutropenic	B-Premise
infections	I-Premise
were	I-Premise
reported	I-Premise
more	I-Premise
frequently	I-Premise
in	I-Premise
patients	I-Premise
who	I-Premise
received	I-Premise
docetaxel	I-Premise
every	I-Premise
3	I-Premise
weeks	I-Premise
(43	I-Premise
[24%]	I-Premise
vs	I-Premise
11	I-Premise
[6%],	I-Premise
p=0Â·002).	I-Premise

Administration	B-Claim
of	I-Claim
docetaxel	I-Claim
every	I-Claim
2	I-Claim
weeks	I-Claim
seems	I-Claim
to	I-Claim
be	I-Claim
well	I-Claim
tolerated	I-Claim
in	I-Claim
patients	I-Claim
with	I-Claim
castration-resistant	I-Claim
advanced	I-Claim
prostate	I-Claim
cancer	I-Claim
and	I-Claim
could	I-Claim
be	I-Claim
a	I-Claim
useful	I-Claim
option	I-Claim
when	I-Claim
3-weekly	I-Claim
single-dose	I-Claim
administration	I-Claim
is	I-Claim
unlikely	I-Claim
to	I-Claim
be	I-Claim
tolerated.	I-Claim

In	O
the	O
Gynecologic	O
Cancer	O
Intergroup	O
International	O
Collaboration	O
on	O
Ovarian	O
Neoplasms	O
7	O
(ICON7)	O
trial,	O
bevacizumab	O
improved	O
progression-free	O
survival	O
in	O
patients	O
with	O
ovarian	O
cancer	O
when	O
used	O
in	O
combination	O
with	O
first-line	O
chemotherapy	O
and	O
as	O
a	O
single-drug	O
continuation	O
treatment	O
for	O
18	O
cycles.	O

In	O
a	O
preliminary	O
analysis	O
of	O
a	O
high-risk	O
subset	O
of	O
patients,	O
there	O
was	O
also	O
an	O
improvement	O
in	O
overall	O
survival.	O

This	O
study	O
aims	O
to	O
describe	O
the	O
health-related	O
quality-of-life	O
(QoL)	O
outcomes	O
from	O
ICON7.	O

ICON7	O
is	O
a	O
randomised,	O
multicentre,	O
open-label	O
phase	O
3	O
trial.	O

Between	O
Dec	O
18,	O
2006,	O
and	O
Feb	O
16,	O
2009,	O
after	O
a	O
surgical	O
procedure	O
aiming	O
to	O
debulk	O
the	O
disease,	O
women	O
with	O
International	O
Federation	O
of	O
Gynecology	O
and	O
Obstetrics	O
(FIGO)	O
high-risk	O
stage	O
I-IV	O
epithelial	O
ovarian	O
cancer	O
were	O
randomly	O
allocated	O
(1:1)	O
by	O
computer	O
program	O
and	O
block	O
randomisation	O
to	O
receive	O
either	O
six	O
cycles	O
of	O
standard	O
chemotherapy	O
(total	O
18	O
weeks)	O
with	O
carboplatin	O
(area	O
under	O
the	O
curve	O
5	O
or	O
6)	O
and	O
paclitaxel	O
(175	O
mg/m(2))	O
alone	O
or	O
with	O
bevacizumab	O
(7Â·5	O
mg/kg)	O
given	O
intravenously	O
with	O
chemotherapy	O
and	O
continued	O
as	O
a	O
single	O
drug	O
thereafter	O
(total	O
54	O
weeks).	O

The	O
primary	O
QoL	O
endpoint	O
was	O
global	O
QoL	O
from	O
the	O
European	O
Organisation	O
for	O
Research	O
and	O
Treatment	O
of	O
Cancer	O
quality-of-life	O
questionnaire-core	O
30	O
at	O
week	O
54,	O
analysed	O
by	O
ANOVA	O
and	O
adjusted	O
for	O
baseline	O
score.	O

Analyses	O
were	O
by	O
intention	O
to	O
treat.	O

The	O
ICON7	O
trial	O
has	O
completed	O
recruitment	O
and	O
remains	O
in	O
follow-up.	O

This	O
study	O
is	O
registered,	O
number	O
ISRCTN91273375.	O

764	O
women	O
were	O
randomly	O
assigned	O
to	O
the	O
standard	O
chemotherapy	O
group	O
and	O
764	O
to	O
the	O
bevacizumab	O
group.	O

At	O
baseline,	O
684	O
(90%)	O
of	O
women	O
in	O
the	O
standard	O
chemotherapy	O
group	O
and	O
691	O
(90%)	O
of	O
those	O
in	O
the	O
bevacizumab	O
group	O
had	O
completed	O
QoL	O
questionnaires.	O

At	O
week	O
54,	O
502	O
(66%)	O
women	O
in	O
the	O
bevacizumab	O
group	O
and	O
388	O
(51%)	O
women	O
in	O
the	O
standard	O
chemotherapy	O
group	O
provided	O
QoL	O
data.	O

Overall,	B-Premise
the	I-Premise
mean	I-Premise
global	I-Premise
QoL	I-Premise
score	I-Premise
improved	I-Premise
during	I-Premise
chemotherapy	I-Premise
by	I-Premise
7Â·2	I-Premise
points	I-Premise
(SD	I-Premise
24Â·4)	I-Premise
when	I-Premise
analysed	I-Premise
for	I-Premise
all	I-Premise
women	I-Premise
with	I-Premise
data	I-Premise
at	I-Premise
baseline	I-Premise
and	I-Premise
week	I-Premise
18.	I-Premise

The	B-Premise
mean	I-Premise
global	I-Premise
QoL	I-Premise
score	I-Premise
at	I-Premise
54	I-Premise
weeks	I-Premise
was	I-Premise
higher	I-Premise
in	I-Premise
the	I-Premise
standard	I-Premise
chemotherapy	I-Premise
group	I-Premise
than	I-Premise
in	I-Premise
the	I-Premise
bevacizumab	I-Premise
group	I-Premise
(76Â·1	I-Premise
[SD	I-Premise
18Â·2]	I-Premise
vs	I-Premise
69Â·7	I-Premise
[19Â·1]	I-Premise
points;	I-Premise
difference	I-Premise
6Â·4	I-Premise
points,	I-Premise
95%	I-Premise
CI	I-Premise
3Â·7-9Â·0,	I-Premise
p<0Â·0001).	I-Premise

Bevacizumab	B-Claim
continuation	I-Claim
treatment	I-Claim
seems	I-Claim
to	I-Claim
be	I-Claim
associated	I-Claim
with	I-Claim
a	I-Claim
small	I-Claim
but	I-Claim
clinically	I-Claim
significant	I-Claim
decrement	I-Claim
in	I-Claim
QoL	I-Claim
compared	I-Claim
with	I-Claim
standard	I-Claim
treatment	I-Claim
for	I-Claim
women	I-Claim
with	I-Claim
ovarian	I-Claim
cancer.	I-Claim

The	O
trade-off	O
between	O
the	O
prolongation	O
of	O
progression-free	O
survival	O
and	O
the	O
quality	O
of	O
that	O
period	O
of	O
time	O
needs	O
to	O
be	O
considered	O
in	O
clinical	O
practice	O
when	O
making	O
treatment	O
decisions.	O

Quality	O
of	O
life	O
(QoL)	O
after	O
breast	O
cancer	O
is	O
nowadays	O
a	O
major	O
challenge.	O

Complementary	O
interventions	O
are	O
necessary	O
because	O
of	O
frequent	O
depression	O
symptoms	O
after	O
treatment	O
and	O
also	O
to	O
favour	O
return	O
to	O
activity.	O

Besides,	O
radio-chemotherapy	O
has	O
side-effects	O
like	O
weight	O
gain	O
and	O
fatigue.	O

Several	O
strategies	O
including	O
group	O
behavioural-educational	O
interventions,	O
physical	O
training	O
and/or	O
dietary	O
education,	O
have	O
been	O
tested	O
to	O
answer	O
these	O
difficulties	O
with	O
moderate	O
success	O
in	O
the	O
long	O
run.	O

Two	O
hundred	O
and	O
fifty-one	O
non-metastatic	O
patients	O
were	O
accrued	O
after	O
chemotherapy	O
in	O
a	O
prospective	O
randomised	O
multicenter	O
trial	O
between	O
2008	O
and	O
2010,	O
testing	O
a	O
2-week	O
intervention	O
in	O
SPA	O
centres.	O

Intervention	O
comprised	O
group	O
physical	O
training,	O
dietary	O
education	O
and	O
physiotherapy.	O

Selected	O
patients	O
were	O
in	O
complete	O
remission.	O

QoL	O
was	O
evaluated	O
with	O
SF36	O
questionnaire,	O
anxiety	O
and	O
depression	O
with	O
the	O
hospital	O
anxiety	O
and	O
depression	O
(HAD)	O
one.	O

Anthropometric	O
measures	O
and	O
QoL	O
evaluations	O
were	O
obtained	O
before	O
randomisation	O
and	O
every	O
6	O
months	O
during	O
3	O
years.	O

Two	O
hundred	O
and	O
twenty	O
patients	O
were	O
evaluable	O
at	O
1	O
year.	O

Intervention	B-Premise
increased	I-Premise
SF36	I-Premise
score	I-Premise
by	I-Premise
9.5	I-Premise
points	I-Premise
(p=0.000006),	I-Premise
4.6	I-Premise
(p=0.032)	I-Premise
and	I-Premise
6.2	I-Premise
(p=0.028)	I-Premise
respectively	I-Premise
at	I-Premise
6,	I-Premise
12	I-Premise
and	I-Premise
24	I-Premise
months.	I-Premise

Effect	B-Premise
size	I-Premise
(ES)	I-Premise
was	I-Premise
0.63	I-Premise
[0.37;	I-Premise
0.90],	I-Premise
0.29	I-Premise
[0.03;	I-Premise
0.55]	I-Premise
and	I-Premise
0.41	I-Premise
[0.04;	I-Premise
0.78].	I-Premise

Anxiety	B-Premise
score	I-Premise
was	I-Premise
shortly	I-Premise
minored	I-Premise
by	I-Premise
intervention	I-Premise
(6-month	I-Premise
ES=-0.24	I-Premise
[-0.42;	I-Premise
-0.05])	I-Premise
and	I-Premise
depression	I-Premise
score	I-Premise
more	I-Premise
durably:	I-Premise
ES=-0.45	I-Premise
[-0.72;	I-Premise
-0.18],	I-Premise
-0.34	I-Premise
[-061;	I-Premise
-0.08],	I-Premise
and	I-Premise
-0.26	I-Premise
[-0.63;	I-Premise
0.11]	I-Premise
at	I-Premise
6,	I-Premise
12	I-Premise
and	I-Premise
24	I-Premise
months.	I-Premise

This	B-Claim
2-week	I-Claim
group	I-Claim
intervention	I-Claim
seemed	I-Claim
to	I-Claim
durably	I-Claim
influence	I-Claim
QoL	I-Claim
of	I-Claim
breast	I-Claim
cancer	I-Claim
patients	I-Claim
treated	I-Claim
by	I-Claim
chemotherapy.	I-Claim

Differences,	B-Claim
smaller	I-Claim
at	I-Claim
12	I-Claim
months	I-Claim
than	I-Claim
at	I-Claim
six,	I-Claim
suggest	I-Claim
that	I-Claim
a	I-Claim
second	I-Claim
but	I-Claim
shorter	I-Claim
intervention	I-Claim
could	I-Claim
help	I-Claim
maintain	I-Claim
the	I-Claim
6-month	I-Claim
benefits.	I-Claim

The	O
addition	O
of	O
mTOR	O
inhibitor	O
everolimus	O
(EVE)	O
to	O
exemestane	O
(EXE)	O
was	O
evaluated	O
in	O
an	O
international,	O
phase	O
3	O
study	O
(BOLERO-2)	O
in	O
patients	O
with	O
hormone-receptor-positive	O
(HR(+))	O
breast	O
cancer	O
refractory	O
to	O
letrozole	O
or	O
anastrozole.	O

The	O
safety	O
and	O
efficacy	O
of	O
anticancer	O
treatments	O
may	O
be	O
influenced	O
by	O
ethnicity	O
(Sekine	O
et	O
al.	O
in	O
Br	O
J	O
Cancer	O
99:1757-62,	O
2008).	O

Safety	O
and	O
efficacy	O
results	O
from	O
Asian	O
versus	O
non-Asian	O
patients	O
in	O
BOLERO-2	O
are	O
reported.	O

Patients	O
were	O
randomized	O
(2:1)	O
to	O
10	O
mg/day	O
EVE	O
+	O
EXE	O
or	O
placebo	O
(PBO)	O
+	O
EXE.	O

Primary	O
endpoint	O
was	O
progression-free	O
survival	O
(PFS).	O

Secondary	O
endpoints	O
included	O
overall	O
survival,	O
response	O
rate,	O
clinical	O
benefit	O
rate,	O
and	O
safety.	O

Of	O
143	O
Asian	O
patients,	O
98	O
received	O
EVE	O
+	O
EXE	O
and	O
45	O
received	O
PBO	O
+	O
EXE.	O

Treatment	B-Premise
with	I-Premise
EVE	I-Premise
+	I-Premise
EXE	I-Premise
significantly	I-Premise
improved	I-Premise
median	I-Premise
PFS	I-Premise
versus	I-Premise
PBO	I-Premise
+	I-Premise
EXE	I-Premise
among	I-Premise
Asian	I-Premise
patients	I-Premise
by	I-Premise
38	I-Premise
%	I-Premise
(HR	I-Premise
=	I-Premise
0.62;	I-Premise
95	I-Premise
%	I-Premise
CI,	I-Premise
0.41-0.94).	I-Premise

Median	B-Premise
PFS	I-Premise
was	I-Premise
also	I-Premise
improved	I-Premise
among	I-Premise
non-Asian	I-Premise
patients	I-Premise
by	I-Premise
59	I-Premise
%	I-Premise
(HR	I-Premise
=	I-Premise
0.41;	I-Premise
95	I-Premise
%	I-Premise
CI,	I-Premise
0.33-0.50).	I-Premise

Median	B-Premise
PFS	I-Premise
duration	I-Premise
among	I-Premise
EVE-treated	I-Premise
Asian	I-Premise
patients	I-Premise
was	I-Premise
8.48	I-Premise
versus	I-Premise
4.14	I-Premise
months	I-Premise
for	I-Premise
PBO	I-Premise
+	I-Premise
EXE,	I-Premise
and	I-Premise
7.33	I-Premise
versus	I-Premise
2.83	I-Premise
months,	I-Premise
respectively,	I-Premise
in	I-Premise
non-Asian	I-Premise
patients.	I-Premise

The	B-Premise
most	I-Premise
common	I-Premise
grade	I-Premise
3/4	I-Premise
adverse	I-Premise
events	I-Premise
(stomatitis,	I-Premise
anemia,	I-Premise
elevated	I-Premise
liver	I-Premise
enzymes,	I-Premise
hyperglycemia,	I-Premise
and	I-Premise
dyspnea)	I-Premise
occurred	I-Premise
at	I-Premise
similar	I-Premise
frequencies	I-Premise
in	I-Premise
Asian	I-Premise
and	I-Premise
non-Asian	I-Premise
patients.	I-Premise

Grade	B-Premise
1/2	I-Premise
interstitial	I-Premise
lung	I-Premise
disease	I-Premise
occurred	I-Premise
more	I-Premise
frequently	I-Premise
in	I-Premise
Asian	I-Premise
patients.	I-Premise

Quality	B-Premise
of	I-Premise
life	I-Premise
was	I-Premise
similar	I-Premise
between	I-Premise
treatment	I-Premise
arms	I-Premise
in	I-Premise
Asian	I-Premise
patients.	I-Premise

Adding	B-Claim
EVE	I-Claim
to	I-Claim
EXE	I-Claim
provided	I-Claim
substantial	I-Claim
clinical	I-Claim
benefit	I-Claim
in	I-Claim
both	I-Claim
Asian	I-Claim
and	I-Claim
non-Asian	I-Claim
patients	I-Claim
with	I-Claim
similar	I-Claim
safety	I-Claim
profiles.	I-Claim

This	B-Claim
combination	I-Claim
represents	I-Claim
an	I-Claim
improvement	I-Claim
in	I-Claim
the	I-Claim
management	I-Claim
of	I-Claim
postmenopausal	I-Claim
women	I-Claim
with	I-Claim
HR(+)/HER2(-)	I-Claim
advanced	I-Claim
breast	I-Claim
cancer	I-Claim
progressing	I-Claim
on	I-Claim
nonsteroidal	I-Claim
aromatase	I-Claim
inhibitors,	I-Claim
regardless	I-Claim
of	I-Claim
ethnicity.	I-Claim

Bacillus	B-MajorClaim
Calmette-GuÃ©rin	I-MajorClaim
and	I-MajorClaim
intravesical	I-MajorClaim
chemotherapy	I-MajorClaim
represent	I-MajorClaim
viable	I-MajorClaim
adjuvant	I-MajorClaim
options	I-MajorClaim
for	I-MajorClaim
intermediate	I-MajorClaim
risk	I-MajorClaim
nonmuscle	I-MajorClaim
invasive	I-MajorClaim
bladder	I-MajorClaim
cancer.	I-MajorClaim

Although	O
bacillus	O
Calmette-GuÃ©rin	O
is	O
perceived	O
as	O
less	O
tolerable	O
than	O
intravesical	O
chemotherapy,	O
to	O
our	O
knowledge	O
no	O
comparative	O
studies	O
have	O
addressed	O
quality	O
of	O
life	O
issues.	O

We	O
compared	O
the	O
quality	O
of	O
life	O
of	O
patients	O
with	O
nonmuscle	O
invasive	O
bladder	O
cancer	O
who	O
received	O
adjuvant	O
intravesical	O
gemcitabine	O
or	O
1/3	O
dose	O
bacillus	O
Calmette-GuÃ©rin.	O

Our	O
multicenter,	O
prospective,	O
randomized,	O
phase	O
II	O
study	O
included	O
120	O
patients	O
with	O
intermediate	O
risk	O
nonmuscle	O
invasive	O
bladder	O
cancer.	O

Of	O
these	O
patients	O
88	O
remained	O
assessable	O
at	O
1-year	O
followup.	O

Only	O
1	O
patient	O
was	O
withdrawn	O
because	O
of	O
adverse	O
events.	O

Overall	O
61	O
patients	O
received	O
2,000	O
mg/50	O
cc	O
gemcitabine	O
weekly	O
for	O
6	O
weeks	O
(maintenance	O
monthly	O
for	O
1	O
year)	O
while	O
59	O
received	O
1/3	O
dose	O
bacillus	O
Calmette-GuÃ©rin	O
Connaught	O
weekly	O
for	O
6	O
weeks	O
(maintenance	O
3	O
weekly	O
instillations	O
at	O
3,	O
6	O
and	O
12	O
months).	O

Quality	O
of	O
life	O
was	O
measured	O
by	O
the	O
EORTC	O
QLQ-C30	O
(European	O
Organization	O
for	O
the	O
Research	O
and	O
Treatment	O
of	O
Cancer	O
Quality	O
of	O
Life	O
Questionnaire	O
Core	O
30	O
version	O
3.0)	O
and	O
QLQ-BLS24	O
(Quality	O
of	O
Life	O
Superficial	O
Bladder	O
Cancer-Specific	O
24)	O
questionnaires.	O

Group	O
differences	O
were	O
calculated	O
using	O
ANOVA	O
(ANOVA/MANOVA).	O

Treatment	B-Premise
was	I-Premise
well	I-Premise
tolerated	I-Premise
in	I-Premise
both	I-Premise
groups,	I-Premise
although	B-Premise
local	I-Premise
and	I-Premise
systemic	I-Premise
side	I-Premise
effects	I-Premise
were	I-Premise
more	I-Premise
frequently	I-Premise
reported	I-Premise
in	I-Premise
the	I-Premise
bacillus	I-Premise
Calmette-GuÃ©rin	I-Premise
arm.	I-Premise

Multivariate	B-Premise
analyses	I-Premise
showed	I-Premise
no	I-Premise
significant	I-Premise
differences	I-Premise
between	I-Premise
the	I-Premise
2	I-Premise
groups	I-Premise
in	I-Premise
all	I-Premise
quality	I-Premise
of	I-Premise
life	I-Premise
dimensions.	I-Premise

No	B-Premise
significant	I-Premise
changes	I-Premise
over	I-Premise
time	I-Premise
in	I-Premise
quality	I-Premise
of	I-Premise
life	I-Premise
domains	I-Premise
were	I-Premise
detected	I-Premise
for	I-Premise
patients	I-Premise
on	I-Premise
bacillus	I-Premise
Calmette-GuÃ©rin	I-Premise
and	I-Premise
gemcitabine	I-Premise
except	I-Premise
for	I-Premise
physical	I-Premise
functioning,	I-Premise
which	I-Premise
decreased	I-Premise
significantly	I-Premise
in	I-Premise
both	I-Premise
groups	I-Premise
(p	I-Premise
=	I-Premise
0.002).	I-Premise

No	B-Premise
significant	I-Premise
differences	I-Premise
were	I-Premise
detected	I-Premise
in	I-Premise
terms	I-Premise
of	I-Premise
recurrence	I-Premise
and	I-Premise
progression	I-Premise
between	I-Premise
the	I-Premise
2	I-Premise
groups	I-Premise
at	I-Premise
1-year	I-Premise
followup.	I-Premise

While	O
a	B-Claim
higher	I-Claim
rate	I-Claim
of	I-Claim
side	I-Claim
effects,	I-Claim
albeit	I-Claim
mild	I-Claim
to	I-Claim
moderate,	I-Claim
was	I-Claim
detected	I-Claim
with	I-Claim
1/3	I-Claim
dose	I-Claim
bacillus	I-Claim
Calmette-GuÃ©rin	I-Claim
compared	I-Claim
to	I-Claim
gemcitabine,	I-Claim
our	B-Claim
study	I-Claim
failed	I-Claim
to	I-Claim
show	I-Claim
significant	I-Claim
differences	I-Claim
between	I-Claim
the	I-Claim
2	I-Claim
drugs	I-Claim
in	I-Claim
terms	I-Claim
of	I-Claim
quality	I-Claim
of	I-Claim
life.	I-Claim

Although	O
chemotherapy-induced	O
cognitive	O
impairment	O
is	O
common	O
among	O
breast	O
cancer	O
patients,	O
evidence	O
for	O
effective	O
interventions	O
addressing	O
cognitive	O
deficits	O
is	O
limited.	O

This	O
randomized	O
controlled	O
trial	O
examined	O
the	O
feasibility	O
and	O
preliminary	O
efficacy	O
of	O
a	O
Tibetan	O
Sound	O
Meditation	O
(TSM)	O
program	O
to	O
improve	O
cognitive	O
function	O
and	O
quality	O
of	O
life	O
in	O
breast	O
cancer	O
patients.	O

Forty-seven	O
breast	O
cancer	O
patients	O
(mean	O
age	O
56.3	O
years),	O
who	O
were	O
staged	O
I-III	O
at	O
diagnosis,	O
6-60	O
months	O
post-chemotherapy,	O
and	O
reported	O
cognitive	O
impairment	O
at	O
study	O
entry	O
were	O
recruited.	O

Participants	O
were	O
randomized	O
to	O
either	O
two	O
weekly	O
TSM	O
sessions	O
for	O
6	O
weeks	O
or	O
a	O
wait	O
list	O
control	O
group.	O

Neuropsychological	O
assessments	O
were	O
completed	O
at	O
baseline	O
and	O
1	O
month	O
post-treatment.	O

Self-report	O
measures	O
of	O
cognitive	O
function	O
(Functional	O
Assessment	O
of	O
Cancer	O
Therapy	O
(FACT)-Cog),	O
quality	O
of	O
life	O
(SF-36),	O
depressive	O
symptoms	O
(Center	O
for	O
Epidemiologic	O
Studies	O
Depression	O
Scale),	O
sleep	O
disturbance	O
(Pittsburgh	O
Sleep	O
Quality	O
Index),	O
fatigue	O
(Brief	O
Fatigue	O
Inventory),	O
and	O
spirituality	O
(FACT-Sp)	O
were	O
completed	O
at	O
baseline,	O
the	O
end	O
of	O
treatment,	O
and	O
1	O
month	O
later.	O

Relative	B-Premise
to	I-Premise
the	I-Premise
control	I-Premise
group,	I-Premise
women	I-Premise
in	I-Premise
the	I-Premise
TSM	I-Premise
group	I-Premise
performed	I-Premise
better	I-Premise
on	I-Premise
the	I-Premise
verbal	I-Premise
memory	I-Premise
test	I-Premise
(Rey	I-Premise
Auditory	I-Premise
Verbal	I-Premise
Learning	I-Premise
Test	I-Premise
trial	I-Premise
1)	I-Premise
(p	I-Premise
=	I-Premise
0.06)	I-Premise
and	I-Premise
the	I-Premise
short-term	I-Premise
memory	I-Premise
and	I-Premise
processing	I-Premise
speed	I-Premise
task	I-Premise
(Digit	I-Premise
Symbol)	I-Premise
(p	I-Premise
=	I-Premise
0.09)	I-Premise
and	I-Premise
reported	I-Premise
improved	I-Premise
cognitive	I-Premise
function	I-Premise
(p	I-Premise
=	I-Premise
0.06),	I-Premise
cognitive	I-Premise
abilities	I-Premise
(p	I-Premise
=	I-Premise
0.08),	I-Premise
mental	I-Premise
health	I-Premise
(p	I-Premise
=	I-Premise
0.04),	I-Premise
and	I-Premise
spirituality	I-Premise
(p	I-Premise
=	I-Premise
0.05)	I-Premise
at	I-Premise
the	I-Premise
end	I-Premise
of	I-Premise
treatment	I-Premise
but	I-Premise
not	I-Premise
1	I-Premise
month	I-Premise
later.	I-Premise

This	B-Claim
randomized	I-Claim
controlled	I-Claim
trial	I-Claim
revealed	I-Claim
that	I-Claim
TSM	I-Claim
program	I-Claim
appears	I-Claim
to	I-Claim
be	I-Claim
a	I-Claim
feasible	I-Claim
and	I-Claim
acceptable	I-Claim
intervention	I-Claim
and	I-Claim
may	I-Claim
be	I-Claim
associated	I-Claim
with	I-Claim
short-term	I-Claim
improvements	I-Claim
in	I-Claim
objective	I-Claim
and	I-Claim
subjective	I-Claim
cognitive	I-Claim
function	I-Claim
as	I-Claim
well	I-Claim
as	I-Claim
mental	I-Claim
health	I-Claim
and	I-Claim
spirituality	I-Claim
in	I-Claim
breast	I-Claim
cancer	I-Claim
patients.	I-Claim

Restorative	O
proctocolectomy	O
with	O
ileal	O
pouch-anal	O
anastomosis	O
(IPAA)	O
is	O
the	O
standard	O
surgical	O
procedure	O
for	O
ulcerative	O
colitis	O
(UC)	O
and	O
familial	O
adenomatous	O
polyposis	O
(FAP).	O

While	O
minimal	O
invasive	O
techniques	O
have	O
been	O
applied	O
increasingly,	O
clear	O
evidence	O
of	O
superiority	O
for	O
laparoscopic	O
pouch	O
procedures	O
is	O
not	O
yet	O
available.	O

The	O
aim	O
of	O
the	O
LapConPouch	O
Trial	O
was	O
to	O
compare	O
the	O
effectiveness	O
of	O
laparoscopic	O
(LAP)	O
versus	O
conventional	O
(CON)	O
ileoanal	O
pouch	O
procedure	O
in	O
patients	O
undergoing	O
elective	O
restorative	O
proctocolectomy.	O

The	O
trial	O
was	O
designed	O
as	O
a	O
single-centre,	O
pre-operatively	O
randomized,	O
controlled	O
trial	O
using	O
a	O
two-group	O
parallel	O
superiority	O
design.	O

Eligible	O
for	O
participation	O
were	O
patients	O
scheduled	O
for	O
restorative	O
proctocolectomy	O
either	O
for	O
FAP	O
or	O
for	O
UC.	O

Patients	O
and	O
outcome	O
assessors	O
were	O
blinded	O
to	O
group	O
assignment.	O

The	O
primary	O
endpoint	O
was	O
defined	O
as	O
the	O
amount	O
of	O
blood	O
loss.	O

Statistical	O
analyses	O
were	O
explorative	O
since	O
the	O
trial	O
had	O
to	O
be	O
stopped	O
prematurely.	O

A	O
total	O
of	O
42	O
patients	O
(21	O
LAP	O
(50.0	O
%);	O
21	O
CON	O
(50.0	O
%))	O
were	O
randomized.	O

The	B-Premise
trial	I-Premise
had	I-Premise
to	I-Premise
be	I-Premise
stopped	I-Premise
prematurely	I-Premise
due	I-Premise
to	I-Premise
insufficient	I-Premise
patient	I-Premise
recruitment.	I-Premise

There	B-Premise
was	I-Premise
no	I-Premise
difference	I-Premise
in	I-Premise
the	I-Premise
amount	I-Premise
of	I-Premise
blood	I-Premise
loss	I-Premise
between	I-Premise
both	I-Premise
groups:	I-Premise
LAP	I-Premise
261.5	I-Premise
Â±	I-Premise
195.4	I-Premise
ml,	I-Premise
CON	I-Premise
228.1	I-Premise
Â±	I-Premise
119.5	I-Premise
ml.	I-Premise

Secondary	O
endpoints	O
differ	O
in	O
both	O
groups.	O

Laparoscopic	B-Claim
surgery	I-Claim
was	I-Claim
superior	I-Claim
regarding	I-Claim
the	I-Claim
length	I-Claim
of	I-Claim
skin	I-Claim
incision;	I-Claim
in	O
contrast,	O
the	B-Claim
conventional	I-Claim
approach	I-Claim
was	I-Claim
superior	I-Claim
in	I-Claim
duration	I-Claim
of	I-Claim
operation.	I-Claim

There	B-Premise
were	I-Premise
no	I-Premise
discrepancies	I-Premise
in	I-Premise
length	I-Premise
of	I-Premise
hospital	I-Premise
stay,	I-Premise
postoperative	I-Premise
pain,	I-Premise
bowel	I-Premise
function,	I-Premise
and	I-Premise
quality	I-Premise
of	I-Premise
life	I-Premise
between	I-Premise
both	I-Premise
approaches.	I-Premise

The	O
conversion	O
rate	O
from	O
LAP	O
to	O
CON	O
approach	O
was	O
23.8	O
%.	O

There	B-Claim
was	I-Claim
no	I-Claim
difference	I-Claim
with	I-Claim
respect	I-Claim
to	I-Claim
blood	I-Claim
loss	I-Claim
between	I-Claim
the	I-Claim
LAP	I-Claim
and	I-Claim
the	I-Claim
CON	I-Claim
group.	I-Claim

The	B-Claim
LAP	I-Claim
approach	I-Claim
is	I-Claim
feasible	I-Claim
for	I-Claim
restorative	I-Claim
proctocolectomy,	I-Claim
and	I-Claim
IPAA	I-Claim
seems	I-Claim
at	I-Claim
least	I-Claim
as	I-Claim
safe	I-Claim
as	I-Claim
CON	I-Claim
surgery.	I-Claim

The	O
most	O
obvious	O
advantage	O
of	O
the	O
minimal	O
invasive	O
technique	O
is	O
the	O
improved	O
cosmesis.	O

Colorectal	O
cancer	O
survivors	O
are	O
at	O
risk	O
for	O
poor	O
health	O
outcomes	O
because	O
of	O
unhealthy	O
lifestyles,	O
but	O
few	O
studies	O
have	O
developed	O
translatable	O
health	O
behavior	O
change	O
interventions.	O

This	O
study	O
aimed	O
to	O
determine	O
the	O
effects	O
of	O
a	O
telephone-delivered	O
multiple	O
health	O
behavior	O
change	O
intervention	O
(CanChange)	O
on	O
health	O
and	O
behavioral	O
outcomes	O
among	O
colorectal	O
cancer	O
survivors.	O

In	O
this	O
two-group	O
randomized	O
controlled	O
trial,	O
410	O
colorectal	O
cancer	O
survivors	O
were	O
randomly	O
assigned	O
to	O
the	O
health	O
coaching	O
intervention	O
(11	O
theory-based	O
telephone-delivered	O
health	O
coaching	O
sessions	O
delivered	O
over	O
6	O
months	O
focusing	O
on	O
physical	O
activity,	O
weight	O
management,	O
dietary	O
habits,	O
alcohol,	O
and	O
smoking)	O
or	O
usual	O
care.	O

Assessment	O
of	O
primary	O
(ie,	O
physical	O
activity	O
[Godin	O
Leisure	O
Time	O
Index],	O
health-related	O
quality	O
of	O
life	O
[HRQoL;	O
Short	O
Form-36],	O
and	O
cancer-related	O
fatigue	O
[Functional	O
Assessment	O
of	O
Chronic	O
Illness	O
Therapy	O
Fatigue	O
Scale])	O
and	O
secondary	O
outcomes	O
(ie,	O
body	O
mass	O
index	O
[kg/m(2)],	O
diet	O
and	O
alcohol	O
intake	O
[Food	O
Frequency	O
Questionnaire],	O
and	O
smoking)	O
were	O
conducted	O
at	O
baseline	O
and	O
6	O
and	O
12	O
months.	O

At	B-Premise
12	I-Premise
months,	I-Premise
significant	I-Premise
intervention	I-Premise
effects	I-Premise
were	I-Premise
observed	I-Premise
for	I-Premise
moderate	I-Premise
physical	I-Premise
activity	I-Premise
(28.5	I-Premise
minutes;	I-Premise
P	I-Premise
=	I-Premise
.003),	I-Premise
body	I-Premise
mass	I-Premise
index	I-Premise
(-0.9	I-Premise
kg/m(2);	I-Premise
P	I-Premise
=	I-Premise
.001),	I-Premise
energy	I-Premise
from	I-Premise
total	I-Premise
fat	I-Premise
(-7.0%;	I-Premise
P	I-Premise
=	I-Premise
.006),	I-Premise
and	I-Premise
energy	I-Premise
from	I-Premise
saturated	I-Premise
fat	I-Premise
(-2.8%;	I-Premise
P	I-Premise
=	I-Premise
.016).	I-Premise

A	B-Premise
significant	I-Premise
intervention	I-Premise
effect	I-Premise
was	I-Premise
reported	I-Premise
for	I-Premise
vegetable	I-Premise
intake	I-Premise
(0.4	I-Premise
servings	I-Premise
per	I-Premise
day;	I-Premise
P	I-Premise
=	I-Premise
.001)	I-Premise
at	I-Premise
6	I-Premise
months.	I-Premise

No	B-Premise
significant	I-Premise
group	I-Premise
differences	I-Premise
were	I-Premise
found	I-Premise
at	I-Premise
6	I-Premise
or	I-Premise
12	I-Premise
months	I-Premise
for	I-Premise
HRQoL,	I-Premise
cancer-related	I-Premise
fatigue,	I-Premise
fruit,	I-Premise
fiber,	I-Premise
or	I-Premise
alcohol	I-Premise
intake,	I-Premise
or	I-Premise
smoking.	I-Premise

The	B-Claim
CanChange	I-Claim
intervention	I-Claim
was	I-Claim
effective	I-Claim
for	I-Claim
improving	I-Claim
physical	I-Claim
activity,	I-Claim
dietary	I-Claim
habits,	I-Claim
and	I-Claim
body	I-Claim
mass	I-Claim
index	I-Claim
in	I-Claim
colorectal	I-Claim
cancer	I-Claim
survivors.	I-Claim

The	O
intervention	O
is	O
translatable	O
through	O
existing	O
telephone	O
cancer	O
support	O
and	O
information	O
services	O
in	O
Australia	O
and	O
other	O
countries.	O

Enhanced	O
recovery	O
programmes	O
(ERPs)	O
have	O
been	O
shown	O
to	O
reduce	O
length	O
of	O
hospital	O
stay	O
(LOS)	O
and	O
complications	O
in	O
colorectal	O
surgery.	O

Whether	O
ERPs	O
have	O
the	O
same	O
benefits	O
in	O
open	O
liver	O
resection	O
surgery	O
is	O
unclear,	O
and	O
randomized	O
clinical	O
trials	O
are	O
lacking.	O

Consecutive	O
patients	O
scheduled	O
for	O
open	O
liver	O
resection	O
were	O
randomized	O
to	O
an	O
ERP	O
group	O
or	O
standard	O
care.	O

Primary	O
endpoints	O
were	O
time	O
until	O
medically	O
fit	O
for	O
discharge	O
(MFD)	O
and	O
LOS.	O

Secondary	O
endpoints	O
were	O
postoperative	O
morbidity,	O
pain	O
scores,	O
readmission	O
rate,	O
mortality,	O
quality	O
of	O
life	O
(QoL)	O
and	O
patient	O
satisfaction.	O

ERP	O
elements	O
included	O
greater	O
preoperative	O
education,	O
preoperative	O
oral	O
carbohydrate	O
loading,	O
postoperative	O
goal-directed	O
fluid	O
therapy,	O
early	O
mobilization	O
and	O
physiotherapy.	O

Both	O
groups	O
received	O
standardized	O
anaesthesia	O
with	O
epidural	O
analgesia.	O

The	O
analysis	O
included	O
46	O
patients	O
in	O
the	O
ERP	O
group	O
and	O
45	O
in	O
the	O
standard	O
care	O
group.	O

Median	B-Premise
MFD	I-Premise
time	I-Premise
was	I-Premise
reduced	I-Premise
in	I-Premise
the	I-Premise
ERP	I-Premise
group	I-Premise
(3	I-Premise
days	I-Premise
versus	I-Premise
6	I-Premise
days	I-Premise
with	I-Premise
standard	I-Premise
care;	I-Premise
P	I-Premise
<	I-Premise
0Â·001),	I-Premise
as	I-Premise
was	I-Premise
LOS	I-Premise
(4	I-Premise
days	I-Premise
versus	I-Premise
7	I-Premise
days;	I-Premise
P	I-Premise
<	I-Premise
0Â·001).	I-Premise

The	B-Premise
ERP	I-Premise
significantly	I-Premise
reduced	I-Premise
the	I-Premise
rate	I-Premise
of	I-Premise
medical	I-Premise
complications	I-Premise
(7	I-Premise
versus	I-Premise
27	I-Premise
per	I-Premise
cent;	I-Premise
P	I-Premise
=	I-Premise
0Â·020),	I-Premise
but	B-Premise
not	I-Premise
surgical	I-Premise
complications	I-Premise
(15	I-Premise
versus	I-Premise
11	I-Premise
per	I-Premise
cent;	I-Premise
P	I-Premise
=	I-Premise
0Â·612),	I-Premise
readmissions	I-Premise
(4	I-Premise
versus	I-Premise
0	I-Premise
per	I-Premise
cent;	I-Premise
P	I-Premise
=	I-Premise
0Â·153)	I-Premise
or	I-Premise
mortality	I-Premise
(both	I-Premise
2	I-Premise
per	I-Premise
cent;	I-Premise
P	I-Premise
=	I-Premise
0Â·987).	I-Premise

QoL	B-Premise
over	I-Premise
28	I-Premise
days	I-Premise
was	I-Premise
significantly	I-Premise
better	I-Premise
in	I-Premise
the	I-Premise
ERP	I-Premise
group	I-Premise
(P	I-Premise
=	I-Premise
0Â·002).	I-Premise

There	B-Premise
was	I-Premise
no	I-Premise
difference	I-Premise
in	I-Premise
patient	I-Premise
satisfaction.	I-Premise

ERPs	B-Claim
for	I-Claim
open	I-Claim
liver	I-Claim
resection	I-Claim
surgery	I-Claim
are	I-Claim
safe	I-Claim
and	I-Claim
effective.	I-Claim

Patients	B-Claim
treated	I-Claim
in	I-Claim
the	I-Claim
ERP	I-Claim
recovered	I-Claim
faster,	I-Claim
were	I-Claim
discharged	I-Claim
sooner,	I-Claim
and	I-Claim
had	I-Claim
fewer	I-Claim
medical-related	I-Claim
complications	I-Claim
and	I-Claim
improved	I-Claim
QoL.	I-Claim

To	O
analyze	O
the	O
clinical	O
course,	O
treatment,	O
complications,	O
outcome,	O
and	O
quality	O
of	O
life	O
(QOL)	O
in	O
patients	O
with	O
perineal/perianal	O
rhabdomyosarcoma	O
(PRMS)	O
treated	O
within	O
the	O
CWS-86,	O
-91,	O
-96,	O
and	O
-2002P	O
trials.	O

Although	O
multiple	O
international	O
study	O
trials	O
exist	O
for	O
the	O
treatment	O
of	O
rhabdomyosarcoma,	O
only	O
very	O
limited	O
information	O
is	O
given	O
on	O
treatment,	O
outcome,	O
and	O
QOL	O
in	O
PRMS.	O

A	O
total	O
of	O
35	O
patients	O
suffering	O
from	O
PRMS	O
were	O
treated	O
with	O
neoadjuvant	O
chemotherapy.	O

Local	O
therapy	O
with	O
radiation	O
and/or	O
surgery	O
was	O
performed,	O
followed	O
by	O
adjuvant	O
chemotherapy.	O

Functional	O
long-term	O
follow-up	O
was	O
evaluated	O
by	O
a	O
gastrointestinal/QOL	O
survey.	O

Thirty-two	O
patients	O
were	O
evaluated	O
(exclusion	O
n	O
=	O
3).	O

Eight	O
patients	O
had	O
embryonal	O
histology,	O
and	O
24	O
patients	O
had	O
alveolar	O
histology.	O

The	O
median	O
age	O
was	O
108	O
months	O
(median	O
follow-up:	O
5.8	O
years).	O

The	O
5-year	O
overall	O
survival	O
was	O
47%	O
(95%	O
confidence	O
interval:	O
29-64).	O

Sixteen	O
IRS	O
(Intergroup	O
Rhabdomyosarcoma	O
Study)	O
III	O
and	O
IV	O
patients	O
had	O
locoregional	O
lymph	O
node	O
involvement	O
at	O
diagnosis.	O

Seven	O
patients	O
were	O
treated	O
with	O
chemotherapy/surgery	O
alone	O
[5-year	O
event-free	O
survival	O
(EFS):	O
85.7%].	O

Eleven	O
patients	O
received	O
only	O
radiochemotherapy	O
(5-year	O
EFS:	O
27.3%).	O

Combined	O
radiochemotherapy/surgery	O
was	O
used	O
in	O
12	O
patients	O
(5-year	O
EFS:	O
63.6%).	O

Two	O
patients	O
were	O
treated	O
only	O
with	O
chemotherapy	O
and	O
they	O
died.	O

Patients	B-Premise
with	I-Premise
embryonal	I-Premise
histology	I-Premise
had	I-Premise
a	I-Premise
significantly	I-Premise
better	I-Premise
5-year	I-Premise
EFS	I-Premise
(87.5%)	I-Premise
than	I-Premise
patients	I-Premise
with	I-Premise
alveolar	I-Premise
histology	I-Premise
(39.1%;	I-Premise
P	I-Premise
=	I-Premise
0.013).	I-Premise

Some	B-Premise
patients	I-Premise
reported	I-Premise
symptoms	I-Premise
of	I-Premise
fecal	I-Premise
incontinence.	I-Premise

The	B-Premise
median	I-Premise
Wexner	I-Premise
fecal	I-Premise
incontinence	I-Premise
score	I-Premise
was	I-Premise
9	I-Premise
(possible	I-Premise
range:	I-Premise
0-20),	I-Premise
and	I-Premise
the	I-Premise
median	I-Premise
QOL	I-Premise
score	I-Premise
was	I-Premise
90.5	I-Premise
(applicable	I-Premise
range:	I-Premise
0-144).	I-Premise

The	B-Claim
outcome	I-Claim
of	I-Claim
these	I-Claim
patients	I-Claim
remains	I-Claim
unsatisfactory.	I-Claim

Prognostic	B-Premise
factors	I-Premise
for	I-Premise
a	I-Premise
favorable	I-Premise
outcome	I-Premise
are	I-Premise
tumor	I-Premise
size	I-Premise
of	I-Premise
smaller	I-Premise
than	I-Premise
5	I-Premise
cm,	I-Premise
negative	I-Premise
locoregional	I-Premise
lymph	I-Premise
nodes,	I-Premise
age	I-Premise
less	I-Premise
than	I-Premise
10	I-Premise
years,	I-Premise
low	I-Premise
IRS	I-Premise
group,	I-Premise
and	I-Premise
embryonal	I-Premise
histology.	I-Premise

Fecal	B-Claim
incontinence	I-Claim
seems	I-Claim
to	I-Claim
be	I-Claim
a	I-Claim
problem.	I-Claim

Menopausal	O
hormone	O
therapy	O
continues	O
in	O
clinical	O
use	O
but	O
questions	O
remain	O
regarding	O
its	O
risks	O
and	O
benefits	O
for	O
chronic	O
disease	O
prevention.	O

To	O
report	O
a	O
comprehensive,	O
integrated	O
overview	O
of	O
findings	O
from	O
the	O
2	O
Women's	O
Health	O
Initiative	O
(WHI)	O
hormone	O
therapy	O
trials	O
with	O
extended	O
postintervention	O
follow-up.	O

A	O
total	O
of	O
27,347	O
postmenopausal	O
women	O
aged	O
50	O
to	O
79	O
years	O
were	O
enrolled	O
at	O
40	O
US	O
centers.	O

Women	O
with	O
an	O
intact	O
uterus	O
received	O
conjugated	O
equine	O
estrogens	O
(CEE;	O
0.625	O
mg/d)	O
plus	O
medroxyprogesterone	O
acetate	O
(MPA;	O
2.5	O
mg/d)	O
(n	O
=	O
8506)	O
or	O
placebo	O
(n	O
=	O
8102).	O

Women	O
with	O
prior	O
hysterectomy	O
received	O
CEE	O
alone	O
(0.625	O
mg/d)	O
(n	O
=	O
5310)	O
or	O
placebo	O
(n	O
=	O
5429).	O

The	O
intervention	O
lasted	O
a	O
median	O
of	O
5.6	O
years	O
in	O
CEE	O
plus	O
MPA	O
trial	O
and	O
7.2	O
years	O
in	O
CEE	O
alone	O
trial	O
with	O
13	O
years	O
of	O
cumulative	O
follow-up	O
until	O
September	O
30,	O
2010.	O

Primary	O
efficacy	O
and	O
safety	O
outcomes	O
were	O
coronary	O
heart	O
disease	O
(CHD)	O
and	O
invasive	O
breast	O
cancer,	O
respectively.	O

A	O
global	O
index	O
also	O
included	O
stroke,	O
pulmonary	O
embolism,	O
colorectal	O
cancer,	O
endometrial	O
cancer,	O
hip	O
fracture,	O
and	O
death.	O

During	B-Premise
the	I-Premise
CEE	I-Premise
plus	I-Premise
MPA	I-Premise
intervention	I-Premise
phase,	I-Premise
the	I-Premise
numbers	I-Premise
of	I-Premise
CHD	I-Premise
cases	I-Premise
were	I-Premise
196	I-Premise
for	I-Premise
CEE	I-Premise
plus	I-Premise
MPA	I-Premise
vs	I-Premise
159	I-Premise
for	I-Premise
placebo	I-Premise
(hazard	I-Premise
ratio	I-Premise
[HR],	I-Premise
1.18;	I-Premise
95%	I-Premise
CI,	I-Premise
0.95-1.45)	I-Premise
and	I-Premise
206	I-Premise
vs	I-Premise
155,	I-Premise
respectively,	I-Premise
for	I-Premise
invasive	I-Premise
breast	I-Premise
cancer	I-Premise
(HR,	I-Premise
1.24;	I-Premise
95%	I-Premise
CI,	I-Premise
1.01-1.53).	I-Premise

Other	B-Premise
risks	I-Premise
included	I-Premise
increased	I-Premise
stroke,	I-Premise
pulmonary	I-Premise
embolism,	I-Premise
dementia	I-Premise
(in	I-Premise
women	I-Premise
aged	I-Premise
â¥65	I-Premise
years),	I-Premise
gallbladder	I-Premise
disease,	I-Premise
and	I-Premise
urinary	I-Premise
incontinence;	I-Premise
benefits	I-Premise
included	I-Premise
decreased	I-Premise
hip	I-Premise
fractures,	I-Premise
diabetes,	I-Premise
and	I-Premise
vasomotor	I-Premise
symptoms.	I-Premise

Most	B-Premise
risks	I-Premise
and	I-Premise
benefits	I-Premise
dissipated	I-Premise
postintervention,	I-Premise
although	B-Premise
some	I-Premise
elevation	I-Premise
in	I-Premise
breast	I-Premise
cancer	I-Premise
risk	I-Premise
persisted	I-Premise
during	I-Premise
cumulative	I-Premise
follow-up	I-Premise
(434	I-Premise
cases	I-Premise
for	I-Premise
CEE	I-Premise
plus	I-Premise
MPA	I-Premise
vs	I-Premise
323	I-Premise
for	I-Premise
placebo;	I-Premise
HR,	I-Premise
1.28	I-Premise
[95%	I-Premise
CI,	I-Premise
1.11-1.48]).	I-Premise

The	B-Premise
risks	I-Premise
and	I-Premise
benefits	I-Premise
were	I-Premise
more	I-Premise
balanced	I-Premise
during	I-Premise
the	I-Premise
CEE	I-Premise
alone	I-Premise
intervention	I-Premise
with	I-Premise
204	I-Premise
CHD	I-Premise
cases	I-Premise
for	I-Premise
CEE	I-Premise
alone	I-Premise
vs	I-Premise
222	I-Premise
cases	I-Premise
for	I-Premise
placebo	I-Premise
(HR,	I-Premise
0.94;	I-Premise
95%	I-Premise
CI,	I-Premise
0.78-1.14)	I-Premise
and	I-Premise
104	I-Premise
vs	I-Premise
135,	I-Premise
respectively,	I-Premise
for	I-Premise
invasive	I-Premise
breast	I-Premise
cancer	I-Premise
(HR,	I-Premise
0.79;	I-Premise
95%	I-Premise
CI,	I-Premise
0.61-1.02);	I-Premise
cumulatively,	I-Premise
there	I-Premise
were	I-Premise
168	I-Premise
vs	I-Premise
216,	I-Premise
respectively,	I-Premise
cases	I-Premise
of	I-Premise
breast	I-Premise
cancer	I-Premise
diagnosed	I-Premise
(HR,	I-Premise
0.79;	I-Premise
95%	I-Premise
CI,	I-Premise
0.65-0.97).	I-Premise

Results	O
for	O
other	O
outcomes	O
were	O
similar	O
to	O
CEE	O
plus	O
MPA.	O

Neither	O
regimen	O
affected	O
all-cause	O
mortality.	O

For	B-Premise
CEE	I-Premise
alone,	I-Premise
younger	I-Premise
women	I-Premise
(aged	I-Premise
50-59	I-Premise
years)	I-Premise
had	I-Premise
more	I-Premise
favorable	I-Premise
results	I-Premise
for	I-Premise
all-cause	I-Premise
mortality,	I-Premise
myocardial	I-Premise
infarction,	I-Premise
and	I-Premise
the	I-Premise
global	I-Premise
index	I-Premise
(nominal	I-Premise
P	I-Premise
<	I-Premise
.05	I-Premise
for	I-Premise
trend	I-Premise
by	I-Premise
age).	I-Premise

Absolute	B-Premise
risks	I-Premise
of	I-Premise
adverse	I-Premise
events	I-Premise
(measured	I-Premise
by	I-Premise
the	I-Premise
global	I-Premise
index)	I-Premise
per	I-Premise
10,000	I-Premise
women	I-Premise
annually	I-Premise
taking	I-Premise
CEE	I-Premise
plus	I-Premise
MPA	I-Premise
ranged	I-Premise
from	I-Premise
12	I-Premise
excess	I-Premise
cases	I-Premise
for	I-Premise
ages	I-Premise
of	I-Premise
50-59	I-Premise
years	I-Premise
to	I-Premise
38	I-Premise
for	I-Premise
ages	I-Premise
of	I-Premise
70-79	I-Premise
years;	I-Premise
for	I-Premise
women	I-Premise
taking	I-Premise
CEE	I-Premise
alone,	I-Premise
from	I-Premise
19	I-Premise
fewer	I-Premise
cases	I-Premise
for	I-Premise
ages	I-Premise
of	I-Premise
50-59	I-Premise
years	I-Premise
to	I-Premise
51	I-Premise
excess	I-Premise
cases	I-Premise
for	I-Premise
ages	I-Premise
of	I-Premise
70-79	I-Premise
years.	I-Premise

Quality-of-life	O
outcomes	O
had	O
mixed	O
results	O
in	O
both	O
trials.	O

Menopausal	B-Claim
hormone	I-Claim
therapy	I-Claim
has	I-Claim
a	I-Claim
complex	I-Claim
pattern	I-Claim
of	I-Claim
risks	I-Claim
and	I-Claim
benefits.	I-Claim

Findings	B-Claim
from	I-Claim
the	I-Claim
intervention	I-Claim
and	I-Claim
extended	I-Claim
postintervention	I-Claim
follow-up	I-Claim
of	I-Claim
the	I-Claim
2	I-Claim
WHI	I-Claim
hormone	I-Claim
therapy	I-Claim
trials	I-Claim
do	I-Claim
not	I-Claim
support	I-Claim
use	I-Claim
of	I-Claim
this	I-Claim
therapy	I-Claim
for	I-Claim
chronic	I-Claim
disease	I-Claim
prevention,	I-Claim
although	B-Claim
it	I-Claim
is	I-Claim
appropriate	I-Claim
for	I-Claim
symptom	I-Claim
management	I-Claim
in	I-Claim
some	I-Claim
women.	I-Claim

To	O
evaluate	O
the	O
effects	O
of	O
the	O
Chinese	O
medicine	O
(CM)	O
five-element	O
music	O
on	O
quality	O
of	O
life	O
for	O
senior	O
and	O
non-senior	O
advanced	O
cancer	O
patients.	O

With	O
a	O
randomized	O
controlled	O
trial,	O
170	O
advanced	O
cancer	O
patients	O
were	O
randomly	O
assigned	O
to	O
three	O
groups:	O
the	O
CM	O
five-element	O
music	O
group	O
(68	O
patients),	O
the	O
Western	O
music	O
therapy	O
group	O
(68	O
cases),	O
and	O
the	O
no	O
music	O
therapy	O
group	O
(34	O
cases).	O

All	O
patients	O
of	O
70	O
years	O
old	O
or	O
older	O
were	O
considered	O
seniors	O
and	O
the	O
remaining	O
patients	O
younger	O
than	O
70	O
years	O
were	O
considered	O
nonseniors.	O

Patients	O
in	O
the	O
CM	O
five-element	O
music	O
group	O
listened	O
to	O
CM	O
five-element	O
music,	O
the	O
patients	O
in	O
the	O
Western	O
music	O
group	O
listened	O
to	O
Western	O
music,	O
and	O
the	O
patients	O
in	O
the	O
no	O
music	O
group	O
did	O
not	O
listen	O
to	O
music.	O

A	O
course	O
of	O
treatment	O
was	O
3	O
weeks,	O
with	O
30	O
min	O
each	O
day,	O
5	O
days	O
a	O
week.	O

The	O
Hospice	O
Quality	O
of	O
Life	O
Index-Revised	O
(HQOLI-R)	O
and	O
Karnofsky	O
performance	O
score	O
(KPS)	O
were	O
measured	O
in	O
the	O
three	O
groups	O
before	O
and	O
after	O
treatment.	O

The	O
symptom	O
diary	O
score	O
was	O
measured	O
in	O
the	O
three	O
groups	O
every	O
3	O
days,	O
7	O
times	O
in	O
total.	O

CM	B-Premise
five-element	I-Premise
music	I-Premise
group	I-Premise
showed	I-Premise
a	I-Premise
significant	I-Premise
difference	I-Premise
of	I-Premise
HQOLI-R,	I-Premise
KPS	I-Premise
and	I-Premise
symptom	I-Premise
diary	I-Premise
score	I-Premise
with	I-Premise
other	I-Premise
groups	I-Premise
(all	I-Premise
P<0.01).	I-Premise

There	B-Premise
were	I-Premise
significant	I-Premise
differences	I-Premise
of	I-Premise
HQOLI-R,	I-Premise
symptom	I-Premise
diary	I-Premise
score,	I-Premise
and	I-Premise
KPS	I-Premise
after	I-Premise
treatment	I-Premise
in	I-Premise
CM	I-Premise
five-element	I-Premise
music	I-Premise
group	I-Premise
and	I-Premise
other	I-Premise
groups	I-Premise
in	I-Premise
the	I-Premise
non-senior	I-Premise
subgroup	I-Premise
(P<0.05).	I-Premise

Additionally,	O
there	B-Premise
were	I-Premise
significant	I-Premise
differences	I-Premise
in	I-Premise
HQOLI-R	I-Premise
and	I-Premise
KPS	I-Premise
after	I-Premise
treatment	I-Premise
among	I-Premise
the	I-Premise
three	I-Premise
groups	I-Premise
in	I-Premise
the	I-Premise
senior	I-Premise
subgroup	I-Premise
(P<0.05).	I-Premise

CM	B-Claim
five-element	I-Claim
music	I-Claim
therapy	I-Claim
could	I-Claim
improve	I-Claim
the	I-Claim
quality	I-Claim
of	I-Claim
life	I-Claim
and	I-Claim
KPS	I-Claim
for	I-Claim
senior	I-Claim
and	I-Claim
non	I-Claim
senior	I-Claim
advanced	I-Claim
cancer	I-Claim
patients,	I-Claim
and	I-Claim
it	I-Claim
could	I-Claim
improve	I-Claim
subjective	I-Claim
symptoms	I-Claim
for	I-Claim
non-senior	I-Claim
advanced	I-Claim
cancer	I-Claim
patients.	I-Claim

Mediating	O
mechanisms	O
of	O
a	O
12-week	O
group-based	O
exercise	O
intervention	O
on	O
cancer	O
survivors'	O
quality	O
of	O
life	O
(QoL)	O
were	O
examined	O
to	O
inform	O
future	O
exercise	O
intervention	O
development.	O

Two	O
hundred	O
nine	O
cancer	O
survivors	O
â¥	O
3	O
months	O
posttreatment	O
(57%	O
breast	O
cancer)	O
aged	O
49.5	O
(Â±	O
10.4)	O
years	O
were	O
assigned	O
to	O
physical	O
exercise	O
(n	O
=	O
147)	O
or	O
wait-list	O
control	O
(n	O
=	O
62).	O

QoL,	O
fatigue,	O
emotional	O
distress,	O
physical	O
activity,	O
general	O
self-efficacy	O
and	O
mastery	O
were	O
assessed	O
at	O
baseline	O
and	O
post-intervention	O
using	O
questionnaires.	O

Path	O
analysis	O
was	O
conducted	O
using	O
Mplus	O
to	O
explore	O
whether	O
improved	O
physical	O
activity,	O
general	O
self-efficacy	O
and	O
mastery	O
mediated	O
the	O
effects	O
of	O
exercise	O
on	O
fatigue	O
and	O
distress	O
and	O
consequently	O
QoL.	O

The	B-Premise
intervention	I-Premise
was	I-Premise
associated	I-Premise
with	I-Premise
increased	I-Premise
physical	I-Premise
activity	I-Premise
(Î²	I-Premise
=	I-Premise
0.46,	I-Premise
95%	I-Premise
confidence	I-Premise
interval	I-Premise
(CI)	I-Premise
=	I-Premise
0.14;0.59),	I-Premise
general	I-Premise
self-efficacy	I-Premise
(Î²	I-Premise
=	I-Premise
2.41,	I-Premise
95%CI	I-Premise
=	I-Premise
0.35;4.73),	I-Premise
and	I-Premise
mastery	I-Premise
(Î²	I-Premise
=	I-Premise
1.75,	I-Premise
95%CI	I-Premise
=	I-Premise
0.36;2.78).	I-Premise

Further,	O
the	B-Premise
intervention	I-Premise
had	I-Premise
both	I-Premise
a	I-Premise
direct	I-Premise
effect	I-Premise
on	I-Premise
fatigue	I-Premise
(Î²	I-Premise
=	I-Premise
-1.09,	I-Premise
95%CI	I-Premise
=	I-Premise
-2.12;0.01),	I-Premise
and	I-Premise
an	I-Premise
indirect	I-Premise
effect	I-Premise
(Î²	I-Premise
=	I-Premise
-0.54,	I-Premise
95%CI	I-Premise
=	I-Premise
-1.00;-0.21)	I-Premise
via	I-Premise
physical	I-Premise
activity	I-Premise
(Î²	I-Premise
=	I-Premise
-0.29,	I-Premise
95%CI	I-Premise
=	I-Premise
-0.64;-0.07)	I-Premise
and	I-Premise
general	I-Premise
self-efficacy	I-Premise
(Î²	I-Premise
=	I-Premise
-0.25,	I-Premise
95%CI	I-Premise
=	I-Premise
-0.61;-0.05).	I-Premise

The	B-Premise
intervention	I-Premise
had	I-Premise
a	I-Premise
borderline	I-Premise
significant	I-Premise
direct	I-Premise
effect	I-Premise
on	I-Premise
reduced	I-Premise
distress	I-Premise
(Î²	I-Premise
=	I-Premise
-1.32,	I-Premise
95%CI	I-Premise
=	I-Premise
-2.68;0.11),	I-Premise
and	I-Premise
a	I-Premise
significant	I-Premise
indirect	I-Premise
effect	I-Premise
via	I-Premise
increased	I-Premise
general	I-Premise
self-efficacy	I-Premise
and	I-Premise
mastery	I-Premise
(Î²	I-Premise
=	I-Premise
-1.06,	I-Premise
95%CI	I-Premise
=	I-Premise
-1.89;-0.38).	I-Premise

Reductions	B-Premise
in	I-Premise
fatigue	I-Premise
(Î²	I-Premise
=	I-Premise
-1.33,	I-Premise
95%CI	I-Premise
=-1.85;-0.83)	I-Premise
and	I-Premise
distress	I-Premise
(Î²	I-Premise
=	I-Premise
-0.86,	I-Premise
95%CI	I-Premise
=	I-Premise
-1.25;-0.52)	I-Premise
were	I-Premise
associated	I-Premise
with	I-Premise
improved	I-Premise
QoL.	I-Premise

Further,	O
increased	B-Premise
physical	I-Premise
activity	I-Premise
was	I-Premise
directly	I-Premise
associated	I-Premise
with	I-Premise
improved	I-Premise
QoL	I-Premise
(Î²	I-Premise
=	I-Premise
3.37,	I-Premise
95%CI	I-Premise
=	I-Premise
1.01;5.54).	I-Premise

The	B-Claim
beneficial	I-Claim
effect	I-Claim
of	I-Claim
group-based	I-Claim
physical	I-Claim
exercise	I-Claim
on	I-Claim
QoL	I-Claim
was	I-Claim
mediated	I-Claim
by	I-Claim
increased	I-Claim
physical	I-Claim
activity,	I-Claim
general	I-Claim
self-efficacy	I-Claim
and	I-Claim
mastery,	I-Claim
and	I-Claim
subsequent	I-Claim
reductions	I-Claim
in	I-Claim
fatigue	I-Claim
and	I-Claim
distress.	I-Claim

In	B-Claim
addition	I-Claim
to	I-Claim
physical	I-Claim
activity,	I-Claim
future	I-Claim
interventions	I-Claim
should	I-Claim
target	I-Claim
self-efficacy	I-Claim
and	I-Claim
mastery.	I-Claim

This	B-Claim
may	I-Claim
lead	I-Claim
to	I-Claim
reduced	I-Claim
distress	I-Claim
and	I-Claim
fatigue,	I-Claim
and	I-Claim
consequently	I-Claim
improved	I-Claim
QoL	I-Claim
of	I-Claim
cancer	I-Claim
survivors.	I-Claim

The	B-MajorClaim
extent	I-MajorClaim
to	I-MajorClaim
which	I-MajorClaim
chemotherapy	I-MajorClaim
may	I-MajorClaim
relieve	I-MajorClaim
tumour-related	I-MajorClaim
symptoms,	I-MajorClaim
improve	I-MajorClaim
quality	I-MajorClaim
of	I-MajorClaim
life	I-MajorClaim
and	I-MajorClaim
prolong	I-MajorClaim
survival	I-MajorClaim
in	I-MajorClaim
patients	I-MajorClaim
with	I-MajorClaim
gastric	I-MajorClaim
cancer	I-MajorClaim
is	I-MajorClaim
not	I-MajorClaim
known	I-MajorClaim
in	I-MajorClaim
spite	I-MajorClaim
of	I-MajorClaim
the	I-MajorClaim
extensive	I-MajorClaim
use	I-MajorClaim
of	I-MajorClaim
this	I-MajorClaim
treatment	I-MajorClaim
modality.	I-MajorClaim

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
estimate	O
any	O
gain	O
in	O
the	O
quantity	O
and	O
quality	O
of	O
life	O
produced	O
by	O
chemotherapy	O
in	O
these	O
patients.	O

Between	O
January	O
1991	O
and	O
February	O
1995,	O
61	O
patients	O
with	O
gastric	O
cancer	O
were	O
randomized	O
to	O
either	O
chemotherapy	O
in	O
addition	O
to	O
best	O
supportive	O
care	O
or	O
to	O
best	O
supportive	O
care.	O

Chemotherapy	O
was	O
allowed	O
in	O
the	O
latter	O
group	O
if	O
the	O
supportive	O
measures	O
did	O
not	O
lead	O
to	O
palliation.	O

Chemotherapy	O
was	O
the	O
ELF-regimen	O
consisting	O
of	O
5-fluorouracil,	O
leucovorin	O
and	O
etoposide,	O
or,	O
in	O
elderly	O
patients	O
with	O
poor	O
performance,	O
a	O
5-fluorouracil/leucovorin	O
regimen	O
(FLv).	O

Quality	O
of	O
life	O
was	O
evaluated	O
with	O
the	O
EORTC-QLQ-C30	O
instrument.	O

More	B-Premise
patients	I-Premise
in	I-Premise
the	I-Premise
chemotherapy	I-Premise
group	I-Premise
(45%,	I-Premise
14/31)	I-Premise
had	I-Premise
an	I-Premise
improved	I-Premise
or	I-Premise
prolonged	I-Premise
high	I-Premise
quality	I-Premise
of	I-Premise
life	I-Premise
for	I-Premise
a	I-Premise
minimum	I-Premise
period	I-Premise
of	I-Premise
4	I-Premise
months	I-Premise
compared	I-Premise
to	I-Premise
those	I-Premise
in	I-Premise
the	I-Premise
best	I-Premise
supportive	I-Premise
care	I-Premise
group	I-Premise
(20%,	I-Premise
6/30,	I-Premise
P	I-Premise
<	I-Premise
0.05).	I-Premise

A	B-Premise
similar	I-Premise
difference	I-Premise
was	I-Premise
seen	I-Premise
in	I-Premise
the	I-Premise
treating	I-Premise
physician's	I-Premise
evaluation	I-Premise
of	I-Premise
whether	I-Premise
the	I-Premise
patient	I-Premise
was	I-Premise
subjectively	I-Premise
improved	I-Premise
or	I-Premise
continued	I-Premise
to	I-Premise
do	I-Premise
well	I-Premise
for	I-Premise
at	I-Premise
least	I-Premise
4	I-Premise
months	I-Premise
(17/31,	I-Premise
55%	I-Premise
versus	I-Premise
6/30,	I-Premise
20%,	I-Premise
P	I-Premise
<	I-Premise
0.01).	I-Premise

Overall	B-Premise
survival	I-Premise
was	I-Premise
longer	I-Premise
in	I-Premise
the	I-Premise
chemotherapy	I-Premise
group	I-Premise
(median	I-Premise
8	I-Premise
vs.	I-Premise
5	I-Premise
months)	I-Premise
although	B-Premise
the	I-Premise
difference	I-Premise
was	I-Premise
not	I-Premise
statistically	I-Premise
significant	I-Premise
(P	I-Premise
=	I-Premise
0.12).	I-Premise

After	B-Premise
corrections	I-Premise
for	I-Premise
imbalances	I-Premise
in	I-Premise
pretreatment	I-Premise
characteristics,	I-Premise
chemotherapy	I-Premise
treatment	I-Premise
was,	I-Premise
however,	I-Premise
associated	I-Premise
with	I-Premise
a	I-Premise
survival	I-Premise
benefit	I-Premise
(P	I-Premise
=	I-Premise
0.003).	I-Premise

Also,	B-Premise
the	I-Premise
quality-adjusted	I-Premise
survival	I-Premise
time	I-Premise
and	I-Premise
time	I-Premise
to	I-Premise
disease	I-Premise
progression	I-Premise
were	I-Premise
longer	I-Premise
for	I-Premise
patients	I-Premise
randomized	I-Premise
to	I-Premise
chemotherapy	I-Premise
(median	I-Premise
5	I-Premise
vs.	I-Premise
2	I-Premise
months,	I-Premise
P	I-Premise
=	I-Premise
0.03).	I-Premise

The	B-Claim
results	I-Claim
show	I-Claim
that	I-Claim
chemotherapy	I-Claim
can	I-Claim
add	I-Claim
to	I-Claim
both	I-Claim
quantity	I-Claim
and	I-Claim
quality	I-Claim
of	I-Claim
life	I-Claim
in	I-Claim
advanced	I-Claim
gastric	I-Claim
cancer.	I-Claim

The	B-Claim
number	I-Claim
of	I-Claim
patients	I-Claim
who	I-Claim
benefit	I-Claim
from	I-Claim
treatment	I-Claim
is,	I-Claim
however,	I-Claim
still	I-Claim
rather	I-Claim
limited.	I-Claim

Oral	O
etoposide	O
is	O
an	O
active	O
single	O
agent	O
in	O
small-cell	O
lung	O
cancer	O
(SCLC)	O
and	O
is	O
widely	O
prescribed	O
as	O
first-line	O
treatment	O
as	O
an	O
alternative	O
to	O
intravenous	O
combination	O
chemotherapy	O
in	O
patients	O
with	O
extensive	O
disease.	O

The	O
intention	O
of	O
this	O
study	O
was	O
to	O
determine	O
if	O
the	O
effects	O
of	O
oral	O
etoposide	O
therapy	O
on	O
survival	O
and	O
quality	O
of	O
life	O
are	O
equivalent	O
to	O
those	O
of	O
intravenous	O
chemotherapy.	O

In	O
a	O
randomized	O
trial	O
of	O
palliative	O
treatment	O
in	O
advanced	O
SCLC,	O
oral	O
etoposide	O
(100	O
mg	O
given	O
twice	O
daily	O
for	O
5	O
days)	O
was	O
compared	O
with	O
intravenous	O
chemotherapy	O
consisting	O
of	O
alternating	O
cycles	O
of	O
cisplatin	O
and	O
etoposide	O
(PE)	O
and	O
cyclophosphamide,	O
doxorubicin,	O
and	O
vincristine	O
(CAV).	O

Six	O
cycles	O
of	O
chemotherapy	O
were	O
administered	O
every	O
21	O
days	O
in	O
both	O
regimens.	O

Symptom	O
control	O
and	O
quality	O
of	O
life	O
were	O
measured	O
with	O
the	O
Rotterdam	O
Symptom	O
Checklist	O
and	O
a	O
daily	O
diary	O
card.	O

In	O
January	O
1996,	O
after	O
155	O
patients	O
had	O
been	O
randomly	O
assigned	O
from	O
a	O
projected	O
intake	O
of	O
365	O
patients,	O
an	O
independent	O
Data	O
Monitoring	O
Committee	O
examined	O
the	O
interim	O
results.	O

Survival	O
was	O
determined	O
by	O
the	O
Kaplan-Meier	O
method,	O
and	O
the	O
logrank	O
test	O
was	O
used	O
to	O
compare	O
treatments.	O

For	O
quality-of-life	O
comparisons,	O
average	O
scores	O
were	O
calculated	O
for	O
each	O
time	O
point.	O

The	O
Mann-Whitney	O
U	O
test	O
was	O
used	O
to	O
determine	O
any	O
significant	O
overall	O
differences	O
between	O
treatments.	O

For	O
the	O
Rotterdam	O
Symptom	O
Checklist,	O
separate	O
analyses	O
were	O
done	O
for	O
each	O
subset	O
(psychological	O
well-being,	O
physical	O
symptoms,	O
lung	O
cancer	O
symptoms,	O
treatment	O
symptoms,	O
activity,	O
and	O
quality	O
of	O
life).	O

Response	O
rates	O
and	O
toxicity	O
scores	O
were	O
compared	O
by	O
using	O
chi2.	O

All	O
statistical	O
tests	O
were	O
two-sided.	O

Survival	B-Premise
was	I-Premise
inferior	I-Premise
at	I-Premise
1	I-Premise
year	I-Premise
in	I-Premise
the	I-Premise
oral	I-Premise
etoposide	I-Premise
group	I-Premise
compared	I-Premise
with	I-Premise
intravenous	I-Premise
therapy	I-Premise
(9.8%	I-Premise
for	I-Premise
oral	I-Premise
versus	I-Premise
19.3%	I-Premise
for	I-Premise
intravenous;	I-Premise
difference	I-Premise
=	I-Premise
9.5%;	I-Premise
95%	I-Premise
confidence	I-Premise
interval	I-Premise
of	I-Premise
difference	I-Premise
=	I-Premise
0.3%-18.7%;	I-Premise
P<.05),	I-Premise
and	I-Premise
there	I-Premise
was	I-Premise
a	I-Premise
trend	I-Premise
toward	I-Premise
inferior	I-Premise
overall	I-Premise
survival.	I-Premise

Median	B-Premise
survival	I-Premise
was	I-Premise
4.8	I-Premise
months	I-Premise
for	I-Premise
oral	I-Premise
treatment	I-Premise
and	I-Premise
5.9	I-Premise
months	I-Premise
for	I-Premise
intravenous	I-Premise
therapy.	I-Premise

Progression-free	B-Premise
survival	I-Premise
was	I-Premise
worse	I-Premise
in	I-Premise
the	I-Premise
oral	I-Premise
etoposide	I-Premise
arm	I-Premise
(median	I-Premise
=	I-Premise
3.6	I-Premise
months	I-Premise
versus	I-Premise
5.6	I-Premise
months;	I-Premise
P<.001),	I-Premise
as	I-Premise
well	I-Premise
as	I-Premise
overall	I-Premise
response	I-Premise
rate	I-Premise
(32.9%	I-Premise
versus	I-Premise
46.3%;	I-Premise
P<.01).	I-Premise

With	B-Premise
the	I-Premise
exception	I-Premise
of	I-Premise
acute	I-Premise
nausea	I-Premise
and	I-Premise
vomiting	I-Premise
associated	I-Premise
with	I-Premise
intravenous	I-Premise
chemotherapy,	I-Premise
all	B-Premise
aspects	I-Premise
of	I-Premise
symptom	I-Premise
control	I-Premise
and	I-Premise
quality	I-Premise
of	I-Premise
life	I-Premise
were	I-Premise
either	I-Premise
the	I-Premise
same	I-Premise
or	I-Premise
worse	I-Premise
in	I-Premise
the	I-Premise
oral	I-Premise
etoposide	I-Premise
group.	I-Premise

Study	O
closure	O
was	O
recommended.	O

These	B-Claim
interim	I-Claim
results	I-Claim
show	I-Claim
that	I-Claim
this	I-Claim
schedule	I-Claim
of	I-Claim
oral	I-Claim
etoposide	I-Claim
is	I-Claim
inferior	I-Claim
to	I-Claim
intravenous	I-Claim
chemotherapy	I-Claim
in	I-Claim
the	I-Claim
treatment	I-Claim
of	I-Claim
advanced	I-Claim
SCLC	I-Claim
and	I-Claim
should	I-Claim
not	I-Claim
be	I-Claim
used	I-Claim
as	I-Claim
first-line	I-Claim
treatment	I-Claim
of	I-Claim
this	I-Claim
disease.	I-Claim

To	O
investigate	O
the	O
effect	O
of	O
two	O
doses	O
of	O
megestrol	O
acetate	O
(MA)	O
compared	O
with	O
placebo	O
on	O
quality	O
of	O
life	O
(QoL)	O
and	O
nutritional	O
status	O
(NS)	O
in	O
patients	O
with	O
advanced	O
endocrine-insensitive	O
cancer.	O

Two	O
hundred	O
forty	O
patients	O
were	O
randomised	O
to	O
double-blind	O
MA	O
480	O
mg/day,	O
MA	O
160	O
mg/day,	O
or	O
matching	O
placebo	O
for	O
12	O
weeks.	O

Nutritional	O
status	O
(including	O
weight,	O
skinfold	O
thickness	O
and	O
midarm	O
circumference)	O
and	O
QoL	O
(using	O
6	O
linear	O
analogue	O
self-assessment	O
(LASA)	O
scales)	O
were	O
assessed	O
at	O
randomisation	O
and	O
after	O
four,	O
eight	O
and	O
12	O
weeks.	O

A	O
QoL	O
ranking	O
incorporating	O
QoL	O
and	O
death	O
was	O
also	O
used	O
ranging	O
from	O
1	O
=	O
dead	O
to	O
5	O
=	O
much	O
better	O
QoL.	O

One	O
hundred	O
seventy-four	O
patients	O
were	O
assessable	O
at	O
week	O
four,	O
136	O
at	O
week	O
eight	O
and	O
103	O
patients	O
at	O
week	O
12.	O

Patients	B-Premise
receiving	I-Premise
MA	I-Premise
reported	I-Premise
substantially	I-Premise
better	I-Premise
appetite	I-Premise
(P	I-Premise
=	I-Premise
0.001),	I-Premise
mood	I-Premise
(P	I-Premise
=	I-Premise
0.001)	I-Premise
and	I-Premise
overall	I-Premise
quality	I-Premise
of	I-Premise
life	I-Premise
(P	I-Premise
<	I-Premise
0.001),	I-Premise
and	I-Premise
possibly	I-Premise
less	I-Premise
nausea	I-Premise
and	I-Premise
vomiting	I-Premise
(P	I-Premise
=	I-Premise
0.08)	I-Premise
than	I-Premise
patients	I-Premise
receiving	I-Premise
placebo,	I-Premise
based	I-Premise
on	I-Premise
a	I-Premise
test	I-Premise
for	I-Premise
trend.	I-Premise

A	B-Premise
larger	I-Premise
benefit	I-Premise
was	I-Premise
seen	I-Premise
with	I-Premise
the	I-Premise
higher	I-Premise
dose	I-Premise
which	I-Premise
(unlike	I-Premise
the	I-Premise
lower	I-Premise
dose)	I-Premise
was	I-Premise
significantly	I-Premise
better	I-Premise
in	I-Premise
pairwise	I-Premise
comparisons	I-Premise
with	I-Premise
placebo	I-Premise
for	I-Premise
appetite,	I-Premise
mood	I-Premise
and	I-Premise
overall	I-Premise
QoL	I-Premise
(each	I-Premise
P	I-Premise
<	I-Premise
or	I-Premise
=	I-Premise
0.001).	I-Premise

Despite	B-Premise
some	I-Premise
missing	I-Premise
data	I-Premise
on	I-Premise
QoL	I-Premise
scores,	I-Premise
QoL	I-Premise
ranking	I-Premise
was	I-Premise
available	I-Premise
on	I-Premise
227	I-Premise
(95%)	I-Premise
of	I-Premise
patients	I-Premise
with	I-Premise
significantly	I-Premise
higher	I-Premise
QoL	I-Premise
ranking	I-Premise
associated	I-Premise
with	I-Premise
MA	I-Premise
(P	I-Premise
=	I-Premise
0.002).	I-Premise

Improvements	B-Premise
in	I-Premise
QoL	I-Premise
occurred	I-Premise
early	I-Premise
within	I-Premise
four	I-Premise
weeks	I-Premise
and	I-Premise
were	I-Premise
sustained.	I-Premise

No	B-Premise
statistically	I-Premise
significant	I-Premise
differences	I-Premise
were	I-Premise
observed	I-Premise
in	I-Premise
NS	I-Premise
measurements,	I-Premise
including	I-Premise
weight	I-Premise
(P	I-Premise
=	I-Premise
0.29).	I-Premise

Side	B-Premise
effects	I-Premise
of	I-Premise
therapy	I-Premise
were	I-Premise
minor	I-Premise
and	I-Premise
did	I-Premise
not	I-Premise
differ	I-Premise
significantly	I-Premise
across	I-Premise
treatments.	I-Premise

Megestrol	B-Claim
acetate	I-Claim
given	I-Claim
at	I-Claim
480	I-Claim
mg/day	I-Claim
is	I-Claim
useful	I-Claim
palliation	I-Claim
in	I-Claim
patients	I-Claim
with	I-Claim
endocrine-insensitive	I-Claim
advanced	I-Claim
cancer.	I-Claim

It	B-Claim
improves	I-Claim
appetite,	I-Claim
mood	I-Claim
and	I-Claim
overall	I-Claim
quality	I-Claim
of	I-Claim
life	I-Claim
in	I-Claim
these	I-Claim
patients,	I-Claim
although	B-Claim
not	I-Claim
through	I-Claim
a	I-Claim
direct	I-Claim
effect	I-Claim
on	I-Claim
nutritional	I-Claim
status.	I-Claim

The	B-MajorClaim
choice	I-MajorClaim
of	I-MajorClaim
reconstruction	I-MajorClaim
after	I-MajorClaim
gastrectomy	I-MajorClaim
and	I-MajorClaim
the	I-MajorClaim
significance	I-MajorClaim
of	I-MajorClaim
remaining	I-MajorClaim
reservoir	I-MajorClaim
function	I-MajorClaim
is	I-MajorClaim
a	I-MajorClaim
matter	I-MajorClaim
of	I-MajorClaim
controversy.	I-MajorClaim

To	O
broaden	O
the	O
criteria	O
for	O
choice	O
of	O
treatment,	O
we	O
conducted	O
a	O
prospective	O
randomized	O
clinical	O
trial	O
to	O
determine	O
the	O
impact	O
of	O
various	O
gastrectomy	O
procedures	O
on	O
quality	O
of	O
life.	O

Consecutive	O
patients	O
(n	O
=	O
64)	O
eligible	O
for	O
curative	O
gastric	O
cancer	O
surgery	O
were	O
randomized	O
to	O
have	O
either	O
a	O
total	O
(n	O
=	O
31)	O
or	O
subtotal	O
(n	O
=	O
13)	O
gastrectomy	O
or	O
a	O
jejunal	O
S-shaped	O
pouch	O
(n	O
=	O
20)	O
implanted	O
as	O
a	O
gastric	O
substitute.	O

The	O
quality-of-life	O
evaluation	O
was	O
based	O
on	O
a	O
battery	O
of	O
questionnaires	O
covering	O
both	O
general	O
and	O
specific	O
aspects	O
of	O
life.	O

The	O
patients	O
were	O
rated	O
by	O
one	O
of	O
two	O
psychiatrists	O
who	O
were	O
blinded	O
to	O
the	O
patients'	O
group	O
affiliation.	O

Assessments	O
were	O
made	O
on	O
three	O
occasions:	O
during	O
the	O
week	O
prior	O
to	O
surgery	O
and	O
3	O
and	O
12	O
months	O
after	O
the	O
surgical	O
intervention.	O

The	B-Premise
postoperative	I-Premise
complication	I-Premise
and	I-Premise
mortality	I-Premise
rates	I-Premise
were	I-Premise
similar	I-Premise
in	I-Premise
all	I-Premise
treatment	I-Premise
groups,	I-Premise
with	I-Premise
few	I-Premise
serious	I-Premise
complications	I-Premise
recorded.	I-Premise

Irrespective	B-Premise
of	I-Premise
type	I-Premise
of	I-Premise
treatment,	I-Premise
the	I-Premise
patients	I-Premise
suffered	I-Premise
from	I-Premise
alimentary	I-Premise
symptoms	I-Premise
and	I-Premise
functional	I-Premise
limitations	I-Premise
in	I-Premise
everyday	I-Premise
life,	I-Premise
whereas	B-Premise
their	I-Premise
mental	I-Premise
well-being	I-Premise
improved	I-Premise
after	I-Premise
surgery.	I-Premise

Patients	B-Premise
who	I-Premise
underwent	I-Premise
subtotal	I-Premise
gastrectomy	I-Premise
had	I-Premise
the	I-Premise
best	I-Premise
outcome,	I-Premise
especially	I-Premise
with	I-Premise
respect	I-Premise
to	I-Premise
complaints	I-Premise
of	I-Premise
diarrhea.	I-Premise

Patients	B-Premise
given	I-Premise
a	I-Premise
gastric	I-Premise
substitute	I-Premise
after	I-Premise
gastrectomy	I-Premise
showed	I-Premise
no	I-Premise
difference	I-Premise
from	I-Premise
those	I-Premise
who	I-Premise
had	I-Premise
only	I-Premise
a	I-Premise
total	I-Premise
gastrectomy.	I-Premise

We	B-Claim
conclude	I-Claim
that	I-Claim
despite	I-Claim
significant	I-Claim
unfavorable	I-Claim
consequences	I-Claim
that	I-Claim
follow	I-Claim
gastrectomy,	I-Claim
patients	I-Claim
recover	I-Claim
with	I-Claim
an	I-Claim
improved	I-Claim
mental	I-Claim
status.	I-Claim

A	B-Claim
pouch	I-Claim
reconstruction	I-Claim
after	I-Claim
total	I-Claim
gastrectomy	I-Claim
does	I-Claim
not	I-Claim
improve	I-Claim
quality	I-Claim
of	I-Claim
life,	I-Claim
but	O
a	B-Claim
subtotal	I-Claim
gastrectomy	I-Claim
has	I-Claim
advantages	I-Claim
that	I-Claim
must	I-Claim
be	I-Claim
considered	I-Claim
when	I-Claim
the	I-Claim
procedure	I-Claim
is	I-Claim
clinically	I-Claim
feasible.	I-Claim

